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A : adenine 
AFB, : aflatoxin B, 
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BSP : sulphobromphthalein 
C : cytosine 
CcR NADPH-dependent cytochrome c reductase 
chL : nitrate reductase gene 
cyt : cytochrome 
°C : degrees Celsius 
DMN : dimethylnitrosamine 
DMSO : dimethylsulphoxide 
DNA: deoxyribonucleic acid 
E, 
E2 
E3 
ECOD 
EROD 
EMIC 
FF : 
oestrone 
oestradiol 
oestriol 
ethoxycoumarin-o-deethylase 
ethoxyresorufin-o-deethylase 
Environmental Mutagen Information Centre 
undefined hypothalamic feminizing factors 
G : guanine 
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GH : growth hormone 
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HSOH : hydroxysteroid dehydrogenase 
IARC : International Agency for Research on Cancer 
ip intraperitoneal 
Km : Michaelis-Menten constant 
kg : ki logram 
i : litre 
LPS : 1 ipopolysaccharide 
LSI : liver somatic index 
M : molar 
3MC : 3-methylcholanthrene 
MGA : minimal glucose agar 
MMC : mitomycin C 
mRNA : messenger RNA 
NADP : nicotinamide adenine dinucleotide phosphate 
NADPH : NADP (reduced form) 
OD650 : optical density at wavelength 65D nm 
+ : wild type gene 
pAQl : multicopy plasmid 
PB : sodium phenobarbital 
PBG progesterone binding globulin 
PCB polychlorinated biphenyl 
PCH polycyclic hydrocarbon 
PCN pregnanolone-'6a-carbonitrile 
pKMIOl : R-factor 
PRG progesterone 
PRL 
psi 
RCF 
rfa 
RNA 
prolactin 
pounds per square inch 
radial centrifugal force 
'deep rough' deletion 
ribonucleic acid 
rpm revolutions per minute 
5 : Svedberg units (sedimentation) 
59 : 9000 g supernatant 
SKF-525-A : 2-diethylaminoethyl 2,2-diphenylvalerate 
SNK : student-newman-keuls procedure 
SPSS : statistical package for the social sciences 
SRF : spontaneous reversion frequency 
T : thymine 
TEBG : testosterone-oestradiol binding globulin 
t~ : biological half-life 
U : uracil 
UDP : uridine diphosphate 
UDPGA : uridine diphosphoglucuronic acid 
uv : ultraviolet 
uurB : uv repair B gene deletion 
Vmax : maximal velocity (enzyme kinetics) 
W : watt 
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ABSTRACT 
Cytochrome P-450, the terminal oxidase of the metabolic mono-oxygenase 
system, is thought to exist in multiple forms, which have differing substrate 
specificities, and are variably inducible by different enzyme inducers. Many 
mutagens, themselves unreactive, require metabolic activation by one or more 
of these cytochrome P-450-dependent microsomal enzymes for mutagenic 
activity. Such mutagens may be detected in the Salmonella mutagenicity test 
only by the incorporation of an hepatic microsomal (59) fraction into the 
assay (as a first approximation to in vivo metabolism). Induction of the 
microsomal enzymes by different agents enhances the metabolic activation of 
mutagens; in fact, many mutagens are only detected when the 59 fraction has 
been induced by appropriate agents. Inducers of the phenobarbital-type are 
known to enhance microsomal steroid hydroxylation 
when administered at supraphysiological levels, 
inducers of several mono-oxygenase activities. 
and, in turn, the steroids, 
have been reported to be 
The inductive effects of the female sex-steroids and the combined effects of 
steroid and phenobarbital (PB) pretreatment on the metabolic activation of 
four mutagens have been investigated using the Salmonella assay. Female 
Sprague-Dawley rats were pret reated with 17a-oestradiol (E2) or progesterone 
(PRG) , at a level of either 1 mg/kg or 20 mg / kg daily for 14 days. A dupli-
cate set of similarly pretreated groups were also induced with PB. Hepatic 
microsomal fractions were prepared from each group and incubated with each of 
the test mutagens in the presence of a tester strain known to detect each 
particular type of mutagen. Induction of the hepatic metabolizing system by 
PB increased the activation of the mutagens significantly (as reflected by an 
increased number of revertant prototrophic S .typhimurium colonies). The 
administration of PRG also caused significant, and dose-dependent, induction 
of the activation of af l atoxin B1, benzo(a)pyrene, and dimethylnitrosamine. 
In general, E2 exhibited no inductive effect, but it did produce an increase 
in the activation of aflatoxin B1 (a reaction which is known to be catalysed 
by a mono-oxygenase prefe rentially inducible by PB). When use was made of a 
microsomal fraction that was prepared from animals which were both steroid-
pretreated and induced by PB, mutagenic activation was of the same order of 
magnitude as that observed when induction was brought about by PB alone. The 
absence of additive effect, taken together with the observations already 
mentioned, indicate that steroids induce the same cytochrome isozymes that 
are induced by PB. 
The implications of sex-hormonal regulation of the metabolic activation of 
mutagens are briefly discussed. 
CHAPTER 1 INTRODUCTION: CYTOCHROME P-450, MUTAGEN METABOLISM 
AND THE AMES TEST 
1.1 THE EXISTENCE OF MULTIPLE FORMS OF CYTOCHROME P-450 
Cytochrome (cyt) P-450 is the terminal oxidase of the microsomal 
electron transport system, responsible for the oxidative metabolism 
of endogenous steroids and fatty acids, as well as of many drugs, 
and other xenobiotics. The chemical nature and reactivity of cyto-
chrome(s) P-450-linked oxidations have been the subject of several 
reviews (86,114,232,258). 
A growing body of evidence suggests the existence of multiple forms 
of cyt(s) P-450 which have distinct (but sometimes overlapping) 
specificities with regard to substrate interaction and mono-oxyge-
nation (114,165,232,288). Two (or more) mono-oxygenase systems may 
exist in the liver microsomes, one employing cyt P-450 (also called 
cyt P-450 LM2 ) as its terminal oxidase, the other cyt P-448 (also 
called cyt Pl -450 or cyt P-450LM4 ) (114,117,232). Antibodies pre-
pared against purified cyt P-450 do not cross-react with cyt P-448, 
and vice versa, a finding which shows that the two haemoproteins 
are dissimilar (165,232). However, it is now known that the terms 
cyt P-450 and cyt P-448 also define classes of P-450 haemoproteins, 
rather than specific cytochromes (118). 
In this study, cyt P-450 is considered to be the labile P-450 
haemoprotein found predominantly in the liver of the untreated or 
phenobarbital-treated rat; cyt P-448 is considered to be the stable 
P-450 haemoprotein found predominantly in livers of rats treated 
with certain polycyclic hydrocarbons (the prototype of which is 
3-methylcholanthrene (3MC)) (118). The term cyt(s) P-450 designates 
any cytochrome which has a spectral maximum of about 450 nm when it 
is reduced and complexed with carbon monoxide; this includes both 
cyt P-450 and cyt P-448 (117). 
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1.2 DIFFERENTIAL INDUCTION OF CYTOCHROME(S) P-450 
Many structurally-diverse compounds are capable of inducing the 
microsomal mono-oxygenases (66). These inducing agents are often 
generally classified as being either phenobarbital-like (preferen-
tially inducing the cyt P-450-dependent systems), or 3MC-like (pre-
ferentially inducing the cyt P-448-dependent systems) (117,232). 
Recently, the existence of a third type of inducing agent has been 
propounded, the administration of which induces enzymes in a 
pattern similar to that observed after the coadministration of 
phenobarbital (PB) and 3MC. In this class of compounds belong the 
polychlorinated biphenyls (for example, Arochlor) and polybromi-
nated biphenyls. Certain of the polychlorinated biphenyls have 
however been resolved into isomers which, when administered separa-
tely, are either PB-type or 3MC-type inducers (232). Therefore, it 
is possible that this class may not constitute a new type of indu-
cer, but that their induction characteristics may be due to the 
fact that these agents are mixtures of PB-type and 3MC-type indu-
cers. The mechanism of enzyme induction by these different com-
pounds, and the physiological and pharmacological implications of 
their action, have been reviewed by several authors (66-
68,103,112,232,248). 
1.3 CYTOCHROME(S) P-450-DEPENDENT ACTIVATION OF MUTAGENS 
The cyt(s} P-450 isozymes are known to be responsible, more so than 
other enzymes, for the in vivo metabolism of certain toxic com-
pounds to mutagenically active intermediates (119,144,172,195,197, 
212,220,222,223,279,289,299). In addition, antibodies against cyt 
P-450 and cyt P-448 inhibit the in vitro mutagenicity of several 
mutagens almost completely (165). 
Mutagenic metabolites may be electrophiles (epoxides, carbonium 
ions or nitrenium ions) capable of random covalent binding to 
numerous cellular nucleophiles, including the oxygen and nitrogen 
atoms of DNA bases (119,157). Alternatively, reactive intermediates 
may be of the free radical variety, thought to induce lipid peroxi-
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dation and the destruction of several cellular components, inclu-
ding DNA (12,144). If the mutagenic metabolite is a planar aromatic 
molecule, it may also intercalate with the DNA structure, at a 
sequence of repeating nucleotides, resulting in frameshift muta-
tions (80,211,212). The complex subject of mutagenesis is outside 
the immediate scope of this work, except insofar as it is mediated 
by the four test mutagens studied (see Chapter 2). A number of 
comprehensive reviews of the biochemistry of mutagenesis have been 
published (80,81,95,113,130,195,220,221,223,264,285,287). 
The contribution of each of the molecular species of cyt(s) P-450, 
towards the metabolic activation of a mutagen, is specific for the 
particular compound (144,165). In addition, the content of indivi-
dual cyt P-450 isozymes in the microsomes is variable according to 
the induced state of the liver (165). Therefore, the contribution 
of each of the individual forms of cyt P-450, to the total activa-
tion of a promutagen to mutagenic metabolites, is dependent, not 
only on the specific catalytic activity, but also on the content 
(level of induction) of the isozyme in the hepatic microsomes 
(144,165). If the specific activity is assumed to be constant, then 
a quantitative estimation of the contribution of each cyt P-450 
isozyme is possible (144,165). 
Also present in the liver are a number of metabolic pathways by 
which mutagenically reactive intermediates may be detoxified; these 
include binding to 'scavenger nucleophiles' such as glutathione, as 
well as various enzyme-catalysed conjugation reactions (119,144, 
172,195,267). 
The net toxicity of mutagens in any in vivo (or in vitro) system is 
thought to depend on the balance between the pathways of activation 
and those of detoxification. This 'balance ' is influenced by the 
levels of induction of both the particular cyt P-450 isozyme (or 
other enzyme) responsible for the activation of the mutagen, and of 
the enzymes of deactivation, and also by the competition for any of 
these enzymes by other endogenous or exogenous substrates (39,119, 
144,157,172,267). 
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1.4 HORMONAL REGULATION OF MUTAGEN METABOLISM 
Present studies on species- and sex-differences in metabolism have 
indicated that the hormonal status of an animal may be an important 
factor in the regulation of mutagen metabolism (24,31,173,209,291). 
The sex-steroids are known to modify, directly or indirectly, 
macromolecular function in the cells of many tis sues, binding to 
specific protein receptors which promote their preferential reten-
tion in hormonally sensitive cells (31). Although steroids, per se, 
are not metabolized to mutagens, they appear to have a highly 
specific regulatory action on hepatic metabolism (31,209). At phy-
siological levels, the endogenous female sex-steroids are competi-
tive inhibitors of the same cyt P-450-dependent mono-oxygenases 
that are responsible for mutagen activation, and are, therefore, 
probably alternative substrates of these enzymes (Section 3.3) 
(233,282). 
These steroids have been reported to enhance the metabolic activa-
tion of mutagens, when administered at high doses, possibly predis-
posing the organism to increased risk (4,31,180). The interaction 
of the steroids with cyt(s) P-450 and their effects on the metabo-
lism of xenobiotics are discussed in Chapters 3 and 4. 
The aim of this study was the investigation of the influence of 
supraphysiological level s of the endogenous femal e sex-steroids, 
17e-oestradiol and progesterone, on the metabolism of four muta-
gens. The metabolic biotransformation of the four test compounds 
to mutagenically reactive intermediates was quantitatively deter-
mined in this investigation using the Ames test as a bioassay (see 
Section 1.5.2). 
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1.5 THE AMES TEST 
1.5.1 Introduction 
Short-term in vitro and submammalian mutagenicity tests have evol-
ved in response to the disadvantages of longer-term animal carcino-
genicity tests. The time and expense required for animal bioassays, 
as well as their low sensitivity, limit their utility in screening 
the vast number of synthetic chemicals to which humans are exposed 
(11,12,208). The short-term mutagenicity assays in current use have 
been described in the literature (75,79,127,169 ,208,212,240,277), 
and have been most comprehensively reviewed by Hollstein et aI. 
(133;678 references) . 
Of the microbial mutagenicity assays, the Ames test is regarded as 
being the only test which presently meets the criteria of an estab-
lished predictive test in genetic toxicology (56,237,239). The 
relative rapidity, sensitivity, simplicity, and low-cost of the 
assay, have contributed to its current use in more than two thou-
sand government, industrial, and academic laboratories (11,16,39, 
125,237). Test results on over 2600 chemical s have been reported in 
the Environmental Mutagen Information Centre (EMIC) bibliography 
(202). A fully computerized system for the performance and analysis 
of the Ames test became available in 1984 (MutascreenR, Labsytems 
Oy, Helsinki). 
The assay method has been recently updated in a detailed publica-
tion by Maron and Ames (202), and is described in Chapter 5. 
The Ames test is performed by the combined incubation, in a 
histidine-deficient medium, of a small amount of test compound, 
about a billion histidine-auxotrophic bacteria, and an hepatic 
microsomal homogenate, usually prepared from rats (39). 
The strain of bacteria used may be one of a set of specially-
constructed mutant SaImoneIIa typhimurium strains, selected for 
their sensitivity and specificity in being reverted from a require-
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ment for histidine to prototrophy (11,20,202). The SaLmoneLLa tes-
ter strains are described in some detail in Section 1.5.4. Because 
these bacteria have few of the enzymes required for the metabolic 
activation of mutagens (214,265), a microsomal (59) fraction is 
incorporated, as an in vitro first approximation to in vivo mamma-
lian metabolism (10,11,13,50,184,197,215,216,237). This facilitates 
the detection, by the SaLmoneLLa strains, of most promutagens which 
require metabolic activation for their mutagenicity (16,37,47,100, 
125,212). 
After incubation on a petri-plate at 37°C for 48-72 hours, the 
number of revertant prototrophic SaLmoneLLa colonies are counted 
(22,33). Each colony is descended from a bacterium that has mutated 
from a defective histidine gene (his-) to a functional one (his+) 
(11,212). The number of revertant colonies per plate provides a 
quantitative estimate of the mutagenic potency of the test compound 
(11,40,75,79,212,214). Normally, test results are either clearly 
negative or clearly positive, and a linear dose-response curve is 
usually observed with positive responses (76,212,214). 
1.5.2 Applications of the Ames Test 
The primary applications of the Ames test are the screening of new 
synthetic chemicals for mutagenicity, and the testing of establis-
hed products for mutagenic impurities (214). 
It is estimated that at least one thousand new chemicals are intro-
duced into the human environment each year, and that over sixty-
three thousand are in everyday use in households and industry 
(11,17,144,208). These products include various drugs, food addi-
tives, pesticides and cosmetics (144). Although mutagenicity tes-
ting per se is not yet a premarketing requirement for new consumer 
products, it may become so in the near future (55) . For the pur-
poses of general mutagenicity screening, efforts have been made 
towards the standardization of the test protocol (2,77,105,111,129, 
260,261), and a recent international collaborative study has indi-
cated that such standardization significantly increases the repro-
ducibility of the assay (3,23,62,83,128,200). 
7 
Several modifications of the Ames assay protocol have broadened the 
utility of the test (19,97,196,202,207,224,301). 
Environmental mutagenic pollution of air and water supplies is 
routinely tested in modified Ames tests, as are complex mixtures 
such as cigarette smoke condensates, food, and the protein pyroly-
sis products of foods (11,12,202,211,214). The urine and faeces of 
animals may also be tested for the presence of the mutagenic meta-
bolites of ingested products (9,64,84,156,166,214,254,308). 
The Ames test finds further application as an enzyme assay, with 
the number of his+ revertant Salmonella colonies being a measure of 
the enzymatic activity of the S9 preparation (20,196) . Differences 
among S9 fractions prepared from various tissues and species may 
thus be determined, and the effect of various pretreatments on the 
metabolic activity of S9 can be investigated (39,125,267). 
The rate of mutagenic 
Salmonella strains, 
bolic capacity of 
activation, as measured by mutagenesis in the 
is assumed to quantitatively reflect the meta-
the liver in the intact animal (31). The 
Salmonel la/microsomal test, used in this way, is not a simple 
enzyme assay, specific for a particular activating enzyme, since 
the S9 homogenate contains the full complement of enzymes involved 
in the metabolism of mutagens (13,281). Therefore, the resulting 
mutagenicity reflects the effects of pretreatment on the overall 
balance of the pathways of both activation and detoxification of 
the test mutagens (281). 
1.5.3 Correlations Between In Vitro Mutagenicity and In Vivo 
Carcinogenicity 
The use of short-term i n vitro and submammalian tests as a predic-
tive indicator of animal carcinogenicity is the subject of some 
controversy. While it is clear that the liver homogenate is able to 
metabolize most promutagens to their active mutagenic forms, it 
cannot faithfully duplicate the absorption, distribution, metabo-
lism, and excretion of a compound in the intact animal (16,27,42, 
125,175,212,237). 
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Again, although it may well be that mammalian and bacterial DNA are 
basically similar, and that it is possible to expose considerably 
more DNA to mutagens using bacteria.! populations (211,237), the DNA 
repair capability of mammalian cells appears to be different to 
that of bacteria (175,212). 
Classes of carcinogens which appear to cause cancer by nonmutagenic 
mechanisms (for example, the steroid hormones), are not detected by 
microbial mutagenicity assays (15-17,19,249). It is possible that 
these carcinogens affect cell growth and thus may act as 'promo-
ters' of tumours rather than 'initiators', which are thought to 
interact with DNA (11,16,175,212). 
Nevertheless, over 80% of known animal carcinogens are mutagenic in 
SaLmoneLLa, and in the majority of reports, there is an excellent 
correlation between in vitro mutagenicity and in vivo carcinogeni-
city (11,56,74,207,211,212,219). 
The value of in vitro mutagenicity tests, including the Ames test, 
as predictors of animal carcinogenicity has been reviewed extensi-
vely (11,15-17,28,35,39,50,55,56,65,74,79,99, 125,127,143,207,208, 
211,212,214,215,219,236,240,241,243,250,277,284). A 'battery' of 
short-term tests is favoured by many investigators, so that the 
strengths of one test can compensate for the inadequacies of anot-
her in detecting specific classes of mutagens (9,11,15-17,50,74, 
182,202). In vitro mutagenicity tests are regarded as an excellent 
method of prescreening environmental chemicals to be submitted to a 
more rigorous set of animal bioassays (39,50,212,214). 
1.5.4 The SaLmoneLLa Tester Strains 
The parent of the strains used in the Ames test is SaLmoneLLa 
typhimurium LT-2, the causative organism of infective diarrhoea 
(20,202). Each of the numerous tester strains contains one of 
several different known mutations of the histidine operon, resul-
ting in a growth requirement for histidine (146). Reversion re-
quires a compensating mutation, almost invariably of the same 
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general type as the original (146). In addition to the basic histi-
dine mutation, the strains possess other mutations which greatly 
enhance their sensitivity to mutagens (202). 
Table 1.1 shows the genotypes of the most useful strains. A set of 
four standard strains (TA97, TA9S, TA100 and TA102) is currently 
recommended for general mutagenicity screening. Used in concert, 
they detect a wide range of mutagen classes with greater efficiency 
than other strains (7,202). The different histidine mutations are 
discussed in the sections dealing with the the individual strains, 
and the additional mutations are described below. 
Table 1.1 Genotypes of Salmonella typhimurium TA Strains Used in Mutagenicity Testing 
Histidine Mutation Additional Mutations 
hisD6610 hisD3052 hi.sG46 hisC20? hisG428 hisC3076 LPS Repa i r R-factor 
his01242 (pKN1Ol! 
TA90 TA1538 TA1535 TA1536 TA1537 rfa UVl"B -R 
(TA97) (TA98) (TA100) TA104 TA2637 rfa uvrB +R 
TA1978 TA1975 TA1976 TA 1977 rfa + -R 
TAl l O TA94 TA92 TA103 TA2425 + + +R 
TA2420 
TA1534 TA 1950 TA1951 TA1952 + uvrB -R 
TA2410 + UV1'B +R 
TA89 TA1964 TA1530 TA1531 TA1532 gal uvrB -R 
TA2641 TA2631 gal uvrB +R 
(TA102) rfa + +R 
TA88 hisDJ052 hisG46 hisC207 hisCJ076 + + -R 
All strains were originally derived from S.typhimurium LT-2. 
Strains in brackets are the current standard tester set (recommended for general mutagenicity screening). 
Abbreviations: LPS; lipopolysaccharide of bacterial cell wall 
+ : wild type gene 
gaZ : "rough" deletion (defectIve lPS) 
rfa : "deep rough" deletion (defective lPS) 
uvrB : deletion of the ultra-violet repair B gene 
R-factor : the plasmid pKM101, which increases error-prone DNA repair 
In TA104. the hisG428 mutation is on the chromosome. whereas in TA102 it is on the multicopy plasmid pAQ1. 
See text for details of mutations. 
Table adapted from 7. 18, 20, 185, 186, 201, and 202. 
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The lipopolysaccharide (LPS) molecules of the normal bacterial cell 
wall act as a barrier to the passage of large molecules, 
many mutagens, into the cell. It is possible to increase 
permeability to these molecules by introducing mutations 
move part of the polysaccharide side-chain of the LPS 
including 
cell wall 
that re-
molecule 
(18). The ga~ ('rough') deletion prevents the synthesis of galac-
tose, causing the loss of that part of the LPS side-chain distal to 
the first galactose unit (18). 
The rfa ('deep rough') deletion prevents the synthesis of a polysa-
ccharide which is distal to the ketodeoxyoctanoate-lipid core of 
the cell wall LPS. This results in the maximum 'stripping' of the 
LPS molecule that is possible without cell lethality, and greatly 
increases the permeability to large molecules (18,202). 
The uvrB mutation inactivates the gene coding for the DNA excision 
repair system, resulting in greatly increased sensitivity to muta-
gens that form repairable DNA lesions, without quantitatively alte-
ring the mutagenic response (18,21,22,202,214). Intercalating 
agents are equally effective on uvrB- and uvrB+ strains, but com-
pounds that alkylate as well as intercalate are detected with much 
increased sensitivity with uvrB- strains (8). The uvrB deletion 
also extends through the ga~, nitrate reductase (ch~) and biotin 
(bio) genes (the latter resulting in a requirement for biotin) 
(186,202). 
The four standard tester strains all contain the R-factor plasmid, 
pKM10l, which increases chemical and spontaneous mutagenesis by 
enhancing the rate of error-prone DNA recombinational repair (202, 
216,279). Strains containing the plasmid show a marked increase in 
sensitivity to mutagens, especially those that cause DNA damage 
that is not directly mutagenic, but becomes so when repaired by 
error-prone repair. 
The details of these additional mutations are presented by Ames et 
a~. (18), and the development of the current tester strain set, and 
the characteristics of the less frequently used strains are well 
documented (8,13,14,18,21,22,76,146,185,186,202,215,216). 
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1.5.4.1 TA 9? : Frameshift Mutagens 
Runs of repetitive base sequences in DNA are often 'hot-spots' for 
frameshift mutagenesis. Shifted base pairings may occur more easily 
in these repetitive sequences (212), and frameshift mutagens can, 
by intercalation into the DNA structure, stabilize the mispairings 
by restoring the correct reading frame for histidine biosynthesis 
(202). The critical site for reversion in TA9? is such a run, 
consisting of six cytosines (hisD6610). The development and charac-
terization of TA9? (outlined briefly below) is detailed by Levin et 
aZ. (186), and the lineage of hisD6610 shown in Figure 1.1. 
VAL -T H"·Pwo-Gi.U-6t.u-- I u -AIJ,-Au.-Au-Gc.u-Au-AAG 
GIJC ACC CCU 6M GAG AOC GeC GeC GeC GGe GCG CGIl ! + C <ICR·1911 
GOC ACC cec UGA 1 .. CA (SPOftTAHEOUS) 
VAl-THlit-PIIO-PRo-Gt..!J"'Gt..tt- lu •• • 
GUC ACA CCC CCU 6M GAG AUC 1 .. C (9-""UNOACAIDINE) 
GUC ACA CCC CCC UGA 
HlsD3018R7 
Figure 1.1 : Lineage of the hisD6610 mutation of TA97 (185) 
The wild-type strain, S.typhimurium LT-2, has four cytosines in 
the hisD gene (which encodes for histidinol dehydrogenase) of the 
mRNA. Another cytosine is added to this by mutagenesis with ICR-191 
(an acridine half-mustard derivative) to form the hisD3018 muta-
tion. A spontaneous revertant of hisD3018, designated hisD3018R7, 
has an extra proline triplet, due to the insertion of two additio-
nal bases in the run of cytosines at the hisD3018 site. Another 
cytosine is introduced to hisD3018R7 by the frameshift mutagen 
9-aminoacridine, resulting in a run of six cytosines, the hisD6610 
mutation. There is also a run of alternating -G:C- base pairs 
several codons to the 3' side of the hisD6610 mutation (see Figure 
1.1), constituting another 'hot-spot' (186). 
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Note on TA97: Subsequent to the completion of this research, TA97 
has been replaced by a new strain TA97a. This new strain was con-
structed from TA97 in response to difficulties encountered with the 
strain, namely, poor viability and growth, pin-point colonies , and 
hypersensitivity to mutagen toxicity. TA97a has a smaller uvrB 
deletion than TA97, and is claimed to lack the disadvantages of 
TA97, while still retaining a mutagenic response identical to its 
parent (7,201). 
1.5.4 .2 TA 98 : Frameshift Mutagens 
The hisD3052 mutation is 
nesis with ICR 364-0H, 
introduced into the wild strain by mutage-
detailed by Isono and Yourno (146), and 
shown in Figure 1. 2. It arises from the deletion of a single -G:C-
pair from the hisD gene, and results in a nonfunctional gene pro-
duct (146). Close to this original -1 frameshift mutation is a rare 
mispairing-prone sequence of eight repeating -G:C- pairs, another 
'hot-spot' for frameshift mutagenesis. Restoration of the original 
base sequence (replacing the deleted cytosine) is extremely rare 
with hisD3052 (146). However, deletion of a -G:C- base-pair doub-
let early in the repeating sequence restores the normal reading 
frame in the mRNA, except for the sequence between the two frame-
shifts (146,212). Hence a gene-product is synthesized with only a 
short region of wrong codes (212). 
Wild Type 
Mutation to tester strain 
Tester Strain 
Treatment with chemical mutagen 
Revertant Strain 
leu 
Figure 1.2 
framesh I ft 
Deleted Nucleotides-L 
Frameshift 
Pm Mg Gly 
Deleted Nucleotide 
Ace Gee eGG C A G G C • _...J _ 
Thr AI.a 
Frameshift 
His Mg Glo 
'Gln " Ala , 
, , 
AI, 
, 
I , 
, 
, 
Formation and reversion of the hisD3052 
detecting mutation of TA98 (212) 
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TA100 contains the hisG46 mutation in the gene which encodes for 
the first enzyme of histidine biosynthesis (22,104). The substi t u-
tion of a cytosine nucleotide for a thymine changes the RNA triplet 
code to encode for proline instead of leucine (Figure 1.3) (21,202, 
212). The incorporation of proline, which disrupts the secondary 
structure of proteins, results in a nonfunctional enzyme. Reversion 
to a functional gene can occur either by restoration of the origi-
nal wild-type code, or by a variety of extragenic suppressor muta-
tions (22,197,212). The lack of specif ic ity of the revertant codes 
may explain why strains containing hisG46 are so efficient for 
detecting a wide variety of base-pair substituting mutagens acting 
at one of the -G :C- pairs, since almost any base change that re-
sults in an amino acid other than proline will allow the enzyme to 
function (202,212). 
Wild Type 
Mutation to tester strain 
Tester Strain 
Treatment with chemical mutagen Base-Pair 
Mutation 
---+-.-rr -- ----- -- r-.- - r t -r-;-i-,- '-1-- - ----
---J . J-..!. -'- ----- ---- r' _:_1_:A:C! C d_._T'_1_1..,.' _____ _ I I I Thr 
Revertant Strain 
- - -~-T-, -:---------r-:-; :T;CIC ri -~,- ,-i-- - --- · 
___ ~...J __ !.._~ _ --------~J_L I 'Ser' ...1_L,._'_"!"...,. ___ --- . 
---t-:-,-r --- ----- 7-;- ~~C' A J C .--- -1-1- -~-- --
___ •. ...1 _ _ 1-.1 ___ _ ____ .L_l....L . ' , ! :_l _:_ r_~i- ____ ~~ 
,I I I His 
-- - ~ --;- -;- -; - - - - - - - - -~ - r T -! C I T I C ,- '--:-- ~ ,. -:-7 - - - -- --
___ }-_ I_.L~_--------~-I_L ' , ! I L-L_I_,_..l._I _______ _ 
I I leu I I : 
Figure 1.3 : Formation and reversion of the hisG46 base-
paIr substitution detecting mutation of TA100 (212) 
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1.5.4.4 TA 102 : Oxidizing Mutagens 
TA102 detects the oxidizing mutagens, which may be the most impor-
tant class of mutagens contributing to cancer and , more controver-
sially, to aging (12,74,185,202). These mutagens, which are not 
detected by the other strains, include X-rays, mitomycin C, 
bleomycin, hydroperoxides and quinones; a variety of aldehydes and 
psoralens, and UV light (185,202). The unique sensitivity of TA102 
is due to its ochre histidine mutation, hisG428 , selected as the 
histidine mutation best reverted by oxidative DNA damage (185). 
HisG428 has -A:T- base pairs at the critical site for reversion, 
not the -G:C- pairs of the other histidine mutations (202). The 
sensitivity of TA102 to reversion was increased markedly by increa-
sing the number of copies of the histidine mutation in each cell 
(185,202). 
Pst! 
C (wild type) 
I 
-CAAGTAAGAGC· 
hisG428 
ochr 
hisG 
pAQI 
6662 bp EcoRI 
Figure 1.4 : Structure of the multicopy plasmid, pAQl, 
of TA102, showing the ochre mutation, hisG428. Tc r : 
tetracycline resistance marker (185) 
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This was achieved by the cloning of the hisOGDC region (which 
includes the hisG428 mutation) onto a multicopy plasmid, pAQl 
(Figure 1.4), which also carries a marker for tetracycline resist-
ance (the basis of the genotype confirmation test for TA102). This 
plasmid was then introduced into a Salmonella strain which con-
tained both the rfa marker and the pKM10l plasmid, forming the 
tester strain TA102. Because the detection of cross-linking muta-
gens requires an intact DNA excision repair system, TA102 was 
constructed with a uvrB+ background (185,202). 
It has been determined that there are about 30 copies of pAQl and 
7-8 copies of pKM10l per cell (185). The sensitivity of TA102 to 
mutagens is increased five- to twelve-fold (and SRF increased by 
six-fold) over strains with the hisG428 on the chromosome (e.g. 
TA104), rather than on a multicopy plasmid (185,202). 
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CHAPTER 2 THE METABOLISM ANO MECHANISM OF MUTAGENICITY OF THE TEST 
MUTAGENS 
2.1 CHOICE OF MUTAGENS 
Each of the four standard tester strains detects a different class 
of mutagenic compound; for this reason, mutagens were selected, for 
each tester strain, which are representative of the class detected 
by the strain. It is known, however, that some of the tester com-
pounds may cause more than one kind of mutation and, therefore, may 
also be detected by others of the tester strain set. 
Wherever possible, mutagens were selected from those to which human 
environmental exposure may be significant. However, the choice of 
mitomycin C was largely governed by the sensitivity of TA102, which 
detects oxidizing mutagens . 
Compounds which require metabolic activation for mutagenicity were 
chosen for this study, in order to investigate the efficiency of 
different pretreatments of the liver on this activation. Although 
the mutagenicity of mitomycin C may be detected without the incor-
poration of a microsomal fraction, metabolic activation has been 
reported to enhance the mutagenic response several-fold (184,185). 
2.2 DIMETHYLNITROSAMINE 
Dimethylnitrosamine (DMN) is representative of a large class of 
compounds, the nitrosamines, which are metabolically activated to 
potent carcinogens. 
Exposure to nitrosamines is primarily brought about through the 
intragastric nitrosation of dietary nitrate and nitrite (as well as 
other nitrogen-containing compounds) (11,141). This nitrosation is 
catalysed by the nitrate reductases of the bacterial flora normally 
resident in the gastrointestinal tract and is optimal under weakly 
acidic conditions (11,141,256). Although the use of nitrates and 
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nitrites as food preservatives is much less prevalent today than in 
the past, DMN can be detected in human blood after the ingestion of 
a normal meal, and it has also been found in stored meat, fish, 
cheese, alcoholic beverages, vegetables and vegetable oils, as well 
as in pesticides and drinking water (141). 
Although DMN is carcinogenic in several species (reviewed in the 
rARC monograph (141)), and mutagenic in DrosophiLa, it cannot be 
detected in bacterial mutagenicity assays, nor in Neurospora, with-
out the incorporation of an hepatic microsomal (59) fraction. This 
phenomenon is thought to be due to the inability of the micro-
organisms to perform the metabolic dealkylation of DMN, which 
yields mutagenically reactive metabolites (95,127,197,237). 
As well as inducing tumours in rat liver, kidney, and lung, DMN has 
acute toxicity, causing haemorrhagic centrilobular necrosis of the 
liver, damage to the hepatic central veins, and less severe injury 
to other organs (primarily the kidney) (195). 
DMN undergoes oxidative demethylation in the liver, a process 
catalysed by the microsomal enzyme, DMN demethylase, and the reac-
tion exhibits a requirement for NADPH and molecular oxygen, indica-
ting the participation of cytochrome(s) P-450, the terminal oxidase 
of the microsomal MFO system (Figure 2.1) (8,13,71). The products 
of dealkylation are formaldehyde (which is rapidly converted to CO2 
and released in expired air), and the unstable monomethylnitros-
amine. This monomethyl derivative apparently decomposes spontan-
eously, both in vitro and in vivo, to yield 
the methyl carbonium and diazomethane ions 
221,223,238) . 
The alkylating metabolites of DMN react with 
including DNA, RNA and prot eins (195,220). 
two alkyl ating species, 
(38,71 ,95, 195 , 198 ,220, 
cellular nucleophiles, 
The active DNA alkyla-
ting agent is not the diazoalkane, but the carbonium ion, which 
alkylates the N-7 position of guanine, as demonstrated with deuter-
ated DMN in rats (95,190,195,197,220). This position (N-7 of 
guanine) is the preferred position for alkylation of double-stran-
ded DNA (95,220). 
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CH 3, N .NO 
CH ,.-
3 
j 
Dimethylnitrosamine 
DMN demethylase 
NADPH, O2 
Monomethylnitrosamine [C:3;N.NO] + HCHO Formaldehyde 
1 
[CH3N2+OH-] Diazomethane Ion 
1 
[ CH3 +J+ N2 Methyl Carbonium Ion 
1 R = DNA, RNA, protein 
Figure 2.1 : Metabolic biotransformations of 
dImethylnItrosamine (adapted from 195,197,222) 
N7-methYlguanine readily ionizes to a form of the base which can 
pair, through hydrogen bonding, with the normally noncomplementary 
base, thymine (220). This constitutes a G-A base-pair transition 
(base-pair substitution mutations involving transitions always 
retain pyrimidine:purine pairings, \~hereas transversions can pro-
duce purine:purine or pyrimidine:pyrimidine pairings) (13,80,95). 
As well as causing transitions initially, N7-alkylation of guanine 
may, much more slowly, cause the hydrolysis of guanine from DNA 
(depurination), and consequently, cleavage of the DNA backbone (80, 
95,220) . 
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• False negative results are obtained with DMN in the standard plate-
incorporation Ames assay, with both uninduced and induced rat 
hepatic S9 fractions. However, DMN can be detected as mutagenic 
when the preincubation modification of the Ames test is utilized 
(16,38,214,237,238,278,307). The failure of the standard test was 
thought to be the result of the short-lived, but highly reactive, 
alkylating metabolites of DMN becoming trapped on the nucleophilic 
hydroxyl groups of the soft agar component, and so being unable to 
reach and methylate the nucleophilic groups of the bacterial DNA 
(36,38,50). Now, however, it is attributed to insufficient enzyma-
tic activation in the standard assay (the mutagen, S9 fraction, and 
bacteria are generally incubated at higher concentrations in the 
preincubation assay) (16,207,214,237,238). 
In support of this latter hypothesis, it has been found that, if 
the concentrations of S9 or DMN in the preincubation assay are 
reduced to those of the standard test, little or no mutagenicity 
results. However, when the concentrations of the standard assay are 
increased to those encountered in preincubation, the mutagenic 
response is equal to that found in the preincubation procedure 
(238). 
Kinetic data have demonstrated that DMN demethylase exists in two 
forms, with different substrate affinities (26). In the rat (and 
the mouse), the apparent Km values of these forms are 0,2 mM and 
51 mM, and the two isozymes appear to be controlled independently 
by enzyme inducers (26,238). These considerations suggest that more 
than one cyt(s) P-450 species (and possibly, other types of enzyme) 
may be involved in DMN activation (26). 
Induction of the rat, hamster, or mouse hepatic microsomal MFO 
system with PB or 3MC causes a two-fold increase in the activation 
of DMN to mutagenic metabolites, although, in vivo, such induction 
appears to protect these species from the acute toxiCity and 
carcinogenicity of DMN (38,71,195). 
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2.3 AFLATOXIN B1_ 
Aflatoxin Bl (AFB 1) is a mycotoxin produced by Aspergillus flavus 
and A.parasiticus, as well as, under some conditions, by A.oryzae 
(136,195,278,304). These widespread fungi thrive on grain and grain 
products under moist storage conditions, though virtually all food-
stuffs have potential for aflatoxin contamination (140,278). 
AFBl is the most potent hepatocarcinogen known in rats, and it is 
also carcinogenic in several other species, including the primates 
(136,140,195,223,273,278,304). Positive correlations between the 
intake of aflatoxin-contaminated dietary stap le and the incidence 
of hepatic carcinoma are reported from Central and Southern Africa, 
and also from Thailand, providing circumstantial evidence for a 
causal relationship in man (140,222,223). AFBl is also mutagenic in 
most submammalian test systems incorporating an hepatic microsoma l 
system (136,140,195,273). 
OCH" 
Figure 2.2 Aflatoxin B1 (304) 
The molecule consists of a bisulfuran ring system, fused to a 
substituted cyclopentanone moiety, with a methoxy group attached to 
carbon-9 of the benzene ring (see Figure 2.2) ( 100,136,195,223, 
304). The 2,3-vinyl ether double bond, methoxy group, and cyclo-
pentanone ring are each crucial to toxicity, and any alteration of 
these structural features decreases the mutagenic activity of AFB1 
( 136 ,304) . 
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Although AFB1 is, itself, unreactive towards nucleophiles, nucleic 
acid- and protein-bound radioactivity, after administration of 3H_ 
labelled AFB 1, suggests the metabolic conversion in vivo to mutag-
enically active intermediates (100,195). In addition, AFB1 requires 
a microsomal enzyme fraction and an NADPH-generating system for 
mutagenicity in Sa1mone11a (136,140,278,304). The hepatic biotrans-
formations of AFB 1, both various oxidative conversions catalysed by 
the microsomal mixed-function oxidases, as well as reduction by the 
cytoplasmic reductase system, are shown in Figure 2.3 (136,140,165, 
223,267,304) . 
Of the AFB1 metabolites isolated and tested in the Sa1mone11al 
microsome assay, aflatoxicol is the most mutagenic, followed by 
aflatoxin 01 and aflatoxin M1 with low activity, and then afla-
toxin P1 and aflatoxin B2a , which are both nonmutagenic 
(100,213,267,304). All these metabolites are, however, less mutage-
nic than AFB 1, a finding which implies that none is the ultimately 
toxic AFB1 metabolite, and that they may be detoxification products 
(304) . 
Although its high reactivity precludes its isolation, it is thought 
that the AFB1 metabolite, which is the ultimate mutagen , may be the 
AFB 1-2,3-epoxide (136,140,195,267,273,304). Evidence in support of 
epoxidation has come from the isolation of 2,3-dihydro-2,3-
dihydroxy-AFB 1 from mi ld-acid hydrolysates of covalent adducts of 
AFB1 with nucleic acids and proteins (dihydrodiols are detoxifica-
tion products of epoxide hydrase activity) (40,100,136,195,223,304). 
An electrophilic carbonium ion, formed at C-2 of the AFB1 epoxide, 
is stabi lized by lone electron pai'rs on the oxygen atom of the 
reduced furan, and it is proposed that covalent adduct formation 
may occur between this ion and a nucleophilic oxygen or nitrogen of 
either a nucleic acid or a protein (195,273). The major DNA adduct 
is between the AFB1 epoxide and the N-7 atom of guanine (2,3-
dihydro-2-(N7-guanyl)-3-hydroxy AFB 1), this being the preferred 
site of alkylator action, as it resides in a sterically accessible 
position in the major groove of DNA (223,273). This alkylation can, 
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Figure 2.3 Metabolic biotransformations of aflatoxin Bl (adapted from 136, 223, 304) 
OH 
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in a similar manner to that described in Section 2.2, result in a 
G-A transition (a base-pair substitution mutation) (273). Although 
simple methylation or ethylation of guanine can induce such base-
pair substitution, the large polycyclic AFB1 molecule is also 
capable of frameshift mutations through intercalation with DNA 
(although the relative frequencies of the two mutation types is 
unknown) (216,223). 
Unlike the metabolic activation of other polycyclic hydrocarbons, 
the epoxidation of AFB1 is catalysed by a cytochrome P-450 isozyme 
which is preferentially inducible by PB (antibodies against this 
isozyme inhibit AFB1 mutagenicity by 60-75%) (165,267). The cyto-
chrome P-448 isozyme supports the hydroxylation of AFB1 to the 
weakly mutagenic AFM1 (267). The induction of rat liver microsomes 
with PB increases the mutagenic response to AFB1 in the Ames test 
(121,267), although, in vivo, induction appears to protect animals 
from the carcinogenic effects of the mycotoxin (120,121,195,217). 
AFB1 toxicity has been found to depend, not only on the catalytic 
activity of the oxidase isozyme, but also on the level of induction 
of the isozyme in the microsomal fraction (165) as well as on the 
balance between activating phase I metabolic reactions (epoxida-
tion), and detoxifying, phase II reactions (primarily conjugation 
with glutathione) (195,267). Therefore, the susceptibility of a 
species to AFB1 carcinogenicity may reflect the net bioactivation 
resulting from the simultaneous activities of various metabolic 
pathways in the liver (136). 
2.4 BENZO{a)PYRENE 
Benzo{a)pyrene (BP), a product of the incomplete combustion of 
organic matter, is representative of the polycyclic hydrocarbons 
(PCH). It is a component of automobile and industrial exhaust 
fumes, as well as of cigarette smoke, and it is also formed in the 
preparation of many cooked and smoked foods (262,264). The environ-
mental occurrence of BP, as well as its carcinogenicity, are 
reviewed in the IARC monograph (138). 
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Figure 2.4 Benzo(a)pyrene (264) 
The BP molecule itself has no sites of high chemical reactivity 
(Figure 2.4). Sufficient reactivity for covalent interaction with 
cellular nucleophiles (including DNA) is introduced however by 
enzymatic epoxidation at various positions (119,195,223,262,302). 
The further metabolism of BP is complex, involving some transforma-
tions which serve to deactivate and eliminate these active interme-
diates, and others which potentiate their toxicity (119,157). 
Figure 2.5 summarizes the proposed metabolic transformations of BP, 
while some of the possible fates of the active electrophilic inter-
mediates are illustrated by the three pathways (A, B, and C) shown 
in Figure 2.6. 
The first metabolic transformation of BP to electrophilic species 
consists of the formation of either the K-region epoxide, BP-4,5-
oxide (Figure 2.6, C), or the non-K-region epoxides, primarily BP-
7,8-oxide and BP-9,10-oxide (Figure 2.6, A and B). The formation of 
the K-region epoxide is supported by a cytochrome P-450-dependent 
mono-oxygenase, which is inducible by PB, whereas the non-K-region 
epoxidations are catalysed by a mono-oxygenase which is inducible 
by 3MC (151,157,172,267). It has been suggested that these enzymes 
may be two forms of the same mono-oxygenase, aryl hydrocarbon 
hydroxylase (AHH), one form being inducible by PB, and the other 
inducible by 3MC (195,233,290). 
The epoxides (or arene oxides) may spontaneously isomerize to form 
phenols (Figure 2.6, B), undergo conjugation with glutathione 
(catalysed by glutathione-s-transferases) (Figure 2.6, C), or may 
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be converted to dihydrodiols by the microsomal enzyme epoxide 
hydrase (Figure 2.6, A) (58,119,159,188,195,262,305). The phenols 
may be oxidized, either spontaneously, or by a mono-oxygenase, to 
form Bp-quinones (Figure 2.5) (58,59,262). These quinones are 
redox-active agents, which can accept electrons enzymatically from 
NADPH to produce hydroquinones, or, when reduced, may donate elec-
trons to molecular oxygen to form quinone oxides (59,157). The 
phenols may also undergo a second oxidation (mediated by a mono-
oxygenase which is inducible by 3MC) to form the phenol oxides 
(Figure 2.5) (58,116,287). Both the phenols and quinones of BP have 
little, or no, inherent mutagenic activity, but their respective 
oxides have the potential for covalent interaction with DNA. How-
ever , they are not thought to contribute significantly to the 
mutagenicity of BP (58,157,159,287,303,306). The phenols, dihydro-
diols, and the hydroquinones are all substrates for UDP glucuronyl-
and sulpho-transferases, and the polar conjugates so formed (which 
are also mutagenically inactive) are readily excreted (58,115,116, 
119,150,264). 
The conjugations with glucuronide, sulphate, or glutathione are 
true phase II detoxific~tion reactions. While hydration by epoxide 
hydrase (EH) is also considered to be a detoxification pathway, 
this enzyme also plays a role in the further activation of BP (119, 
172). In the special case when the dihydrodiol formed by EH is on 
an angular benzene ring (a so-called 'bay region'), as is the case 
with BP-7,8-dihydrodiol, a secondary oxygenation by the microsomal 
mono-oxygenases produces a 'vicinal diol-epoxide', BP-7,8-dihydro-
diol-9,10-oxide (Figure 2.5 and Figure 2.6, A) (58,116,172,267,306). 
Early observations suggested that the K-region epoxide was the 
ultimate carcinogenic BP metabolite. Certainly, BP-4,5-oxide has 
been found to be a potent alkylating mutagen in bacteria and 
isolated mammalian cells, whereas the non-K-region epoxides are 
only weakly mutagenic in these systems (137,167,188,251,303,305). 
However, BP-4,5-oxide (and BP-9,10-oxide) induced few, if any, 
tumours when applied to the skin of mice, whereas the BP-7,8-oxide 
was found to be highly carcinogenic in the mouse-skin test (119,157, 
251,303,305,306). 
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In addition. the incorporation of an hepatic microsomal fraction. 
or of purified EH. into in vitro mutagenicity test systems (inclu-
ding SaLmoneLLa). completely eliminated the mutagenicity of BP-4.5-
oxide. while the number of mutations induced by BP-7.8-diol-epoxide 
was unchanged. or considerably enhanced (306). Hence. while BP-4.5-
oxide may account for a significant amount of DNA-binding in the 
absence of EH. it is rapidly deactivated by EH. and it is excreted 
either unchanged. or as the glucuronide (119.157.306). The diol-
epoxides on the other hand are poor substrates for EH because of 
steric hindrance by the 7.8-diol 
deactivation by way of hydrolysis. 
nonenzymatic (119.157.167.306). 
group. and. therefore. their 
to form tetrols. is primarily 
It is now thought that it is not BP-4.5-oxide but the vicinal 
epoxide. BP-7.8-diol-9.10-oxide. produced from BP-7.8-oxide through 
the secondary mono-oxygenation of BP-7.8-diol. that is the ultimate 
carcinogenic BP metabolite (116.119.137.157.262.305.306). In parti-
cular. the (+)anti-BP-7.8-diol-9.10-oxide enantiomer has been iden-
tified as the major DNA-binding metabolite in several biological 
systems. including mouse skin. rodent embryo cells. and human 
bronchial transplants (131.150.151.306). This epoxide is also more 
mutagenic than the primary epoxides both in bacterial and mammalian 
cells (151). 
DNA-binding by BP metabolites was enhanced about three-fold in the 
presence of Tepa (1.2-epoxy-3.3.3-trichloropropane). an inhibitor 
of EH activity. although BP-dihydrodiol formation was completely 
prevented. This indicates that an electrophilic metabolite(s). 
other than those derived from the BP-7.8-dihydrodiol. may contri-
bute to DNA-binding (58.150). There is evidence that an active 
electrophilic product of 9-hydroxy BP is an important DNA-binding 
species. and it has been tentatively identified as the 4.5-epoxide 
of 9-hydroxy-BP (116.150.151.167). 
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Susceptible sites for the binding of the reactive intermediates 
formed from BP-7,8-diol have been shown to involve the exocyclic 
and N-7 nitrogen atoms of guanine, the exocycl ic nitrogen of 
adenine, and phosphate; the sites involved in the binding of 9-0H-
BP intermediates are largely unknown (116,149,150). 
The profile of the primary metabolites of BP, as well as the prop-
ortions of the major ONA-binding intermediates (BP-7,8-dihydrodiol-
9,10-oxide and 9-hydroxy-BP-4,5-oxide) are altered significantly by 
enzyme inducers such as 3MC and PB (150,151). Induction with 3MC 
resulted in DNA-binding by product(s) of 9-0H-BP, almost exclusive-
ly, while induct ion with PB was associated with the binding of BP-
4,5-oxide and product(s) of BP-7,8-dihydrodiol to DNA (151,245). 
EH is inducible by PB and also, to a much lesser extent, by by 3MC 
(149,245). Following pretreatment with PB, the principle dihydro-
diol formed was the 4,5-dihydrodiol, with the production of other 
diols little increased over controls; after pretreatment with 3MC, 
the production of all three dihydrodiols was enhanced, with that of 
the 9,10-dihydrodiol increased to the greatest extent (245). 
The overall activation of BP in rat liver microsomes, to mutageni-
cally active intermediates, appears to be preferentially mediated 
by a cyt P-448-dependent mono-oxygenase; induction by 3MC enhanced 
the activation of BP four- to thirty-fold (20,132,267). In addi-
tion, monospecific antibodies against cyt P-448 purified from the 
livers of rats pretreated with 3MC were found to inhibit the 
mutagenicity of BP completely (165,267). 
In the metabolism of BP then, several pathways exist which activate 
intermediates to DNA-binding or mutagenic species, and these are 
variously affected by different types of enzyme inducers. There are 
also a number of pathways by means of which the active metabolites 
can be detoxified. These include various conjugation reactions as 
well as hydrolysis by EH, which is similarly affected by different 
inducers and also plays a part in reactivation of certain dihydro-
diols. The enzyme-catalysed addition of glutathione, a polar tri-
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peptide and general scavenger of electrophiles within the cell, may 
be another pathway of deactivation for the primary epoxides 
(58,119,131,150). The formation of glutathione conjugates of the 
diol-epoxides has been postulated but not directly demonstrated 
(119). Nonspecific binding of the active intermediates of BP to 
macromolecular nucleophilic sites in the cell may also constitute a 
pathway of deactivation (116,150). 
It appears then that the balance between the pathways of activation 
and those of detoxification is critical with regard to the net 
activation and resulting mutagenicity of BP. This 'balance' affects 
not only the total amount of DNA-bound metabolites but their 
relative proportions as well (58,116,150,157,267). 
In the Ames test, BP is detected, after metabolic activation by an 
hepatic microsomal fraction, as a reactive mutagen capable of both 
frameshifts and base-pair substitutions (281). BP is detected wi th 
greatest efficiency in strains containing the R-factor (186,216). 
2.5 MITOMYCIN-C 
Mitomycin C (MMC) , an antitumour antibiotic isolated from Strepto-
myces caespitosus (70,140,192), is active against a variety of 
human malignancies (70,192). Although human data are not available, 
MMC has been found to be carcinogenic in mice and rats (140), and 
has been detected as an oxidizing mutagen in several short-term 
mutagenicity assays (140,221). MMC has limited mutagenic activity 
in the the Ames test without the incorporation of an hepatic micro-
somal fraction, but the inclusion of 59 increases the mutagenic 
response several -fold (140,184,185,202,216). 
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Figure 2.7 Mitomycin C (193) 
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The MMC molecule (Figure 2.7) possesses three potentially reactive 
groups: a quinone nucleus, an aziridine ring and a carbamate group. 
After chemical or enzymatic reduction, MMC becomes a reactive 
bifunctional alkylator, although it is also capable of causing 
other DNA lesions (147) . In its natural oxidized form however MMC 
shows hardly any alkylating function; it is thought that this lack 
of reactivity may be related to the partial withdrawal of electrons 
from nitrogen-4 into the quinone ring (Figure 2.8, A) (147). 
10 ~ 
:,CH20CNH2 
Figure 2.8 
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NADPH~dependent enzymatic reduction of the quinone ring (Figure 
2.8, 8), by two consecutive 1-electron steps to form the hydroqui-
none, is a prerequisite for MMC activation in vivo (147,192,246). 
The subsequent spontaneous loss of the tertiary-9a-methoxy group 
(Figure 2.8, C) is probably caused by the regaining of the elec-
trons by nitrogen-4, coupled with the high driving force for the 
formation of the fully aromatic indole system (12,70,147,185,247). 
The loss of the methoxy group facilitates the opening of the 
aziridine ring (Figure 2.8 , D) because of the stabilization of the 
positive charge by the indole ring which occurs in the transition 
state of the reaction before ring fission (Figure 2.8, E) (147). 
This event results in an alkylating carbonium ion being exposed at 
carbon-1 (147). A second carbonium ion arises at carbon-10 of the 
substituted indole (Figure 2.8, F), once again due to the stabili-
zation of the positive charge by the indole nitrogen, but also 
because the carbamate ion is a good leaving group (70,147,192). 
These two resonance-stabilized electrophilic centres account for 
the bifunctional alkylating activity of MMC and, therefore, for its 
ability to cause DNA cross-linking (Figure 2.8, G) (95,192,247). 
The presence of interstrand cross-links in DNA has been confirmed 
with the ethidium fluorescence assay and by Sl-endonuclease sensi-
tivity (192,193). It is thought that the carbonium ion at carbon-1 
is the first to bind covalently to DNA (as the aziridine ring 
opens), followed by that at carbon-10 (192,247). The most likely 
sites for interstrand linkages by MMC seem to be those between the 
amino groups of adenines or cytosines and the oxygen groups of 
guanine (especially oxygen-6) (147,192). The intercalation of the 
MMC ring system into the DNA double helix may be a preliminary step 
to the covalent cross-linking of DNA (94). 
Monoalkylation of DNA is a potentially mutagenic event (base pair 
substitution), and it may also lead to depurination, which often 
results in single DNA strand breaks. DNA crosslinking on the other 
hand prevents replication; further DNA synthesis ceases whenever 
the replicating fork reaches a crosslink (80). In addition, mono-
33 
alkylation presents a more easily-repairable DNA lesion than cross-
linking . Therefore, although DNA cross-linking by MMC is less 
common (by a factor of ten-twenty) than monoalkylation, the former 
is more likely to constitute a lethal cytotoxic event rather than a 
mutagenic one (192,193,247). Both monoa lky lation and the concomi-
tant (interstrand and intrastrand) DNA cross-linkage increase pro-
portionally with the guanine and cytosine content of the DNA (70, 
147,192,193) . 
In addition to both alkylation and DNA cross-linkage, MMC has also 
been shown to degrade DNA by means of successive cyclic redox 
processes 
hydroxyl 
with oxygen, resulting in the production of reactive 
free radicals (12,185,192,247). The presence of free 
radical intermediates has been confirmed by electron paramagnetic 
resonance spectroscopy (246). 
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The proposed mechanism for cleavage of DNA by free radicals is 
outlined in Figure Z.9. 
The antibiotic, after reduction by NADPH to the hydroquinone (MHZ) 
(step 1), is reoxidised to produce the semiquinone (MH·) and the 
hydroperoxy radical (HOZ·) (step Z). The latter species exists in 
equilibrium with the superoxide anion (0/) (step 3) . The cell is 
normally protected from the latter by the enzyme superoxide 
dismutase (step 4) and, similarly, the enzyme catalase removes HZOZ 
(step 5). Hydroxyl radicals (OH·) are thought to be generated by 
the reaction of HZOZ with traces of iron complexed with either 
protein or with ATP in a Fenton-type reaction (steps 6 and 7). 
Hydroxyl radicals are very short-lived, but they may give rise to 
membrane lipid peroxidation and/or DNA damage if formed in close 
proximity to these cellular macromolecules (95,193). The degrada-
tion of DNA by the OH· radical is thought to occur in a series of 
reactions involving initial hydrogen abstraction from position-4 of 
the ribose (19Z,193) (Figure Z.9). 
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Figure 2.10 summarizes how species are formed from MMC, which may 
either alkylate, cross-link, depurinate, or cleave DNA (in cyclic 
redox processes). 
TA102 is the only strain of the standard set that can detect MMC 
since this strain has an intact (uvrB+) DNA excision repair system 
(185,186,202,214,216,277). DNA cross-link ing is lethal to those 
Salmonella strains which lack a functional repair system (uvrB-) 
(185,186,201,202). Detection of MMC also requires a strain which 
contains the R-factor (185, 186 ). Previously, mutational reversion 
of TA102 by MMC was attributed to -A:T- base pair substitution at 
the hisG428 ochre mutation (see Section 1.5.4.4), but it has 
recently been shown that the antibiotic reverts by causing extra-
genic suppressor mutations (7). 
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CHAPTER 3 THE ENDOGENOUS FEMALE SEX STEROIDS 
3.1 INTRODUCTION 
The two steroids investigated, 17~-oestradiol (E2) and progesterone 
(PRG), are naturally occurring female sex hormones in all verteb-
rate species. 
E2, shown in Figure 3.1, is the most active of the natural 
oestrogens, which, together with other hormones, are responsible 
for the maintenance of the functions of female sexual organs as 
well as for the regulation of the menstrual cycle in primates, and 
for the oestrus cycle in other mammals (44,139). 
HO 
Figure 3.1 : 17~-Oestradiol (229) 
Progesterone (PRG), shown in Figure 3.2, is the only important 
natural progestin, but many synthetic ones have similar biological 
properties. The normal role of PRG is to prepare the uterus for 
implantation of the fertilized ovum and to maintain pregnancy (139). 
o 
Figure 3.2 : Progesterone (229) 
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Binding Globulin 
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(TEBG) (191). 
a-globulin, Testosterone-Oestradiol 
PRG, secreted by the corpus luteum 
in large quantities during pregnancy, 
plasma glycoprotein (Progesterone Binding 
In this protein-bound form the steroids 
bloodstream and become available to both 
also binds to a specific 
Globulin - PBG) (30,142). 
are transported in the 
target tissues (primarily 
the uterus) and to certain nontarget tissues, which include liver, 
kidney, lung, pituitary, intestine, adrenal, and testes (4,53,276). 
Unbound steroid molecules can pass freely through the cell 
membranes of these tissues, by passive diffusion, due to their 
lipophilic nature and (relatively) small size (22B). 
E2 and PRG are similar in several respects, including their biosyn-
thesis from a common precursor (cholesterol), their molecular modes 
of action, and their metabolism and excretion (51,139). However, 
considerable species- and sex-dependent variation is noticed in 
steroid metabolism, particularly in the proportions of metabolites 
produced and in the types of conjugations they undergo (30,49,142). 
3.2 METABOLISM OF THE F~MALE SEX-STEROIDS 
3.2.1 Introduction 
Both E2 and PRG undergo rapid metabolic conversions to more polar 
metabolites in the cells of certain nontarget tissues. Although 
some peripheral conversions do occur, the liver is the primary 
organ of metabolism (30,106,139,142). PRG has a reported t~ of 
between 3 and 90 minutes (30), and the t~ of E2 is estimated to be 
about 20 minutes (139). 
The principal reactions in steroid metabolism are the oxidative-
reductive interconversions of hydroxyl and keto groups at certain 
positions, catalysed by the steroid dehydrogenases, and the intro-
duction of molecular oxygen, through cytochrome P-450-dependent 
hydroxylations, at various other sites (30,51,53,86,139). 
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Metabolites of the steroids are conjugated to form water-soluble 
compounds, which are eliminated mainly in the urine, often after 
cleavage, reabsorption, and reconjugation in the enterohepatic 
circulation (51,53,106,139). The metabolism of both E2 and PRG will 
be described, together with the common features of their metabolic 
fate. 
3.2.2 Metabolism of 176-0estradiol 
3.2.2.1 Primary Biotransformations 
The major metabolic transformations undergone by E2 are shown in 
Figure 3.3. 
Although E2 and E1 can be interconverted by a 176-hydroxy steroid 
dehydrogenase, the oxidation of E2 to E1 predominates quantitative-
ly (53,106,142,155), so that E1 is the main substrate for the 
subsequent metabolic hydroxylations (44). E1 is converted to E3 via 
the reduction of the 16a-hydroxylated intermediate (44,106). 
The metabolism of the three oestrogens is very similar in charac-
ter; . in rats, nonhuman primates and in humans, transformation 
occurs principally by 2-hydroxylation and, to a lesser extent, by 
the competitive 16a-hydroxylation (44,46,51,57,106,121,142,191). 
High levels of thyroid hormone cause an increase in 2-hydroxylation 
and a decrease in 16a-hydroxylation (91), while in liver cirrhosis, 
2-hydroxylation is diminished and 16a-hydroxylation is enhanced 
(44). A decrease in the oxidation of E2 to E1 is also observed in 
human liver cirrhosis (44). 
Other possible hydroxylation sites are at the aromatic C-4 atom, 
and the cycloaliphatic positions 6, 7,11,14,15 and 18 (44,108). 
About 1% of injected E2 is recovered as 4-hydroxyoestrone from the 
urine of the human (44) . Hydroxylations at C-6 or C-7 of ring B of 
either E1 or E2 are minor pathways in rats (142). 
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Polyhydroxylated (that is, with more than three hydroxyl groups) 
and other polyoxygenated oestrogen metabolites are also reported 
(not shown in Figure 3.3) (44). In rat bile, 2-hydroxyoestriol, 
2-methoxyoestriol, 16~-hydroxy-2-methoxyoestrone, 2,6~-dihydroxy­
oestradiol, 2-hydroxy-16-keto-oestradiol and its 2-methylether, 
have all been identified (44). From human bile, 15~-hydroxyoestrone 
and 15~-hydroxyoestriol (oestetrol) have been isolated, and 2-
hydroxyoestriol has been identified in the urine of human late 
pregnancy (44). 
3.2.2.2 Secondary Biotransformations 
The 2-hydroxyoestrogens ('catechol oestrogens'), and the 4-hydroxy-
oestrogens, may undergo other biotransformations, besides conjuga-
tion (44). 
The most important of these biotransformations is methylation at 
C-2 or C-3 (shown in Figure 3.3), catalysed by catechol-o-methyl-
transferase (44,142). The main methylated metabolite is 2-methoxy-
oestrone, though all the catechol oestrogens are probably 
methylated, as catechol-o-methyltransferase has a relatively low 
substrate specificity (44). 
In both the rat and the human (in vitro), the catechol oestrogens 
may also undergo further oxidation to the semiquinone, followed by 
conjugation with glutathione at C-6 or C-4 (44). 
It is thought possible that further metabolism of the oxidized 
catechol structure may eventually result in the opening of ring A, 
although no conclusive evidence has yet been presented in support 
of this hypothesis (44). 
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3.2.2.3 Conjugation of the Oestrogens 
The polyhydroxylated oestrogens are sufficiently water-soluble to 
be excreted without further modification, but conjugation is a 
prerequisite for the urinary or biliary excretion of all other 
steroids (44). Conjugation occurs mainly in the liver, but also 
takes place in the kidney, and in the intestinal mucosa (44,102). 
E3 is conjugated in the liver as rapidly as it is formed from El 
and E2, and little or none appears free in the blood (142). 
The main conjugating reactions are glucuronidation and, to a lesser 
degree, sulphation of the 2- and 3- methyl ethers of the catechol 
oestrogens (44). Glucuronidation has been reported at ring D, as 
has 'double conjugation' (44). 
Sulphation is catalysed by the cytoplasmic sulphotransferases, 
which appear to utilize 3 '-phosphoadenosine-5'-phosphosulphate as 
the sulphate donor, and also require ATP and Mg2+ (44,102,108). 
Glucuronides are formed from the glucuronide donor, uridine 
diphosphoglucuronic acid (UDPGA), and are catalysed by specific 
UDP-glucuronyltransferases , present in the microsomal fraction of 
the liver and other tissues (51,102,108,294). Glucuronyltransfer-
ases seem to be specific both for the steroid as a substrate, and 
for the position of the steroid to be glucuronidated (44,126). 
Although conjugation is generally regarded only as a prerequisite 
for excretion, it has been reported that oestrone-3-sulphate may 
playa special role (44). It is formed rapidly from E2 in the liver 
and its plasma level exceeds that of E2 by about ten-fold. In 
addition, it may be rapidly reconverted to El by arylsulphatases 
and, then, to E2 by 178-hydroxysteroid dehydrogenase in both the 
liver and the target tissues (44). On the basis of these observa-
tions, it has been proposed that oestrone-3-sulphate, in equilib-
rium with E2 (or E1), may represent a 'storage form' of the free 
and physiologically active oestrogens (44). 
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3.2.2.4 Excretion 
In the human, conjugated oestrogen metabolites are preferentially 
excreted via the kidney, though some may undergo biliary excretion. 
Steroid glucuronides excreted in the bile may be deconjugated by 
the enzymes of the intestinal microflora and reabsorbed into the 
enterohepatic circulation, where reconjugation can occur (53,142). 
In man, most conjugated steroid metabolites are ultimately excreted 
in the urine, with small amounts in the faeces; in the rat, 
however, faecal excretion predominates (44,106,139,142). 
In man, the main urinary metabolites of E2 and El are the 
conjugates of E3, 2-hydroxyoestrone, El , 16-hydroxyoestrone, and 
E2, given in order of decreasing quantitative importance; approxi-
mately twenty other minor metabolites are also eliminated via this 
route (106). Ball et aZ. (32) have reported, however, that urinary 
excretion of 2-hydroxyoestrone during the menstrual cycle reaches, 
or even exceeds, that of E3. During pregnancy, however, the excre-
tion of the 'classical' oestrogens (E l , E2, and E3) predominates, 
as a result of direct oestrogen production by the 'foeto-placental 
unit'(44). 
3.2.3 Metabolism of Progesterone 
3.2.3.1 Primary Biotransformations 
The first transformation in the hepatic metabo lism of PRG (shown in 
Figure 3.4), is the reduction of the ~4_3 ketone group (catalysed 
by 4-ene-reductase, a microsomal cytochrome P-450-dependent en-
zyme), to 5~- and, predominantly, 5e-pregnanediones (51,53). 
The hepatic hydroxysteroid dehydrogenases reversibly reduce the 
keto groups at positions C-3 and C-20. At both positions, ~-hydroxy 
dehydrogenases are more active in humans, 
steroid form predominates (53) . In rats, 
formation is significant (280) . 
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The metabolism of PRG in extrahepatic, nonendocrine tissues, for 
example the uterus, appears to differ somewhat; the main 
metabolites here have been found to be 5~-pregnenes, with 3~- and 
20~-hydroxyl groups (51). 
3.2.3.2 Conjugation and Excretion 
As in the case of the oestrogens, the progestins are conjugated, 
with either glucuronic acid or with sulphuric acid, and then 
excreted, primarily in the urine (about 50-60% of a labelled dose). 
Although about 30% of a labelled dose of PRG is originally excreted 
in the bile, only about 10% is eliminated in the faeces, a finding 
which indicates that considerable reabsorption into the enterohepa-
tic circulation occurs (30,106,139,142). 
In humans, the main urinary metabolite has been found to be the 
glucuronide of 58 pregnan-3~,20~-diol (pregnanediol) (30,106,108). 
About 5% of an administered dose of PRG is excreted in the form of 
pregnanolones, and about 2% as pregnanediones (51). PRG itself does 
not appear in the urine, except for the small amounts which have 
been detected in late pregnancy (30). 
In the rhesus monkey, and in some other nonhuman primates, 
pregnanediol is only excreted in trace amounts, yet PRG metabolism 
in the chimpanzee and baboon resembles the human pattern much more 
closely (30). 
3.2.4 Metabolism of the Synthetic Steroids 
The synthetic oestrogens and progestins (which are frequently used 
components of oral contraceptive formulations) are metabolized by 
mechanisms similar to those by which the natural steroids are 
transformed, and both natural and synthetic steroids have similar 
modes of action. The metabolism of the synthetic oestrogens has 
been reviewed by Bolt (44). 
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3.3 SIMILARITIES BETWEEN STEROID- AND DRUG-METABOLIZING ENZYMES 
Certain similarities have been found to exist between the enzymes 
of drug metabolism and those which metabolize the steroids. These 
similarities suggest that the steroids are the natural substrates 
for the same microsomal enzymes as are responsible for the metabo-
lism of many exogenous compounds, including drugs (44,66,67,109 , 160, 
270,282). 
The similarities between the drug- and steroid-metabolizing enzymes 
are briefly listed below: 
1. The enzymes are localized in the hepatic microsomes, and both 
exhibit a requirement for NADPH and molecular oxygen for 
activity (which is a characteristic of the mixed-function 
oxidases) (51,57,66,154,171,270). 
2. Higher enzyme activity is noticed in the adult male rat than in 
the adult female (66). See Section 4.1. 
3. Higher enzyme activity is noticed in adult male rats than in 
immature male rats (234). See Section 4.1. 
4. The enzymes are inhibited i n vitro by the addition of SKF-525-A 
and in vivo by administration of CCl 4 to rats (66-68,300). 
5. The activity of the microsomal enzymes is inhibited by carbon 
monoxide, and this inhibition is reversed by monochromatic light 
at 450 nm. This behaviour indicates the dependence of the 
enzymes on cytochrome P-450 (44,66,67). 
6. The steroid hormones appear to be alternative substrates for, 
and therefore competitive inhibitors of, the enzymes of drug 
metabolism (66,67,96,282). 
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Both E2 and PRG, as well as the other steroids, have been found 
to inhibit competitively numerous cyt P-450-mediated drug oxida-
tions by rat liver microsomes in vitro (46 , 109,154,170,227,233, 
282), resulting in the metabolism of both substrates (steroid 
and drug) being slower than if either were the only substrate 
(231). 
Pasleau et ar. (233) have reported that increasing the concen-
tration of PRG or testosterone rapidly inhibited the in vitro 
hepatic activity of AHH in the rat. Maximal inhibition was 
attained at equimolar substrate (BP) / inhibitor (steroid) 
concentrations, and greater amounts of steroids did not further 
inhibit AHH activity. 
AHH has been found to be supported by two cyt(s) P-450 forms ; a 
specific form , which is inducible by 3MC, and a less specific 
form, which is inducible by PB, which is capable of accepting a 
wider range of substrates (including the steroids) (233). The 
less-specific form was inhibited i n vitro by the steroids in the 
livers of both male and female rats (233). However, the 3MC-
inducible form of AHH was not inhibited, even at steroid concen-
trations of up to ten times the substrate concentration (233). 
In the adult female rat, the administration of BP inhibited the 
16a-hydroxylation of progesterone slightly, but did not inhibit 
any of the other steroid 16a-hydroxylases. These steroid-16a-
hydroxylases have been found to be completely independent of cyt 
P-448, and they are not inducible by 3MC (233). 
These observations suggest therefore that while the 16a-hydroxy-
lation of steroids is not affected by BP, the steroids are, 
nevertheless, able to inhibit part of the activity of AHH (233). 
7. The enzyme activity of the hepatic enzymes is enhanced after 
protracted pretreatment of rats with various drugs or halogen-
ated hydrocarbons. 
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The pretreatment of rats with PB for several days has been found 
to increase the activity of the hepatic microsomal enzymes that 
hydroxylate the steroids (67,68,231). This increased steroid 
hydroxylase activity was reflected, in vivo, by accelerated 
steroid metabolism and by alterations in the physiological 
action of the steroids (66-68,187,191,300). 
Many inducers of drug metabolizing enzymes, such as diphenyl-
hydantoin, chlorcyclizine, orphenadrine, phenylbutazone, and 
halogenated hydrocarbon insecticides (such as chlordane, DDT and 
dieldrin) also appear to be capable of inducing the steroid 
hydroxylases (30,66-68). The metabolism of the synthetic 
steroids is similarly enhanced by inducers of the microsomal 
enzymes (67,187). 
The 16a-hydroxylation of PRG, and the 2-hydroxylati on of E2 can 
be induced by pretreatment with PB but not by inducers of the 
3MC-type (57,232). This fact may indicate that the steroid 
hydroxylases are independent of the cytochrome P-448 isozyme 
(57,66,107,109,112,232,233). 
The rate of the 4-hydroxylation of E2 in the human placenta has 
been found to be elevated three- to five-fold in cigarette 
smokers (34,66,155). 
8. The in vi vo metabolism of both steroids and drugs is similarly 
affected by alterations in the intake of dietary macronutrients 
(25,160). 
3.4 THE STEROID-RECEPTOR MODEL 
3.4.1 The Steroid-Receptor-Response Sequence 
In the cells of target tissues, both E2 and PRG bind to specific 
high-affinity saturable receptor proteins in the cytosol. Subse-
quent to this noncovalent binding to the cytosolic receptor, the 
steroid-receptor complex is translocated to the nucleus, where it 
interacts with specific 'acceptor' sites (chromatin DNA and asso-
ciated histones) on the genome (4,30,53,106). 
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This interaction results in the unmasking of a number of cistrons 
from which specific mRNA is transcribed. These mRNAs code for 
either initiation, or acceleration, of the biosynthesis of certain 
structural and functional proteins (see Figure 3.5) (48,189,228, 
229) . 
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The Oestrogen-Receptor 
The longest, and therefore, best known of the steroid receptors is 
the oestrogen-receptor, which is thought to be a globular protein 
with a molecular mass of around 200 000 dalton. The oestrogen-
receptor, originally with a sedimentation coefficient of 8 S, 
dissociates into a 4 S form when it binds to oestrogen. Following 
an additional modification, the complex is converted to a 5 5 
species, which is transported to the nucleus (106). Oestradiol has 
a greater affinity for the oestrogen-receptor binding site than any 
of the other natural steroids (44). For example, the affinity of E2 
for the oestrogen-receptor is about ten times that of oestrone (E 1) 
(48) . 
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3.4.3 The Progesterone-Receptor 
The progesterone-receptor is estimated as having a molecular mass 
of between 60 000 and 110 000 dalton and a sedimentation coeffi-
cient of around 4 S (30). The interaction of the PRG-receptor 
complex and the nuclear chromatin fractions is analogous to that of 
the oestrogen-receptor complex, although there is no apparent need 
for receptor alteration, as is the case with the oestrogen-receptor 
(106). 
3.4.4 Physiological Manifestations ot the Receptor-Response 
Sequence 
Considerable evidence supports a unitary hypothesis of steroid 
action; viz., that the phYSiological manifestations of the steroid 
hormones result from their initial interaction with specific recep-
tors in target cells (30). 
A steroid hormone may induce the synthesis of its own specific 
receptor protein, as well as that of another steroid hormone (4,48, 
229,276). 
For example, the PRG-receptor concentration appears to be dependent 
on the action of both oestrogen and PRG, as E2 administration 
results in an eight-fold increase in the basal concentration of the 
PRG-receptor after twenty hours (30,48,189). The observation that, 
under most circumstances, PRG can only exert its physiological 
effects after 'priming' by oestrogen is now understood in terms of 
the stimulation of PRG-receptor synthesiS by oestrogen, thereby 
mediating the progestational response (30). 
The receptor-response sequence, which results in the increased 
synthesis of specific proteins, may also possibly account for the 
reported ability of the steroids to induce enzyme synthesis (see 
also Section 4.2.) (4,183). 
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3.5 STEROID NONMUTAGENICITY 
Despite evidence of their carcinogenicity, neither E2 nor PRG (at 
low concentrations) can be detected as mutagenic by the use of 
SaLmone LLa strains, even with the addition of a metabolic activa-
tion system. Such nonmutagenicity is found even when the metabolic 
system (usually a microsomal fraction of hepatic tissue) is induced 
by anyone of a variety of inducing agents (125,174,208,237,259). 
It has been reported that as the steroid concentration in the assay 
mix was increased to concentrations of greater than 500 ~g/plate, 
there was a tendency for the number of visible colonies to fall 
below the count range of spontaneous reversion and for 'thinning' 
of the background lawn as a result of cytotoxicity (145,174,202, 
259). 
IARC monographs (139,142), and a computer-generated review of 
mutagenicity data on the two hormones (requested from the EMIC) 
confirm the nonmutagenicity of E2 and PRG both in SaLmoneLLa and in 
other short-term test systems. 
Microbial mutagenicity assays are not capable of detecting carcino-
gens which act by nonmutagenic mechanisms, and there is, in these 
test systems, little evidence of a direct genotoxic interaction 
between the steroids and DNA (240,279). 
The present concept of sex-steroid carcinogenicity strongly impli-
cates the involvement of the cytoplasmic receptor protein, and it 
may be that the steroid hormones act by promoting the growth of 
tumours previously initiated, either spontaneously or by true 
mutagens (129,139,145,174,183,214). 
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CHAPTER 4 THE INFLUENCE DF THE ENDOGENOUS FEMALE SEX-STEROIDS ON 
METABOLISM 
4.1 SEX-RELATED DIFFERENCES IN HEPATIC METABOLISM IN THE RAT 
4.1.1 Introduction 
In the rat, marked sex-related differences have been observed in 
hepatic cytochrome(s) P-450-dependent microsomal enzyme activities. 
In general, hepatic microsomes from male rats have been found to 
metabolize various drugs more rapidly than those from female rats, 
with a correspondingly shorter duration and intensity of action 
often observed in the intact male (4,66,103,290). 
The magnitude of these sex-related differences has been found to 
depend on the substrate and the nature of the reaction; for 
example, the hydroxylation of hexobarbital and the N-demethylation 
of aminopyrine appear t o be sex-dependent, whereas the hydroxyla-
tions of aniline and zoxazolamine do not (109). Differences in 
enzyme activities are reportedly reduced, to varying extents 
(again, depending on the substrate), by starvation, adrenalectomy, 
hypoxia, and various drugs (66 ,103,109,210,232). 
The observed sex-related differences in the metabolism of the rat 
have been reviewed by Kato (162) and Colby (63), and several of 
these are shown in Table 4.1. 
4.1.2 The Role of Discrete Species of Cytochrome(s) P-450 
Sex-related variations in metabolism are sometimes accompanied by 
differences in the activity (Vmax ) and apparent affinity constant 
(Km) of the particular cytochrome(s) P-450-supported enzyme invol-
ved (109). However, sex-differences in the microsomal content of 
cytochrome (cyt) P-450 and in the activities of NADPH-dependent cyt 
c reductase (CcR) and cyt P-450 reductase, reportedly, are slight, 
and it is thought that these, alone, cannot be responsible for the 
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Table 4.1 Sex-Related Differences in Hepatic Metabolism in the Rat 
Enzyme Activity or MetaboliC 
Parameter Measured 
Cyt P-450 content 
Cyt P-450 reductase 
NADPH-dependent CcR 
ECOO 
EROO 
E2 hydroxylatIon 
Testosterone hydroxylation 
PRG-16-o-hydroxylase 
Mestranol-o-demethylation 
Cholesterol-7-o-hydroxylase 
17-Hydroxysteroid oxidoreductase 
6-a- & 16-.-HSOH 
ll-a-HSOH 
3-.- & 3-a-HSOH 
Sa-Reductase 
Hexobarbital hydroxylatIon 
Pentobarbital demethylation 
Ethylmorphine-N-demethylation 
Aminopyrine-N-demethyiatlon 
Aryl Hydrocarbon (BP) Hydroxylase (AHH) 
Aniline-p-hydroxylation 
Zoxazolamlne hydroxylation 
Glutathione reductase 
p-Nitroanisole-o-demethylation 
Dimethylaniline mono-oxygenase 
Steroid glucuronyltransferases 
PB metabolism 
Carisoprodol metabolism 
Ethanol dehydrogenase 
Ethanol oxidation 
3-hydroxy-3-methyl glutaryl Coenzyme A 
Morphine & Methadone-N-dealkylation 
Chlorpromazine demethylation 
Nicotine dealkylation 
Guthion metabolism 
Schradan metabolism 
Sulphanilamtde metabolism 
Picrotoxin metabolism 
Strychnine metabolism 
Sex in which Metabolic 
Act i v i ty ILeve lIs Greater 
male (minor diffs.) 
male (minor diffs.) 
male (minor diffs.) 
male 
female 
male 
male 
ma le 
male 
male 
male 
male 
male 
male 
female 
male 
male 
male 
male 
male 
no sex diffs. 
no sex diffs. 
no sex diffs. 
male 
female 
female 
male 
male 
female 
male 
female 
male 
male 
male 
male 
male 
male 
male 
male 
literature 
Reference 
(5.103.158.290) 
(290) 
(63.103.124.162.290) 
(162.290) 
(290) 
(4.66) 
(4.66) 
(4.66.101 ) 
(181 ) 
(101 ) 
( 122) 
( 122) 
(177) 
(180) 
(180) 
(4.45.103.164.210) 
( 109) 
(103.109.210) 
(101.109.164.210) 
(4.101.158.210) 
(109.210) 
(109.210) 
(310) 
( 101.109) 
(310) 
(244) 
(210) 
(210) 
(283) 
(283) 
(60) 
(45.102 .210) 
(45) 
(45) 
(102.210) 
( 102.210) 
(45.102) 
(45.102) 
(45.102) 
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observed sex-differences in metabolism (109,290). It has been 
suggested that sex-dependent differences in drug and steroid 
metabolism may be related to the existence of varying amounts of 
discrete species of cyt(s) P-450 in the liver (103,117,158,290). 
Male rats have been found to have greater hepatic cyt P-450-depen-
dent mono-oxygenase activity than females, but females possess 
inherently greater cyt P-448-mediated mono-oxygenase activity (290). 
These conclusions have been drawn partly on the basis of the 
activities of two enzymes; ethoxyresorufin-o-deethylase (EROD), and 
ethoxycoumarin-o-deethylase (ECOD) (290). 
EROD has been found to be supported almost exclusively by cyt P-448 
and, therefore , its activity levels reflect cyt P-448-mediated 
mono-oxygenase activities (290). Similarly, ECOD activity is an 
indicator of cyt P-450-mediated mono-oxygenation since it has been 
found to be supported by this isozyme (290). ECOD activity was 
significantly higher in hepatic microsomes from the intact male rat 
than in those from the female, whereas EROD activity was found to 
be higher in microsomes from female rat liver (290). 
There is some evidence to support the hypothesis that sex-differen-
ces in mono-oxygenase activities in rats may be due to a difference 
in substrate affinity for cyt(s) P-450 (158,164,290). The 
'feminizing' effect of oestrogen administration on the metabolism 
of male rats (Section 4.1.7) may also be explained by this hypothe-
sis (an increase in substrate binding to cyt P-448 mediated by 
oestrogens) (290). 
Alternatively, oestrogens may stimulate the production of a 
haemoprotein P-450 that is highly specific for cyt P-448-type 
substrates (290). 
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4.1.3 The Effect of Gonadectomy and Antagonistic Hormone Treatment 
Orchidectomy of the adult rat reduced the activities of several 
hepatic microsomal enzymes (103,109), including aminopyrine-N-
demethylase, hexobarbital hydroxylase, ECOD, AHH, and the 3a- and 
11e-hydroxysteroid dehydrogenases (HSOH) (5,164,242,290). A small 
(15%) decrease in hepatic cyt P-450 content after castration of the 
male has been reported (5,93,290). The effects induced by orchidec-
tomy can be reversed by the prolonged exogenous administration of 
testosterone (5,162,164,180,234,288,290). 
The administration of testosterone to the intact male rat had no 
effect on CcR activity, cyt P-450 content, or on either ECOD or 
EROD activity (290). E2 administration to intact male rats caused 
slight decreases in hepatic ECOD activity and in CcR and cyt P-450 
content, while it increased EROD activity (290) . The drug-metaboli-
zing activities of immature male rats were increased significantly 
after testosterone pretreatment (232). 
Ovarectomy of the adult rat had no effect on the activities of AHH, 
ECOD, or several other androgen-dependent microsomal enzymes (4 ,5, 
109 , 180,242) ; in addition , no effect was observed on hepatic 
cyt P-450 content (5). 
The pretreatment of intact females with E2 had no effect on cyt P-
450 content or ECOD activity, although it decreased CcR and 
increased EROD activities (290). 
The administration of testosterone (and other androgens) to intact 
or ovarectomized female rats, or to orchidectomized males (177), 
resulted in an increase in the rate of metabolism of several drugs 
(102,164,180): aniline (234), hexobarbital (43,45,232), and guthion 
(45,102), among others. Pretreatment of the intact female rat with 
testosterone had no effect on hepatic cyt P-450 level s or EROD 
activity , but increases in the activities of ECOD and CcR were 
observed (290). 
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4.1.4 The Development of Sex-Differences in Metabolism 
4.1.4.1 Foetal Metabolism 
Cytochrome P-4S0-dependent mono-oxygenase activities are barely 
detectable in the foetal liver of many species, including that of 
the rat (117,118,288). 
The absence of activity of these enzymes in the foetus may be due 
to their competitive inhibition by high levels of maternally-
derived substances, such as reduced progesterone metabolites 
(69,88,89,117,118). Alternatively, their absence may be due to 
either a lack of stimulation by endogenous inducing agents, of the 
enzymes responsible for the synthesis of hepatic microsomal mono-
oxygenase systems, or to the inability of the mechanisms responsib-
le for the synthesis of these systems to respond to endogenous 
inducing agents (117). 
It has been reported in support of the latter hypothesis that 
hepatic cyt P-450 content (118) and various cyt P-4S0-dependent 
mono-oxygenase activities, which are normally inducible by PB in 
the adult and neonatal rat liver, were not inducible by PB in the 
foetus (although PB freely crosses the placental barrier) (117). 
Although both AHH activity and cyt P-448 levels are not inducible 
by PB in the foetal liver, they may be induced by 3MC (117,118). 
These findings suggest that, in foetal liver, cyt P-448-dependent 
mono-oxygenases are responsive to appropriate inducing agents, 
whereas cyt P-450-dependent mono-oxygenases are not (117,118). 
Thus, a mechanism which suppresses the induction of cyt P-450-
mediated mono-oxygenases, without preventing the induction of cyt 
P-448-dependent enzymes, may exist in the foetus (117,118). 
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4.1.4.2 Neonatal Metabolism and the Onset of Sexual Maturity 
No sex-related difference in hepatic metabolism has been observed 
in the neonate or the sexually-immature rat (69,102). 
The in utero suppression of foetal P-450 haemoprotein systems seems 
to be lost when the foetus is removed from the maternal environ-
ment, and at this time also, both mono-oxygenase systems appear to 
become responsive to inducing agents (117). It has been reported 
that a gradual increase in mono-oxygenase levels and cyt P-450 
content, in both sexes, begins to occur immediately post parturi-
tion, reaching adult levels on about days 60-75 (117,288). Up until 
puberty, no difference between the two sexes was observed in mono-
oxygenase activities, but, at the onset of sexual maturation, an 
abrupt and lasting increase in both these activities and in cyt 
P-450 content (117), was observed in the male; activity in the 
female remained at the levels attained at puberty (66,180,242,288). 
The delayed development of hepatic metabolism in the neonate is 
possibly due to the gradual removal of the in utero suppression of 
the induction of foetal metabolism (117). Alternatively, it may be 
mediated by the stimulat ion of the enzymes responsible for the 
synthesis of the drug -metabolizing system, by increasing amounts of 
either endogenous or exogenous inducing agents (or both) (117). 
4.1.4.3 Metabolism During Pregnancy 
In the pregnant rat, during the course of pregnancy, a progressive 
decrease, has been observed in the in vitro hepatic metabolism of 
aniline, p-nitroanisole, aminopyrine and p-nitrobenzoic acid (73). 
Other in vitro studies have also shown decreases in the specific 
activity of the glucuronyltransferases (nmol/min/mg protein) vis-a-
vis several substrates (bilirubin, morphine, p-nitrophenol, 4-
methylumbelliferone, E1 and E2) during pregnancy 
(69,89,226,270,294). Conjugations with sulphate were also reduced 
in the pregnant rat (226), as was the biliary excretion of the 
glucuronide-conjugated metabolites of phenytoin and sulphobrom-
phthalein (SSP) (52). 
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An inverse correlation was found to exist between these in vitro 
findings and the in vivo duration of pentobarbital- or hexobarbital-
induced anaesthesia during pregnancy (73,89,226). 
Pregnant women, or women using oral contraceptives, have also been 
reported to metabolize several drugs more slowly than nonpregnant 
adult women (52,69,230). 
These diminished enzyme activities have been attributed to competi-
tive inhibition of the enzymes by the elevated levels of female 
gonadal hormones (particularly PRG and its reduced metabolites) 
which are present in pregnancy (73,87,89,226,271). However, the 
period of maximal depression of enzymatic activities, in late 
pregnancy (days 19-20), did not correlate well with the period of 
maximal elevation of plasma PRG levels (days 14-16) (73). In 
addition, no difference in the level of PRG was observed between 
microsomal enzyme preparations from pregnant and nonpregnant female 
rats (73). These findings tend to rule out direct competitive 
inhibition as the mechanism for reduced in vitro metabolism during 
pregnancy in the rat (73). 
The administration of PRG to nonpregnant rats, in doses designed to 
mimic the plasma levels which occur in pregnancy, failed to depress 
metabolism, a finding which possibly indicates that PRG also has no 
indirect role in controlling levels of microsomal enzyme metabolism 
(73). 
The depression of drug metabolism in pregnancy has been found to be 
linked most closely to reduced levels of hepatic cyt P-450 (226), 
although correlations were not consistent for all pathways (73) . A 
differential depression of cyt{s) P-450-dependent enzymes, however, 
might explain these results (73). 
In support of the latter hypothesis, a selective depression of 
induction by PB of the hepatic cyt{s) P-450 mono-oxygenase system, 
similar to that which occurs in the foetus, was 
the adult female liver in pregnancy (118,226). 
found to develop in 
In the liver of the 
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pregnant rat, as in the foetal liver, the induction of AHH and cyt 
P-448 by 3MC was not impaired (52). Therefore, the suppressive 
mechani sm that is present in the foetal liver of rats (see Section 
4.1.4.1) appears to exist in the maternal liver as well (118). 
This suppress : 1n (of the induction of the cyt P-450-dependent mono-
oxygenases) may be a reflection of the need to maintain elevated 
levels of the female sex-hormones in pregnancy (the endogenous 
steroids are preferentially metabolized by these enzymes) (73,117). 
The elevated levels of PRG observed in pregnancy may therefore be 
the consequence of, and not the reason for, the observed decrease 
in enzyme activity (73). 
It has been reported that the liver mass, and the total protein 
content of the hepatic microsomes, increased during pregnancy 
(226). Therefore, the decrease in enzyme activities appeared less 
when measurements were based on the metabolic activity of the whole 
liver than when calculated as activity per unit mass of liver 
tissue, or per unit mass of hepatic microsomal protein (73,226). An 
increase in the total body mass, and in the liver mass/body mass 
ratio has also been observed in pregnancy (73). These findings may 
indi cate a differential synthesis of hepatic proteins during 
pregnancy, with little or no synthesis of the cyt P-450 mono-
oxygenases (73). 
It may also be possible that pituitary growth-promoting factors are 
responsible for the depression of hepatic cyt P-450-mediated drug 
metabolism in pregnancy (see also Section 4.1.8) (52,63,73,226,252). 
It has been established that cyt P-450 content and microsomal drug-
metabolizing enzyme activities are lower than normal in many 
conditions characterized by the rapid growth of liver cells, for 
example in the foetus and neonate, after partial hepatectomy, and 
in hepatic tumours (226). In all of these circumstances, and in 
pregnancy, the presence of increased levels of growth-promoting 
factors has been reported (226). 
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4.1.5 Androgen-Dependent and Androgen-Independent Enzyme Activities 
Sexual variations in metabolism appear to be under the control of 
the sex hormones, particularly the androgens; for gonadectomy, or 
the administration of an antagonistic gonadal hormone, reverses 
sex-related differences (102). In addition, no difference in 
metabolism has been observed among sexually immature rats of either 
sex (109,242). 
It has been suggested that drugs may be classified into two groups; 
those which are metabolized by androgen-dependent mechanisms, and 
those which are metabolized by androgen-independent ones 
(4,158,180). The effects of inducers on the enzymes that catalyse 
the metabolism of these two groups of drugs have been shown to 
differ; androgen-dependent activities were induced by pretreatment 
with PB but not by pretreatment with 3MC, whereas androgen-
independent activities were induced by pretreatment with either 
enzyme inducer (158). 3MC (a cyt P-448-type inducer) has been shown 
to decrease androgen-dependent drug-metabolizing activities of the 
rat liver but to increase markedly those which are androgen-
independent (290). 
AHH, which has higher activity in the male, is unusual in that it 
has been found to be supported by two cyt(s) P-450 forms; the type 
predominating in the male is inducible by PB, while the type pre-
eminent in females is inducible by 3MC (233,290). 
Reportedly, androgen-independent enzymes are present at similar 
activity levels in both male and female rats, but the androgen-
dependent enzymes are present at significantly higher levels in the 
male. It has been suggested that this phenomenon may be due to the 
continuous presence of androgens (acting as enzyme inducers) 
(45,180,288). The androgens may inactivate an active endogenous 
repressor which represses the action of a regulator gene responsib-
le for the synthesis of the activities of the microsomal drug-
metabolizing system (see also Section 4.2 and Figure 4.2) (167). 
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It appears then that the enzyme inducing ability of the androgens 
may be more closely related to their anabolic activity rather than 
to their androgenic activity (45,102,109,164,232). 
4.1.6 Oestrogen-Dependent Enzyme Activities 
Only a very limited number of enzymes seem to be oestrogen-depen-
dent (180), and they appear to require the presence of an intact 
pituitary gland for activity (63,290). 
Female rats were found to have a two- to three-fold higher level of 
hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity 
than do males ; gonadectomy reduced this activity level to that of 
the male, and the administration of E2 reversed the latter effect 
(60). Therefore , physiological levels of oestrogen appear to playa 
role as a positive effector of reductase activity (60). 
The activities of the specific UDP-glucuronyltransferases that 
catalyse the glucuronidation of E1, E2, and testosterone, were 
found to be higher in female rats than in males (244). Ovarectomy 
reduced El glucuronyltransferase activity by 50%, and E2 adminis-
tration for a period of twelve days induced the enzyme to normal 
levels (244). The activity of El glucuronyltransferase was not 
induced by prolonged pretreatment with PB, whereas a single dose of 
3MC led to moderate induction (244). Gonadectomy of the male rat 
had no effect on testosterone glucuronyltransferase, and the subse-
quent administration of testosterone did not influence the activity 
levels of the enzyme either (244). 
Hepatic EROD activity is also higher in the female rat than in the 
male, and the administration of E2 to intact, or gonadectomized, 
male rats increased hepatic EROD activity (290). It is not clear 
whether the effect of E2 on EROD activity is due to the direct 
action of the hormone on the liver or whether it is dependent on 
the pituitary (290). 
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Sa-Reductase activity has been found to be higher in the liver of 
the female rat than in that of the male, and the administration of 
E2 restored the loss of activity which resulted from ovarectomy 
(180). Lax et aZ. (180) have suggested that Sa-reductase may not be 
oestrogen-dependent but may be androgen-dependent; only, androgens 
may act as repressors, not as inducers (as with other androgen-
dependent enzymes), of enzyme synthesis. 
4.1.7 The Androgen-Antagonizing Action of Oestrogens 
The administration of E2, at relatively low doses (5 ~g-100 ~g/kg), 
exerts a powerful antagonizing effect on the androgen-dependent 
enzyme activities of hepatic metabolism in the intact male rat (43, 
122,170,180,189,234,252,290). In addition, E2 also causes nearly 
complete reversal of androgen-mediated metabolic effects in the 
intact female and in castrates of either sex (176,179,180). 
The 'feminizing' effects of E2 on metabolism were still 
demonstrable in intact male rats receiving exogenous 5a-dihydroxy-
testosterone (180). In fact, the E2-mediated decrease of androgen-
dependent 3B-HSDH activity in the male rat liver was not reversed 
by a 100-fold higher dose of androgen, a finding which shows the 
potent anti-androgenic nature of E2 on androgen-dependent enzyme 
activities (176,179). 
These observations suggest that E2 acts on the mono-oxygenase 
system independently of its inhibition of androgen biosynthesis 
(mediated by suppression of gonadotropin release) (180). The 
androgen-antagonizing nature of oestrogens may be mediated by their 
interference with the binding of androgens to the repressor of the 
gene responsible for the synthesis of the microsomal enzyme system. 
Therefore, oestrogens may prevent the inactivation of this repres-
sor by androgens and, thus may block the subsequent induction of 
enzyme synthesis (164). 
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However, it has been suggested that the androgen-antagonizing 
effects of low doses of oestrogens are not likely to be mediated by 
hepatic oestrogen receptors since 
still influence enzyme activities 
cause translocation of the steroid 
physiological levels it may be that 
the lowest E2 doses which can 
(1-10 ~g) are insufficient to 
receptors (180). 
steroid receptors 
In fact, at 
role in mediating sex-steroid action on the liver 
do not playa 
(4,180) since 
hepatic steroid metabolism is so rapid that endogenous steroids 
(including the androgens) are unlikely to reach the nucleus of 
hepatocytes (204,297). 
4.1.8 The Role of the Hypothalamo-Pituitary Axis 
A more conceivable target for the androgen-antagonizing action of 
oestrogen is the hypothalamus, and experiments on hypophysectomized 
rats support this theory. 
Sex-differences in xenobiotic and steroid metabolism in rats only 
become apparent after the maturation of the hypothalamo-pituitary 
system (63,92,275). Hypophysectomy of the male rat had little 
effect on hepatic androstenedione metabolism (122), or on 116-HSOH 
activity (177). However, masculinization of hepatic microsomal 
mono-oxygenase activities followed hypophysectomy of the female rat 
(122,123,177), and once the pituitary was removed, the activities 
of these enzymes were no longer influenced by the administration of 
either androgen or oestrogen (177). 
These observations indicate an obligatory role for the hypophysis 
in modulating sex-steroid action on the liver; specifically, a 
repressive influence on the metabolism of the female rat 
(92,170,177,275). Several reports have also demonstrated that the 
'feminizing' effects of oestrogens in the intact female rat can be 
mimicked by the administration of growth hormone (GH) to the hypo-
physectomized rat (180,252). However, it is not known at present 
which hypophyseal hormone(s) might be physiologically responsible 
for in vivo sex differences in the rat. GH and prolactin (PRL) are 
the most likely candidates, but an as yet undefined 'feminizing 
factor' (FF) may be involved (180). 
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Figure 4.1 : Schematic representation of the possible modes 
ot actIon of androgens and oestrogens on hepatic androgen-
dependent enzyme activity in rats. HIF; undefined hypothalamic 
inhibiting factors: ~ ; inductive influence : 
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antagonizing action (adapted from 180) 
According to this model of hormonal regulation of the activity of 
androgen-dependent hepatic enzymes (represented in Figure 4.1), 
pituitary feminizing factors (GH, PRL, or FF) are the prime physio-
logical factors responsible for changes in hepatic enzyme activity. 
In the presence of androgens, hypothalamic FF release is inhibited, 
with a resultant masculinization of metabolism. Low doses of 
oestrogens override the androgenic suppression of FF release, and 
high doses of oestrogens saturate hepatic steroid metabolism and, 
by way of the oestrogen receptor system, cause induction of enzyme 
activity (see also Section 4.2) (180). 
The masculinization of hepatic metabolism in the female rat, which 
occurs following hypophysectomy, may therefore be due to the remo-
val of the source of the 'feminizing factor', thought to maintain 
female-type metabolism in the liver (122). 
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4.1.9 Effect of Adrenalectomy 
Adrenalectomy is reported to decrease microsomal enzyme activity in 
male rats (66). Normal levels were restored, not by the 
administration of testosterone (levels of which should be normal in 
adrenalectomized rats), but by cortisone (66,232). No difference in 
cytochrome P-450 levels have been observed in adrenalectomized rats 
(205,232). Therefore, although the adrenal may have a regulatory 
role in the increased enzyme activity of males, the role of 
cortisone is unclear, as adrenalectomy has no effect on the enzyme 
activities of the female rat (232). 
4.1.10 Sex-Related Metabolic Ditferences in Other Species 
Although it is generally reported that no sex-related differences 
in drug-metabolizing activities exist in the rabbit, cat, dog, 
guinea-pig, or hamster, differences are thought to exist in certain 
strains of mice and fish, but reported findings often conflict (66, 
164,232,288,290). 
Adult female Swiss-Webster mice were found to metabolize dimethyl-
aniline, aminopyrine, pentobarbital, and ethylmorphine faster, than 
the male mouse, and also to have a higher hepatic cyt P-450 content 
(232,288,310). The sex-related difference in dimethylaniline-N-
oxidase activity was nullified by the administration of testoste-
rone to the female mouse (288) and decreased by ovarectomy 
(although the differences were partially restored by PRG adminis-
tration) (82,310). 
Castration of the male mouse generally resulted in an increase in 
mono-oxygenase activity (abolishing the sex-difference) (310) , 
although the activity of dimethylaniline-N-oxidase was reduced 
(82). These effects were reversed by testosterone administration 
(82,310 ). Testosterone administration to intact male mice reduced 
the metabolism of nortestosterone, but increased that of hexobarbi-
tal (66). Testosterone administration to gonadectomized mice of 
both sexes caused a decrease in AHH activity (4,295). Pretreatment 
65 
with E2 caused an increase in the activity of hepatic AHH in the 
gonadectomized female but no similar change in the male (189,295). 
Testosterone or E2 administration to the neonate increased AHH 
activity in the male mouse but not in the female (295). 
These findings infer an inhibitory action of androgens in mice, 
contrary to their stimulatory effect in rats (288). 
Hepatic cyt P-450 content and mono-oxygenase activities are 
reportedly higher in the male rainbow trout than in the female fish 
(92). The administration of E2 to juvenile rainbow trout resulted 
in a statistically significant decrease in the activity of mono-
oxygenase activity (92) 
4.2 ENZYME INDUCTION BY THE STEROIDS 
Several studies have supported the suggestion that the sex-steroids 
exert their physiological effects, in both target and nontarget 
tissues, by influencing the synthesis of protein at the level of 
gene transcription (228). 
Although short-term treatments of rats with sex-steroids have shown 
competitive inhibition of drug metabolism, inductive effects on the 
enzymes of drug metabolism have been reported after protracted 
administration of high doses of steroids (66,152,154,230,248). 
According to the Jacob-Monod model (Figure 4.2), an enzyme inducer 
alters the configuration of a repressor protein, which is 
responsible for inhibiting the synthesis of a specific enzyme. The 
inactivated repressor can no longer block DNA transcription, and 
synthesis of the specific mRNA molecules, which encode for the 
enzyme, is enhanced (108,148). 
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The 'steroid-receptor' model of steroid action in target tissues 
(Section 3.4) illustrates a mechanism whereby a steroid may enter a 
nontarget cell, translocate, and interact with nuclear DNA to exert 
an inductive effect on metabolic enzymes (31,108). In addition, the 
presence of oestrogen-receptors in the (nontarget) hepatic tissue 
of rats has been demonstrated (4). 
Kato et a1. (163) observed that pretreatment with E2 (ZOO ~g/kg/day 
for 15 days) had no effect on the hepatiC drug-metabolizing activi-
ties of ovarectomized rats. Similarly, Bulger and Kupfer (57) found 
that EZ administration (100 ~g/kg/day, ip for 4 days) did not alter 
the in vitro -hepatic microsomal activities of Ez-Z-hydroxylase, EZ-
3-methoxy-o-demethylase, benzphetamine-N-demethylase, or ethyl-
morphine-N-demethylase, in the intact or gonadectomized female rat. 
However, AI-Turk et a1. (4) observed that protracted pretreatment 
with EZ or E1 at doses which were ten-fold higher than these (1 
mg/kg/day, for 7 days) induced a two-fold increase in the in vitro 
hepatic and intestinal AHH and ECOD activity in the female rat 
(5Z,57,189,Z76). At these supraphysiological doses, significant 
increases in cyt P-450, parallelling those of AHH activity, were 
also observed (4,Z76). 
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The protracted pretreatment of nonpregnant female rats with E2 
(1 mg/kg/day, for 14 days) has been reported to induce E1 and 
morphine glucuronyltransferase activity by 53% and 50%, respective-
ly, in the isolated perfused liver (52). Rao et al. (244) have also 
reported that E2 administration for 15 days to ovarectomized rats 
increased the in vitro hepatic microsomal activity of E1 glucur-
onyltransferase, to 140% of the normal values of the untreated, 
nonovarectomized rat (244). 
Vodicnik et al. (290) have reported that treatment with E2 
(2,5 mg/kg, twice daily for 4 days) induced the hepatic microsomal 
activity of EROO in male and female rats in vitro. 
Therefore, although the reported action of E2 on androgen-dependent 
(and therefore normally sexually differentiated) enzyme activities 
in male rats is of a feminizing nature, 
reverse effect, masculinizing the activity 
The administration of PRG to virgin female 
for 4 days) has also been found to result 
metabolizing activities in vitro (73,98). 
higher doses can have the 
of female rats (85,178). 
rats (10 mg/kg/day, i.p. 
in enhanced hepatic drug-
Several synthetic oestrogens and progestins of the type commonly 
used in oral contraceptive formulations have been found to induce 
microsomal drug-metabolizing enzymes in rats, although at concen-
trations greater than those required for contraception (98,230). 
Juchau and Fouts (154) have reported that norethynodrel, adminis-
tered to male rats, exerted a biphasic effect on the hepatic 
hydroxy lations of hexobarbital and zoxazolamine in vitro; following 
an initial inhibition, induction of these enzyme activities was 
observed. Jori et al. (152) have noticed that protracted adminis-
tration of medroxyprogesterone acetate, alone or in combination 
with ethinyloestradiol, and norethynodrel combined with mestranol, 
increased the metabolism of pentobarbital in vivo. 
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The norethynodrel + mestranol combination has also been found, by 
Carter et al. (61) to stimulate the hepatic metabolism of ethyl-
morphine in vitro, and to increase cyt P-450 levels, after the 
protracted pretreatment of female rats. Pretreatment with 
lynoestranol enhanced the metabolism of phenobarbital, hexobarbi-
tal, and phenytoin (253,286). 
The combinations of lynoestranol + mestranol, norethynodrel + mes-
tranol, and norethindrone + mestranol, administered to female rats 
for 4 days or more, at doses adequate for contraception, induced 
aniline hydroxylase, p-nitroanisole-o-demethylase and aminopyrine-
N-demethylase activities (153). Two other contraceptive combina-
tions, norethisterone + mestranol, and quingestranol acetate + 
ethinyl oestradiol, have also been reported to be inducers of 
hepatic microsomal enzymes (88,90). 
Daily administration of oestradiol benzoate to female rats (25 ~g 
and 100 ~g/kg for 21 days), resulted in a 1,7- and 2,5-fold 
increase in ~-hydroxy-~-methylglutaryl coenzyme A reductase activi-
ty in normal and ovarectomized rats respectively (1). Increases in 
AHH activity have also been observed in foetal rat liver cultures 
which were exposed to diethylstilboestrol (DES) in the medium (189). 
Some steroids with anabolic (testosterone propionate, 19-nortes-
tosterone (45), and methyltestosterone (124)), anti-mineralocorti-
coid, or glucocorticoid (spironolactone (124,268,269)) properties 
have been shown to enhance hepatic microsomal N-demethylation and 
aliphatic hydroxylation (124,268). Pregnanolone-16a-carbonitrile 
(PCN), as well as being a potent inducer of hepatic drug-metaboli-
zing activities, increased microsomal protein, CcR, and cyt P-450 
content (194,269,270). 
As described in Section 4.1.7, it may be that the oestrogens, at 
physiological levels, are metabolized too rapidly for them to 
regulate metabolism by acting on the hepatic steroid-receptor 
system (180). However, high doses of physiological oestrogens, or 
moderate doses of less easily-metabolized synthetic oestrogens, may 
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saturate or bypass hepatic steroid metabolism respectively (180). 
These steroids may then activate the cytosolic receptor system, 
translocate, and activate or modify the genome, causing induction 
of androgen-dependent enzymes (or, not impossibly, repression of 
some enzymes) (4,180,276) . There is some evidence that these 
general observations about induction by oestrogens may also be true 
of progestins as well as of other steroids. However, the levels of 
endogenous steroid which are required to induce the hepatic mixed-
function oxidases have been supraphysiological; lower doses have 
either no effect or an inhibitory effect on these enzymes (4,170). 
4.3 MULTIHORMONAL REGULATION OF HEPATIC ENZYME ACTIVITIES 
There is no substantial evidence supporting a unifying theory of 
hormonal regulation of hepatic drug- and steroid-metabolism. The 
manner in which different enzyme activities react to changes in the 
endocrine system suggests that the opposite may be true (180). The 
ba lance between male and female sex-hormones does however seem to 
be important in determining the activities of the metabolizing 
systems. Evidence to date pOints to the presence of distinct multi-
hormonal regulatory modes for different types of enzyme activity 
(180). 
In general, the observed effects of the steroids on the mixed-
function mono-oxygenases are dependent on the organ studied, the 
steroid administered, and the dose and duration of steroid adminis-
tration (4,52,88,180,230,276). 
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CHAPTER 5 METHODS 
5.1 RAT PRETREATMENT 
5. 1.1 Establishment and Maintenance of the Animal Colony 
Only virgin female Sprague-Dawley rats, bred from original stock 
acquired from the S.A. Institute for Medical Research, were used 
to eliminate possible strain and stock differences in metabolism 
(66). Twelve groups (A to L) of two rats each were established in 
separate plastic cages, and all groups were subject to a 12 hour 
dark/light cycle, in a room with stable temperature and humidity 
(210). The animals were allowed food and drinking water ad libitum 
as starvation has been shown to alter the microsomal enzyme system 
to varying degrees (110,210). 
All drinking water was freshly distilled to eliminate the 
possibility of any impurities in tap water altering the microsomal 
enzymes (64) . 
The use of insecticides in the animal room was prohibited as 
several of these are known to be inducers of the mixed-function 
oxidases (MFO) (93), and no bedding was provided for the same 
reason (67 ,210,289). As it has been reported (289) that the freque-
ncy of cage cleaning may also alter the activity of the microsomal 
enzymes, all cages were cleaned every day to standardize any 
such effects. The animals were allowed one month to equilibrate 
under these conditions before treatment commenced. 
The test animals weighed 210 ± 25 g on their first treatment day. 
They were weighed daily thereafter, which provided an opportunity 
both to examine the animals for any observable changes in condition 
and to accustom them to handling. 
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5.1.2 Pretreatment - Rationale and Protocol 
The rat pretreatments are summarized in Table 5.1, and the methods 
of preparation of all the reagents used may be found in Appendix 1. 
5.1.2.1 Steroid Pretreatment 
The test rat groups received daily ip injections of E2 or PRG, at 
either the 1 mg/kg or 20 mg/kg level, in an ethyl oleate vehicle. 
One control group was injected with vehicle only while another was 
untreated, making a total of six groups. 
The steroid dose levels were chosen after a literature survey (4,52, 
96,135,152,154,186,276). Doses of E2 greater than 0,5 mg/kg/day 
have been found to be necessary to elicit inductive changes in the 
activities of ECOD and AHH and to increase the hepatic cyt P-450 
content (4). Brock and Yore (52) have reported that the administra-
ti on of E2, at 1 mg/kg/day for 14 days, increased hepatic RNA and 
DNA synthesis, and liver size to those observed in the pregnant 
rat. 
Tabl e 5.1 Summary of the Rat Pretreatments 
TREATMENT RAT GROUP 
UN INDUCED PB-INDUCED 
No Treatment A G 
Ethyl Oleate Only B H 
17s-0estradiol 1 mg/kg C 
17s-Destradiol 20 mg/kg 0 J 
Progesterone 1 mg/kg E K 
Progesterone 20 mg/kg F L 
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Treatment was administered daily at a fixed time (08hOO-09hOO), for 
14 days , and animals were sacrificed 24 hours after the last 
treatment (4,96,158,276). 
Animals were regularly monitored for abdominal pain and, on dissec-
tion, were examined for inflamed intestinal membranes, both 
symptomatic of peritonitis, which, along with other pathological 
states, may affect the microsomal enzymes (218). Any animal showing 
signs of morbidity was excluded from the study. 
5.1.2.2 ~nzyme Induction 
For the purposes of routine environmental screening with the Ames 
assay, the hepatic microsomes are normally maximally induced to 
increase the efficiency of the test in mutagen detection (20,202). 
It has, in fact, been reported that many mutagens are undetected 
without the incorporation of induced S9 (202). The usual method of 
maximal induction is by a single ip injection of Arochlor (see 
Section 1.2), 5 days before sacrifice (6,125,166,202). 
This investigation did not require the sensitivity essential for 
mutagenicity screening, since well-established mutagens were used. 
In addition, deliberate maximal induction may mask any steroidal 
inductive effects, especially if these are slight. Arochlor is also 
a stable, hazardous carcinogen with a very viscous nature, and it 
is thus difficult to handle (202). The presence of Arochlor in the 
S9, albeit in small amounts, may influence the mutagenic reversion 
of the tester strains (202). 
Consequently, each treatment group was duplicated, with one set of 
groups (A to F) uninduced, and another set (G to L) induced by PB, 
a generally effective inducer, although less efficient than 
Arochlor (20,202). Induction was achieved by substituting a 1 mg/ml 
PB solution for the drinking water, starting 7 days prior to sacri-
fice (13). 
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The rats were sacrificed by cervical dislocation 24 hours after the 
last steroid administration. Sacrifice was at a fi xed daily time 
(between 09hOO and 09h30) to avoid circadian variation in the 
activity of the microsomal enzymes (210). 
5.2 PREPARATION OF THE S9 FRACTION 
The S9 fractions were prepared according to the method of Garner et 
al. (100), as adapted by Ames (13,20,202) . All procedures were 
performed at 0-4°C to prevent degradation of the microsomal 
enzymes. 
All glassware was soaked in chromic acid so lution for 24 hours 
before being rinsed three times with double-distilled water and 
then autoclaved. 
The livers were excised immediately after sacrifice, under aseptic 
conditions, to avoid microbial contamination of the S9 fraction. 
The skin was swabbed with 95% ethanol before incision, and care was 
taken to exclude fur from the abdomen and not to rupture the 
oesophagus or the gastrointestinal tract. 
The freshly excised liver was weighed in a beaker containing 
approximately 1 m£ 0,15M KCl solution per gram of wet liver. The 
liver was then washed several times with 0,15MKCl, to help ensure 
a sterile preparation, and to remove haemoglobin, which may inhibit 
cytochrome P-450 (202,2 10). 
The liver was not perfused before homogenization, 
reported to reduce the hepatic cyt P-450 content 
as this has been 
(210). Further-
more, the increase in liver size and mass (by as much as 25%) which 
occurs on perfusion must then be taken into account when preparing 
subcellular fractions to study induction (210). 
The washed liver was transferred to a beaker containing 3 m£ 0,15 M 
KCl per gram of wet liver and minced as finely as possible (to 
shorten homogenization time), using ster i le scissors. At this 
pOint, the livers of both rats in each group were pooled. 
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The minced liver was homogenized using a Braunsonic 1510 ultrasoni-
cator, with the homogenate flask held in crushed ice. Four 15 sec 
homogenization cycles were interspersed with cooling cycles of 
2 min. Only small quantities of tissue were homogenized at one 
time, since the heat generated by prolonged homogenization may 
result in the destruction of the microsomal enzymes (210). 
The homogenate was centrifuged (in teflon centrifuge tubes) at 
9 g x 1000 for 10 min in an MSE 18 refrigerated (4°C) centrifuge. 
With the centrifuge head used (MSE :69181, R = 10,7 cm), centrifu-
gation was at 8,7 x 10-3 rpm, calculated from 
Where RCF 
R 
N 
RCF = D,0000111 x R x N2 
Radial Centrifugal Force (g x 1000) 
Radius (cm) from shaft to tip of centrifuge tube. 
revolutions per minute 
The supernatant (the S9 fraction) was decanted and distributed into 
sterile plastic cryotubes. These were frozen and stored in liquid 
air (at -180°C) in a 5 1 high-vacuum storage flask. 
5.2.1 Stability of the S9 Preparations 
The period for which frozen S9 preparations retain their activity 
on storage is still an unresolved issue. The storage periods used 
by different investigators range from several weeks to a few years 
(78,100,202,245). 
Stanton et aL. (272) have found that the microsomal enzymes were 
stable for several days in soft agar, at the temperatures employed 
in the Ames test. 
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5.3 RECEIPT AND STORAGE OF THE SALMONELLA STRAINS 
The SaLmoneLLa strains were received from the Ames laboratory as 
fresh cultures on paper discs and surrounded by soft agar. On the 
arrival of the strains, the culture discs were immediately placed 
into 10 ml sterile nutrient broth and incubated for 10 hours in a 
shaking waterbath at 37°C. This results in a culture density of 
approximately 1-2 x 109 cells/ml (7,20). 
After incubation, sterile OMSO was added to the cultures as a 
cryoprotective agent (0,09 m1 DMSO/ml culture). The cultures were 
then distributed into sterile cryotubes; each tube was filled 
nearly to the top to protect against oxidative damage, but allowing 
for expansion on freezing. The cu ltures were frozen and stored in 
liquid air (-180°C) until required. Tester strains stored at these 
low temperatures have been found to retain their viability and 
genetic characterisitics for up to three years (7,29,185,202). 
In this investigation, tester strain cultures were always grown 
directly from these 'frozen permanents' (Section 5.5.2.3). Enough 
perma nents were prepared to avoid the problems associated with 
frequent inoculation from one frozen culture (202). Tester strains 
were not subcultured since thi s may result in the loss of the R-
factor (202). 
5.4 TESTER STRAIN GENOTYPE CONFIRMATIONS 
Initial genotype tests were performed immediately upon arrival of 
the tester strains to ensure that they had retained their genetic 
markers in transit. Strains are expected to arrive in good 
condition 
affected 
if received within a week of dispatch, though they 
by prolonged delivery time and/or hot weather 
are 
(7) . 
Genotype confirmations were also routinely incorporated into each 
mutagenicity assay, as were sterility tests on all reagents. Test 
methods were those of Maron and Ames (202), and the reagent 
formulae may be found in Appendix 1. 
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5.4.1 The Histidine Requirement 
All four tester strains have a his- character, that is, require 
histidine for growth. Since the uvrB deletion also extends through 
the bio gene, TA97, TA98, and TA100 also require biotin (but the 
bio gene is not revertable, and therefore it is not necessary to 
test for biotin requi rement) (20,202). 
By means of a glass spreader, 0,1 mi of a 0,1 M histidine solution 
and 0,1 mi of a 0,5 M biotin solution were distributed over a 
minimal glucose agar plate. Control plates, as well as those for 
TA102, contained biotin but no histidine. An inoculum of each 
strain was streaked across the control plate and then the histi-
dine/biotin plate. After overnight incubation at 37°C, growth on 
the histidine/biotin plate, and none on the control, is indicative 
of the presence of the his- deletion. The wild strain should grow 
on both plates. 
5.4.2 The rfa Mutation 
The rfa mutation permits large molecules such as crystal violet to 
enter and kill the bacterium and, therefore, strains with this 
character were tested for crystal violet sensitivity. 
Fresh overnight Salmonella culture (0,1 mi) was mixed with 2 mi of 
molten soft agar (at 50°C), overlayed onto a nutrient agar plate, 
and allowed to set. A disc, impregnated with crystal violet, was 
placed onto the surface of the seeded plate, which was then 
incubated overnight at 37°C. A clear zone of inhibition surrounding 
the disc indicates the presence of the rfa mutation. Wild-type 
strains, or strains with the gal deletion, are not inhibited since 
crystal violet cannot penetrate the cells. 
5.4.3 The uvrB Deletion 
This mutation is quite stable and is not easily lost; however, its 
presence can be confirmed by demonstrating uv-sensitivity in bacte-
rial strains which contain the deletion. 
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The four tester strains were streaked across the same nutrient agar 
plate in parallel stripes and a piece of foil so placed over the 
plate that it covered half of each streak. The plate was irradiated 
with a 15 W germicidal lamp at a distance of 33 cm for 8 sec (non 
R-factor strains were streaked on a separate plate and irradiated 
for 6 sec). After incubation at 37°C for 12 hr, the strains with 
the uvrB deletion (TA97, TA98 , and TA100) grow only on the nonirra-
diated section of the plate. TA102 and the wild-type strains are 
not inhibited by irradiation. 
5.4.4 The R-Factor 
The four standard strains all contain the R-factor (pKM10l) , which 
also contains an ampicillin marker, the basis of the genotype test 
for this plasmid. Nutrient agar plates were seeded with the tester 
strain (as for the rfa mutation) and commercially available 
ampicillin discs were embedded in the overlay (76,309). In this 
case, a zone of inhibition indicates the wild-type genome, and 
uninhibited growth the presence of the R-factor. 
5.4.5 The pAQl Plasmid 
TA102 is the only standard strain containing this plasmid, which 
contains a tetracycline resistance marker. This strain was there-
fore tested with both ampicillin and tetracycline discs (on the 
same plate), and an R-factor strain was used as a control for 
tetracycline sensitivity. 
5.4.6 Spontaneous Reversion 
Spontaneous reversion of his- mutants to histidine prototrophy, in 
the absence of a mutagen, occurs at a characteristic frequency for 
each strain (the SRF), and this phenomenon may be used as a diag-
nostic indicator for genotype (20,201). 
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Reportedly, the SRF of any strain may differ from one laboratory to 
another, but should be consistent within each (202), and each 
should establish its own acceptable SRF ranges (76). Historically 
encountered SRF ranges for the standard tester strains are shown in 
Table 5.2. 
Table 5.2 : Acceptable SRF Ranges for Standard Strains 
Data are for plates without S9, and the SRF may be very 
slightly higher if S9 is included. The SRF with the 
preincubation procedure is no different to that using 
the plate incorporation assay (307). Adapted from 202. 
SaLmonella Strain SRF Range 
TA97 90 - 180 
TA98 20 - 50 
TA100 100 - 200 
TA102 240 - 360 
Although the SRF may vary over an extended period of time, extreme 
fluctuations between experiments, or deviations from the acceptable 
ranges, mean the genotype of the strain should be retested and, if 
necessary, the strain should be reisolated (202). 
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5.5 THE MUTAGENICITY ASSAY 
5.5.1 Introduction 
The method followed was that of the plate-incorporation test (13, 
18,20), modified by the use of a preincubation step (207,307) and 
by certain of the recommendations of Belser (40), which reportedly 
increase the precision of the assay. 
The mutagen, bacterial strain and the differently pretreated 59 
preparations were incubated together for a period at 37°C (pre-
incubation), then soft agar was added, and the mix poured onto a 
minimal glucose agar plate. After incubation at 37°C for 48 hour, 
the revertant colonies visible on the plates were counted. 
The preincubation modification, recommended by several workers (78, 
125 , 184,202,277), is as sensitive, and with some mutagens (such as 
DMN, AFB 1, and BP) more so than the standard plate-incorporation 
test (20,36,202,207). 
All glassware, instruments, and reagents were sterile. Since 
ethylene oxide, used to steri lize petri-plates, is a potent muta -
gen, only plates sterilized by gamma-radiation were used in the 
assays (20,202). The methods of preparation of the reagents and 
media may be found in Appendix 1. 
5.5.2 The Components of the Assay 
5.5.2.1 The S9 Mix 
In order to approximate intact mammalian metabolism in an in vitro 
microbial assay, it has been found necessary to add an NADPH-
generating system (i.e., NADP and glucose-6-phosphate, which may be 
converted into NADPH by the glucose-6-phosphate dehydrogenase 
present in the cytosol) as well as a phosphate buffer (which stabi-
lizes the 59 activity) (100,207). 
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The microsomal fraction was therefore incorporated into a buffered 
solution which contained these cofactors (the 59 mix). The 59 mix 
was prepared freshly for each assay as soon as the frozen 59 frac-
tion had thawed (202). 
For general mutagenicity screening, a standard 59 mix, resulting in 
20 ~1 59 per plate, is recommended (184,202,224); and this was the 
concentration employed for most of the assays of this investigation 
(see Table 5.4). A greater concentration of 59 (100 ~1 per plate) 
has been found necessary for the activation of DMN (202), and this 
'high' 59 mix was also used to confirm the nonmutagenicity of the 
sterOids, DMSO, and phenobarbital. 
5.5.2.2 The Soft Agar 
Before each assay, 100 m1 of soft agar was melted, and 10 m1 of a 
0,5 mM histidine/biotin solution was thoroughly mixed into the 
molten agar (18,29,202). 
The trace of histidine in the soft agar allows the plated bacteria 
to undergo several divisions; this DNA replication is necessary for 
mutageneSiS (202), but it also results in a faintly visib le 
'background lawn' of bacterial growth . 
This lawn is comprised of his- bacteria, which are able to utilize 
the trace of histidine in the soft agar (33,40,76,78). A minimal, 
or absent, lawn is indicative of bacterial toxicity, and colonies 
appearing in such a background are not scored (18,20,207). 
An increase in the plated histidine levels results in enhanced 
mutageneSis but also causes heavy growth of the background lawn, 
obscuring the revertants (18,20,202). Care was therefore taken to 
accurately pipette soft agar, and to maintain consistency of 
technique in pouring the agar overlay, in order to eliminate varia-
tions in the histidine content of the plates (202). 
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5.5.2.3 The Tester Strain Cultures 
An inoculum of tester strain, from a frozen culture, was incubated 
in 10 mi of nutrient broth for 10 hr in a shaking water-bath at 
37°C. This procedure results in a culture density of approximately 
1-2 x 109 cells/ml, which is considered ideal for the mutagenicity 
assay (40,76,78,202). 
The culture density was determined spectrophotometrically by 
optical density at 650 nm (OD650 ) and the titre was adjusted, if 
necessary, with sterile nutrient broth. The relationship between 
the OD650 and the viable cell count was previously determined by 
the serial dilution/plate count method. However, the actual number 
of cells plated, within broad limits, is not critical (40,202). 
The culture bottles were wrapped in foil during incubation to 
protect them from light and were used immediately as there is 
reported to be some loss of viability in nutrient broth cultures of 
rfa strains if kept at room temperature for several hours (27,78, 
202). 
5.5.2.4 The Mutagen Solutions 
It is a criterion of mutagenicity that there must be a range of 
mutagen concentrations within which the number of induced rever-
tants increases linearly with increasing dose (202). All the 
mutagens chosen exhibit this relationship at subtoxic levels (184, 
202,219). Most mutagens are also toxic to some extent, either to 
the bacteria or to the enzymes, so that the number of revertants 
usually decreases at higher concentrations. Mutagen concentrations 
were therefore chosen from the lower ranges of the dose-response 
curve. 
Choosing low concentrations also meant that, on incubation, the 
revertant colonies were fewer and therefore easier to score accura-
tely . In addition, if a mutagen concentration is high enough to 
induce as many as 1000 revertants/plate, the colony density may 
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become so great that mutual growth inhibition of the colonies may 
occur. This phenomenon results in the formation of many small 
'microcolonies', which are difficult to count (54,201,202). 
All mutagens were handled under a fume hood, and the incubator air 
outlet was led into the same. Latex gloves and a face mask were 
worn when manipulating mutagens, and all items in contact with 
mutagens were stored in double heavy-duty plastic bags for later 
incineration (202). 
5.5.3 The Assay Procedure 
Into a set of sterile test-tubes, held in an ice bath, was pipetted 
0,5 m£ of S9 mix (containing the relevant S9 type and concentra-
tion). Similar amounts of plain buffer were used in control assays 
(see Section 5.5.4) (13,18,20,202). 
To the S9 mix was added, in order, 0,1 m£ of a fresh overnight 
tester strain culture and 0,1 m£ of the test mutagen solution (18, 
20,40,202) . 
This mixture was vortexed gently (without allowing foaming) for 
3 sec, and then incubated for 20 min at 37°C in a darkened water-
bath under a fume hood (16,40,207). 
After the preincubation was complete, a 2 m£ 
(containing the histidine/biotin solution) 
aliquot of soft agar 
was added to each 
incubate, and the mixture vortexed for 3 sec before being poured 
onto the centre of a minimal glucose agar plate (40,184,207). 
The assay mix was evenly distributed over the surface of the plate 
and left to set for a few minutes on a level surface. This proce-
dure ensured an even distribution of the agar overlay, which is 
critical for uniform colony density (40,202,207) . The pouring and 
distribution was performed within a strictly observed 20 sec time 
limit (20,202) to prevent the soft agar from setting in mid-
operation. Should the agar set too early, a stippled overlay may 
result, which makes the scoring of revertants difficult. 
83 
The plates were then incubated at 37°C (20,202) in a Forma 3028 
incubator (this specific model has been recommended for use in the 
Ames assay as it was found to have a maximum temperature grad ient 
of only 0,25°C (40)). A relative humidity of 80% was employed as 
this has been found to retard the drying of the agar without 
causing excess condensation, which would permit the mobile 
Salmonella colonies to migrate (40). 
The number of revertant colonies was counted manually after 48 hr, 
63 hr, and 72 hr, until a plateau in colony count was reached (40, 
76,78), and the presence of a background lawn was confirmed (see 
5ection 5.5.2.2). The number of revertant colonies/plate was 
assumed to reflect the metabolic activation of the test mutagen by 
the various 59 preparations. 
5.5.4 Protocol of Mutagenicity Assays Performed 
The mutagen/tester strain combinations used are shown in Table 5.4, 
and the mutagenicity assays performed are summarized in Table 5.3. 
Experiments 17-28 of this investigation assayed the activation of 
the test mutagens, by the differently pretreated 59 preparations. 
The balance of the experimental protocol consisted of controls. 
Tests 1-3 determined the spontaneous reversion frequency of each 
strain. Tests 4-6 tested DM50 for mutagenicity and tests 7-9, 
sodium phenobarbital. Tests 10- 15 were used to confirm the 
nonmutagenicity of the two steroids. Each set of controls was 
performed with no 59 (phosphate buffer only), uninduced 59, and 
induced 59 (see Table 5.3). Test 16 was included in order to test 
the mutagenicity of the test compounds without activation by 59. 
It is generally recommended that each assay be duplicated (56,76, 
78); all the tests and controls in this study were repeated in 
triplicate. 
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Table 5.3 Protocol for Mutagenicity Assays 
Test Test Compound Dose/P late S9 Source 
1 None Buffer only 
1 None A 
3 None G 
4 OMSO 0,10 m£ Buffer only 
5 OMSO 0.10rnR A 
6 OMSO 0,10 m£ G 
7 P8 5,00 m9 Buffer only 
hble 5.4 Tester-Strain / Mutagen Combinations 
8 P8 5,00 m9 A 
9 PB 5,00 m9 G 
10 £2 500,00 .9 Buffer only Tester Mutagen Mutagen Solvent 59 Cone. Strain Dose (~l/plate) 
11 £2 500,00 .9 A 
12 £2 500,00 .9 G TA 97 BP 0.50 \.Ig OMSO 20 
13 PRG 500,00 
.9 Buffer only 
14 PRG 500,00 A TA 98 AF8, O. 10 ~g DMSO 10 
.9 
15 PRG 500,00 
.9 G fA 100 OMN 1,48 mg "10 100 
16 Test Mutagen See Table 5.4 Buffer only fA 102 MMC 0.25 1019 
"10 10 
17 Test Mutagen See Table 5.4 A 
18 Test Mutagen See Table 5.4 G 
19 Test Mutagen See Table 5.4 8 
20 Test Mutagen See Tab Ie 5.4 
" 21 Test Mutagen See Table 5.4 C 
21 Test Mutagen See Table 5.4 I 
23 Test Mutagen See Table 5.4 0 
24 Test Mutagen See Table 5.4 J 
25 Test Mutagen See Table 5.4 E 
26 Test Mutagen See Ta ble 5.4 K 
27 Test Mutagen See Table 5.4 F 
18 Test Mutagen See Table 5.4 l 
Test compounds were compounded so that dose could be added to the mix in 0.1 mt solvent (see Appendix 1). 
Each assay was performed in triplicate for each of the 4 tester stra ins (TA9? TA9S. TAtOO and TA102). 
The S9 pretreatments are summdrized in Table 5.1 , reproduced here. 
TREATMENT RAT GROUP 
UNINDUCEO PB-INOUCEO 
No Treatment A G 
Ethyl Oleate Only B 
" 
17s-0estradiol 1 m9/k9 C 
17s-0estradiol 10 m9/k9 0 J 
Progesterone 1 mg/kg E K 
Progesterone 20 mg/kg F l 
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5.6 STATISTICAL ANALYSIS 
Data analysis was 
procedure, described 
performed by the Student-Newman-Keuls (SNK) 
by Kirk (168), at the 95% level of significan-
ce (a = 0,05). The SNK procedure is an a posteriori contrast, which 
systemat ically compares all possible pairs of group data means, and 
divides the groups into homogeneous subsets, within which the 
difference between any two group means is not significant. 
Differences between two group means which exceed a critical value 
for any subset are significant. This critical value varies, depen-
ding on the number of means in the subset. The procedure is based 
on the test: 
where R (a,g,f) is a range based on a significance level (a), the 
number of groups in the subset (g), and the degrees of freedom (f) 
in the between-groups sum of squares. Sx is the standard error in 
the combined subset. The SNK procedure was performed using a 
subprogramme of the StatisticaL Package for the SociaL Sciences 
(SPSS) (Voge lback Computing Centre, Northwestern University). This 
subprogramme also generated various descriptive statistics on the 
data in addition to performing a one-way analysis of variance (F 
Ratio) and two tests for homogeneity of variance (Cochran's and 
Bartlett-Box) (see Appendix 2 for programmes). 
Statist ical models for the analysis of data in mutagenicity screen-
ing, using the Ames test, have been discussed in considerable 
detail in the literature, although no particular method is present-
ly recommended (41,62,77,134,161,199,200,224,225,202,236,257,266, 
274,293,298) . 
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CHAPTER 6 RESULTS AND DISCUSSION 
6.1 EFFECTS OF PRETREATMENT ON THE RATS 
6.1.1 Steroid Pret reatment 
6.1.1.1 Effects on General Appearance 
Pretreatment of fema le Sprague-Dawley rats with norethynodrel or 
ethinyl oestradiol (at 20 mg/kg/day for 2 days or more) has been 
reported to cause a change in coat-colour from white to cream, as 
well as a certain amount of hair-loss in some animals (135). Loss 
of hair has also been reported after protracted pretreatment with 
high doses of a norethynodrel/mestranol combination (61) . 
Although no changes in coat-colour were observed with the E2 or PRG 
pretreatments of this study, slight alopecia was observed in rats 
receiving 20 mg PRG per kg (groups F and L). 
Rats receiving the higher doses of both E2 and PRG became · list less 
and appeared unwell. These rat groups also showed the greatest loss 
in body weight after steroid treatment (see Section 6.1.1.2), and 
it is possible that these observations are interrelated. 
A pronounced increase in general fat deposition was observed, on 
dissection, in rats treated with E2. Tissues affected were the 
breasts and several abdominal organs, including the liver, spleen, 
kidneys, and the gastrointestinal tract. These clearly visible 
fatty deposits were 'patchy' at 1 mg/kg, but were more extensive in 
rats receiving the higher dose. 
This phenomenon was not observed in either the untreated or 
vehiCle-injected control rats, or in rats receiving the lower doses 
of PRG . A certain amount of fat deposition was evident in the 
breast tissue of rats receiving PRG at the higher dose level. 
87 
Figure 6.1 : Effect of Pretreatment with E2 
(20 mg/kg/day) on the Uterine Horns. Untreated 
control on left. 
Figure 6.2: Effect of Pretreatment with E2 
(20 mg/kg/day) on the Liver. Untreated control 
on left. 
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The uterine horns of rats pretreated with E2 were considerably 
enlarged and filled with clear fluid (see Figure 6.1); this 
uterotropic effect was more pronounced in those rats receiving the 
higher E2 dose. Welch et aZ. (300) have also reported an increase 
in uterine mass after E2 pretreatment. 
The livers of rats pretreated with E2 were also visibly enlarged, 
and the lobes of the liver were more 'rounded' in shape than those 
of either control or vehicle-injected rats (Figure 6.2). Post-
mortem tests, performed by the State Veterinary Laboratory, Graham-
stown, confirmed the absence of any infection; thus, the observed 
changes were probably the result of the steroid pretreatments. 
6.1.1.2 Effects on Body Mass 
It has been reported that pretreatment with E2 (1 mg/kg/day for 14 
days) (52), or with various synthetic oestrogens and progestins 
(61,96,255), cause a decrease in the body mass of experimental 
rats. The effects of the steroid pretreatments on body mass in this 
study conform to the reported findings, and are shown in Table 6.1 
and represented graphically in Figure 6.3. 
Control rats (group A) weighed 109% of their original mass after 
two weeks, a percentage increase which is in agreement with the 
reported findings of other investigators (61,135). The mass gain in 
vehicle-injected control rats (group B) was not significantly 
different from that of the rat group which was untreated. 
After two weeks of E2 pretreatment at 1 mg/kg (group C) or 20 mg/kg 
(group D), rats weighed 97% and 93% of their original mass respec-
tively. Although mass loss at the higher dose of E2 was greater 
than that at the lower dose, the difference was not statistically 
significant. 
Progesterone pretreatment also caused a significant loss of body 
mass. Rats in group E (1 mg/kg) weighed an average of 98% of their 
original mass after two weeks. Those in group F (20 mg/kg) weighed 
92% of their original mass, a significantly greater loss than that 
observed with the lower dose of PRG. 
Table 6.1 Effect of Pretreatment on Mass Gain, Liver Mass and Liver/Body Mass Ratio. 
Data represent means ± S.E. for groups of 2 rats. See also Figure 6.3 and 6.4 
Rat 
Group 
A 
B 
C 
0 
E 
F 
G 
H 
J 
K 
l 
Initial Mass 
(l.M. ) 
(g) 
204,68 • 13,68 
205,78 • 1,23 
219,47 :t 7,99 
209.75 • 2.75 
205,48. 2,88 
218,50 • 13,50 
218,25 • 10,95 
200,45 • 4,75 
217,60 .8,40 
217,58 ± 6,73 
220,50 • 8,50 
207,75 t 7,55 
Final Mass 
(F .M .) 
(g) 
223,58. 17,08 
220,49 • 0,91 
213,80. 10,BO 
195.75 • 2,85 
201,OB • 0,41 
200,65 • 15, 20 
236,79 • 10,69 
212,54 ± 6,54 
20B,14. 8,23 
203,16 • 4,33 
212,63 • 6,50 
189,19 • 4,85 
F .M.II .M. 
x 100 
(%) 
109,17 • 1,04 
107,16 • 0,19 
97,37 ± 1,38 
93,29 • 0,17 
97,88 ± 1,57 
91,75 • 1,29 
108,52 • 0,55 
106,01 • 0.75 
95 ,65 • 0,09 
93,40 ± 0,90 
96,46 • 0,77 
91,10 • 0,98 
liver Mass 
(g) 
8,30. 0,53 
8,56. 0,03 
10,48. 0,62 
10,45.0,15 
9.01 .0,10 
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6.1.1.3 Effects on Liver Mass and Liver Somatic Index 
There was an increase in liver size, both in actual terms and in 
relation to the body mass, in all the steroid-pretreated groups, 
when compared with control values. 
Due to the concomitant variations in body mass, statistical 
analysis was not performed on the changes in liver mass but on the 
relationship between liver mass and total body mass. This 
relationship is expressed as the liver mass/body mass ratio, or as 
the liver somatic index {LSI} {units g/100g, or %} {73,92}. The 
effects of the steroid pretreatments on the LSI are shown in Table 
6.1 and Figure 6.4. 
The mean LSI of uninduced control rats {group A} was 3,72, a value 
similar to those reported for untreated rats {52,73,135,235}. 
A significant and dose-dependent increase in LSI over contro l 
values was observed with both E2 and PRG pretreatment. The mean LSI 
of rats receiving 20 mg/kg of E2 was significantly higher than that 
of rats receiving 1 mg/kg. Similarly, the mean LSI of the rats 
pretreated with PRG at a level of 20 mg/kg was significantly higher 
than that observed after pretreatment at 1 mg/kg. 
The observed increases in the LSI following pretreatment with E2 
were in agreement with the reported effects of similar doses of the 
steroid {4,52}. In these other studies, no change in liver mass was 
found and, therefore, the increase in LSI was attributed to 
decreased body mass alone. 
In this study however the increased LSI, which followed steroid 
pretreatment was associated with both a decrease in body mass and a 
real increase in liver mass. 
Similar findings have been reported after the pretreatment of mice 
with E2 and PRG {82}, and of rats with several synthetic sex-
steroids {61,135,255,290}. A significant increase in liver mass of 
between 33% and 50% has also been observed in pregnant rats 
{72,73,226,294}. 
7,50 
92 
Figure 6.4 Effect of Pretreatment on Liver/Body Mass Ratio 
For each observation. n = 2 
Graph shows both data measurements and means 
of each rat group 
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6.1.2 Effect of Induction by PB 
Each of the control and steroid pretreated groups were duplicated, 
one set of groups (A-F) being uninduced while a second (G-L) were 
induced by PB. 
Rats which were induced by PB, but which otherwise were either 
untreated (Group G) or injected with vehicle only (Group H) 
experienced an increase in mass, which was similar to that of the 
equivalent uninduced control groups (Figure 6.3). This is in agree-
ment with the findings of McLean and Marshall (217) and Peraino et 
al. (235). 
Induction by PB also did not alter any of the changes induced by 
the various steroid-pretreatments, in mass gain (Figure 6.3), fat 
deposition, or uterine size. 
Induction by PB increased both the liver mass and, since the body 
mass was unaffected, the LSI of all the rat groups (both control 
and treatment). The increased liver size, which was observed after 
induction by PB, was of the same order of magnitude as the 
increases (20%-60%) reported in the literature (66,120,248,296). 
Rat groups which were induced by PB responded to the steroid 
pretreatments 
groups, but 
(Figure 6.4). 
in a very similar way to the equivalent uninduced 
there was a pronounced upward 'shift' of the pattern 
A strongly positive relationship has been found between the liver 
hypertrophy produced by PB (and other inducing agents) and the 
level of enzyme induction produced (66). It is possible therefore 
that the hypertrophy of the liver produced by the steroid pretreat-
ments of this study may be indicative of the increased synthesis of 
drug-metabolizing enzymes, among other proteins. 
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6.2 THE MUTAGENICITY ASSAYS 
6.2.1 Genotype Confirmations 
Genotype tests were performed, as detailed in Section 5.4, on 
arrival of the tester strains, and all four of the strains were 
found to have retained their genetic characteristics in transit. 
Genotypic confirmations were also incorporated into each mutageni-
city assay, and, in the very few instances when these were 
inconclusive, the assays were repeated with fresh cultures. 
6.2.2 Mutagenicity Controls 
The results of all the mutagenicity assays, both tests and 
controls, for the four tester strain/mutagen combinations are 
represented as summarized here 
Strain/Mutagen Table Figure 
-_. 
TA97/BP 6.2 6.5 
TA98/AFB 1 6.3 6. 7 
TA100/DMN 6.4 6.10 
TA102/MMC 6.5 6.12 
6.2.2.1 Spontaneous Reversion 
In this study, the SRF, without S9, was determined by test 1, while 
tests 2 and 3 corresponded to the SRF with un induced S9 (A) and PB-
induced S9 (G), respectively. 
The mean SRFs of the three uvrB- tester strains, TA97, TA98, and 
TA100 were found to lie well within the published limits (Tables 
6.2, 6.3, and 6.4), while the mean SRF of TA102 was just below the 
published lower limit (Table 6.5). 
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Maron (201) has confirmed that, despite the low SRF observed for 
TA102 in this study, the extent of reversion by the standard 
mutagen (MMC) implies that this SRF is still acceptable. Also, the 
SRF of all four strains was consistent within the ranges 
established in this laboratory, a fact which is another important 
consideration (76). Apparently, difficulty in the establishment of 
a good 5RF range is a problem inherent with a strain carrying a 
multicopy plasmid (201), and several laboratories have experienced 
this problem (7). 
There was' no change in the SRF of any of the tester strains when S9 
(either uninduced or PB-induced) was added to the incubate. 
6.2.2.2 Mutagenicity of DMSO 
The mutagenicity of the solvent DMSO, used for BP and AFB 1, was 
investigated in tests 4, 5 and 6. For all four tester strains, no 
increase in reversion frequency was observed in these tests, and, 
therefore, the reported nonmutagenicity of DMSO, and its suitabili-
ty as a solvent for nonpolar mutagens in the Ames test (74,174,202, 
203) was confirmed. 
6.2.2.3 Mutagenicity of PB 
Although PB, administered in the drinking water to induce the 
enzymes of groups G-L, is reported to be nonmutagenic (127,213,215, 
217,284), tests 7, 8, and 9 were included to confirm these 
findings. PB was found to be nonmutagenic, both with and without 
the incorporation of 59, when tested with the standard tester 
strain set (Tables 6.2, 6.3, 6.4 and 6.5). 
6.2.2.4 Mutagenicity of the Steroids 
As described in Section 3.5, E2 and PRG have been found to be 
nonmutagenic in Salmonella, at concentrations below those which 
were toxic to the bacteria. Neither E2 (test 10, 11 and 12) nor PRG 
(tests 13, 14 and 15), at the highest concentration which is still 
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considered to be subtoxic (SOD ~g/plate), caused any increase in 
the number of revertant colonies/plate with any of the tester 
strains (Figures 6.5, 6.7, 6.10, and 6.12). These results confirmed 
the reported nonmutagenicity of the sex-steroids. 
6.2.2.5 Mutagenicity Without Metabolic Activation 
Each mutagen was tested with the strain chosen to detect it in the 
absence of a microsomal (S9) fraction (test 16). 
OMN, 8P and AF8 1 failed to increase the number of his+ revertants 
per plate when tested with their respective tester strains (Figures 
6.5, 6.7, and 6.10), a finding which confirmed their reported 
requirement for metabolic activation to mutagenic metabolites 
(Chapter 2). 
MMC however caused a two-fold increase in the number of revertants 
per plate over the SRF of TA102. (Figure 6.12). This was not 
unexpected as MMC is known to cause mutation in TA102 without S9 
activation (Section 2.5). 
6.2.3 Effects of Sex-Steroids on Mutagen Activation 
6.2.3.1 8enzo(a)pyrene 
The results of the mutagenicity assays using TA97 and different 
liver microsomal fractions to activate 8P are shown in Table 6.2, 
and graphically represented in Figures 6.5 and 6.6. 
The incubation of BP with S9 from untreated rats (test 17; S9:A) or 
from rats injected with vehicle only (test 19; S9:8) caused no 
increase in reversion frequency over controls. 
S9 pretreated with either dose of E2 (test 21; S9:C and test 23; 
S9:0) also failed to increase the number of his+ revertants per 
plate. 
Table 6.2 Results of TA97 / BP Mutagenicity Assays 
Tester Strain ; TA 97 Mutagen : BP Mutagen Dose 0,5 ~g 
Spontaneous Reversion limits: 90 - 180 
59 Concentration 20 loll . 
Data represent 3 plate counts (visible revertant colonies / plate), listed from sma l lest to largest count; 
count means, standard errors (S.E.). and 95% confidence intervals (C.I. ) of means, the latter calculated from 
antilogs of transformed data. Also shown are the logarithmic transformations (base 10) of the original data. 
Plate 95% C. Lof Means Lag l0 Transformations Test Means S.E. 
A B C Lowe r Upper Means S.E. 
Revertant Colonies/Plate 
"- "-
01 143 144 153 146,67 3,18 133,66 160,77 2,166 0,009 
02 147 157 163 155,67 4,67 136,58 177 ,09 2,192 0,013 
03 139 146 154 146,33 4,33 128,74 166,07 2,165 0,013 
04 143 151 152 148,67 2,85 136,74 161,51 2,172 0,008 
05 140 142 151 144,33 3,38 130,56 159,40 2,159 0,010 
06 141 148 157 148,67 4,63 129,93 169,79 2,172 0,014 
07 138 145 149 144,00 3,21 130,68 158,53 2,158 O,OlD 
08 144 145 153 147,33 2,85 135,61 159,92 2,168 0,008 
09 138 145 147 143,33 2,73 131,92 155,60 2,156 0,008 
10 143 151 154 149,33 3,28 135,68 164,21 2,174 0,010 
11 141 149 154 148,00 3,79 132,40 165,20 2,170 0,011 
12 141 153 155 149,67 4,37 131,64 169,B6 2,175 0,013 
13 143 150 153 148,67 2,96 136,33 161 ,99 2,172 0,009 
14 136 139 14B 141,00 3,61 126,36 157,14 2,149 0,011 
15 139 149 154 147,33 4,41 129,27 167,61 2,168 0,013 
16 151 157 162 156,67 3,18 143,48 170,92 2,195 0,009 
17 144 156 157 152,33 4,18 135,05 171,55 2,183 0,012 
18 450 459 465 458,00 4,36 439,54 477 ,09 2,661 0,004 
19 155 167 169 163,67 4,37 145,58 183,74 2,214 0,012 
20 455 468 471 464,67 4,91 443,92 486,30 2,667 0,005 
21 152 156 164 157,33 3,53 142,86 173 ,10 2,197 o ,OlD 
22 44 1 453 462 452,00 6,08 426,48 478,96 2,655 0,006 
23 147 155 161 154,33 4,06 137,69 172 ,78 2,188 0,012 
24 457 470 472 466,33 4,70 446,38 487,08 2,669 0,004 
25 274 285 290 283,00 4,73 263,21 304,09 2,452 0,007 
26 470 479 489 479,33 5,49 456,25 503,50 2,6Bl 0,005 
27 251 255 266 257,33 4,48 238,78 277 ,14 2,4lD 0,008 
28 460 461 479 466,67 6,17 440,96 493 ,74 2,669 0,006 
'" 
" 
Si2nificance of F in One-wdl Ana1lsis of Va riance 
L0910 Oata : F-Prob = 0,0000 
P Values for 2 Data Homoscedasticit~ Tests 
I. Cochran's Test (Max.variance/sum of variances) 
Raw Data P = 1,000 (approx.) 
l09 1D Data P = 1,000 (approx.) 
2. Bartlett-Box Test (Max .va ri ance/Min .variance) 
Raw Data P = 1,000 
L0910 Oata P = 0,999 
See also Figure 6.S and 6.6 
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A significant increase in the number of colonies per plate over 
control values was observed when S9 pretreated with PRG was used. 
The lower PRG dose (1 mg/kg, test 25; S9: E) caused significantly 
more revertants than the higher dose (20 mg/kg, test 27; S9:F). 
S9 prepared from each of the rat groups which were induced by PB 
(G-L) (tests 18, 20, 22, 24, 26 and 28) showed a three-fold 
increase in the reversion rate over uninduced untreated controls 
(test 17; S9:A). No statistical differences were detected among any 
of these groups. 
The metabolism of BP (Section 2.4) is complex, invo lving pathways 
of mutagenic activation and detoxification catalysed by different 
groups of enzymes. 
The hepatic microsomal fraction in the assay contains both the 
enzymes involved in BP epoxidation, cyt P-450 and cyt P-448, and 
EH, which hydrolyses the BP epoxides to the corresponding dihydro-
diols (281). Therefore, the resultant mutagenicity of BP in 
Salmonella is dependent on the ratio of the activities of the 
different enzymes (including level of induction) involved (281). 
The metabo lic activation of BP to mutagenic intermediates in 
Salmonella is reportedly enhanced by the induction of the S9 
fraction by 3MC, a phenomenon which suggests that the mutagenicity 
of BP may be preferentially mediated by a cyt P-448-dependent mono-
oxygenase (132,267). However, the K-region epoxidation of BP is 
supported by a cyt P-450 inducible by PB, as is the activity of EH, 
which facilitates the secondary activation of BP-7,8-dihydrodiol to 
another mutagenic metabolite. 
Therefore, the enhanced mutagenic activation of BP by an S9 
fraction which was induced by PB is not inexplicable . These 
findings would seem to reflect that the active metabolites 
mentioned above contribute significantly to the in vitro mutageni-
city of BP when the liver is induced by PB. 
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Tauc et aL. (281) have also shown an increase in the mutagenicity 
of BP when the 59 was induced by PB, yet far greater mutagenic 
activity was observed after induction with 3MC. 
Although it is not clear why the lower dose of PRG caused a greater 
response than the higher dose, the results at both dose levels 
indicate that PRG is capable of the induction of the enzymes invol-
ved in the mutagenic activation of BP. 
A possible explanation for this phenomenon might be that the higher 
dose of PRG enhances the activity of one or more of the enzymes 
involved in the detoxification of the mutagenic metabolites of BP. 
5ince the microsomal fraction contained a fu!i complement of 
metabolic enzymes, it is not possible to characterize the particu-
lar haemoprotein P-450 (or other enzyme) induced by PRG. 
6.2.3.2 Aflatoxin B1 
The effects of the different 59 fractions on the metabolic activa-
tion of AFB1 to mutagenic metabolites (as detected by TA98) are 
shown in Table 6.3, and Figures 6.7 and 6.8. 
The reversion produced by the 59 of the untreated (test 17; 59:A) 
and vehicle-injected (test 19; 59:B) control groups was unchanged 
from the spontaneous reversion rate for this strain. 
No increase in the number of his+ colonies/plate over controls 
occurred with E2-pretreatment at 1 mg/kg (test 21; 59 :C). When 
administered at 20 mg/ kg (test 23; 59 0) however, significant 
increases over controls were observed. 
Both doses of PRG enhanced AFB1 activation considerably. Adminis-
tration at 20 mg/kg (test 27; 59 :F) resulted in significantly 
greater induction than at 1 mg/ kg (test 25; 59 :E). 
Table 6.3 Results of TA98 / AF8 1 Mutagenicity Assays 
Tester Strain: TA 98 Mutagen : AFB, Mutagen Dose 0,1 .g S9 Concentration 20 .f 
Spontaneous Reversion Limits: 20 - 50 
Data represent 3 plate counts (visible revertant colonies / plate), listed from smallest to largest cQunt; 
count means, standard errors (S.E.), and 95~ confidence intervals (C . l.) of means, the latter calculated from 
antilogs of transformed data. Also shown are the loga rithmic transformations (base 10) of the original data. 
Plate 95% C.I.of Means Lag 10 Transformations Test Means S.E. 
A 8 C lower Upper Means S.L 
Revertant Colon ies/Plate !. !. 
01 29 33 37 33,00 2,3 1 24,26 44,45 1,516 0,031 
02 31 32 40 34,33 2,85 24,15 48,16 1,533 0,035 0 
03 29 31 37 32,33 2,40 23,52 43 ,96 1,507 0,032 N 
04 26 30 34 30, 00 2,31 21,36 41,62 1,475 0,034 
05 33 37 42 37,33 2,60 27 ,53 50,13 1,570 0,030 
06 33 34 41 36,00 2,52 26,75 48,00 1,554 0,030 
07 27 29 37 31,00 3,06 20,38 46,29 1,487 0,041 Signi ficance of F in One-wax Analysis of Variance 
08 29 34 35 32,67 1,86 25,32 41,87 1,513 0,025 
09 26 31 35 30,67 2,60 21,00 44 , 13 1,484 0,038 log'0 Oata : F-Prob " 0,000 
10 28 32 37 32,33 2,60 22,72 45,42 1,507 0,035 
II 28 35 35 32,67 2,33 23,59 44,75 1,512 0,032 
12 26 29 33 29,33 2,03 21,70 39,27 1,465 0,030 P Values tor 2 Data Homoscedasticity Tests 
13 25 28 32 28 ,33 2,03 20,74 38,32 1,450 0,031 
14 32 37 39 36,00 2,08 27,82 46,27 1,555 0,026 1. Cochran I 5 Test (Max. varianceisum of vari ances) 
15 28 29 35 30,67 2,19 22,65 41,11 1,485 0,030 
16 26 27 33 28,67 2,19 20,73 39, 19 1,455 0,032 Raw Data P " 0,012 ,app ro,.) 
17 29 35 40 34,67 3 ,18 23,01 51,35 1,536 0,041 
18 361 374 392 375,67 8,99 338,84 416,01 2,575 0,010 log,O Oata P " 1,000 ,appro,.) 
19 32 39 39 36,67 2,33 27,49 48,48 1,562 0,029 
20 374 393 407 391,33 9,56 351,88 434 ,61 2,592 0,011 2. Bartlett-Box Test (Max.variance/Min.variance) 
21 32 40 41 37,66 2,85 26,67 52,55 1,573 0,034 
22 373 417 425 405,00 16,17 339,39 481,73 2,607 0,018 Raw Data P " 0,006 
23 59 73 81 71,00 6,43 47,13 105,15 1,848 0,041 
24 367 375 384 375,33 4,91 354,73 397,01 2,574 0,006 log,O Oata P = 0.973 
25 97 109 117 107,67 5,81 84,86 135,80 2,031 0,024 
26 377 398 413 396,00 10,44 353 , 10 443,51 2,597 0,012 
27 263 271 296 276,67 9,94 237,19 321,88 2,441 0,015 
28 383 420 427 410,00 13,65 354,08 473,70 2,612 0,015 See also Figure 6.7 and 6 .8 
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Figure 6. 7 Results of TA98/AFBl Mutagenicity Assays 
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6.9 a) His+ Revertant TA98 Colonies Produced After Incubation 
of AFBl with control (untreated) 59 (Test 17; 59:A) 
6.9 b) His+ Revertant TA98 Colonies Produced After Incubation 
of AFBl with 59 induced by PB (Test 18; 59:G) 
Figure 6.9 Effect of Induction by PB on Activation of AFBl 
to mutagenically active metabolites, using S.typhimurium TA98. 
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Figure 6.9 shows the ten-fold increase in reversion rates (over 
controls ) produced by 59 induced by PB. No significant differences 
were found among any of the groups which were induced by PB (tests 
18, 20, 22, 24, 26 and 28). 
The toxicity of AFB 1, like that of BP, depends on the balance 
between activation and detoxification reactions, specifically the 
relative rates of the epoxidation reaction giving rise to AFB l -2,3-
epoxide and on the subsequent conjugat i on with glutathione (Section 
2.3) (267). However, unlike the metabolic activation of other 
po lycyclic hydrocarbons, the epoxidation of AFBl is more definit-
ively characterized as being dependent on a cyt P-450 isozyme which 
is induced by PB-type inducers (165,267). 
Hence, the finding that induction by PB enhances the metabolic 
act ivation of AFBl is consistent with what is known about the 
metabolism of the mutagen. Also, since metabolic activation has 
been characterized as being preferentially induced by PB-type 
inducers, it may be justifiable to presume that the steroids are 
PB-type inducers, and that the enhancement of AFBl mutagenesis, by 
both PRG and E2, reflects the induction of a cyt P-450-dependent 
mono-oxygenase (see also Chapter 7). 
6.2.3.3 Dimethylnitrosamine 
The effects of the different 59-pretreatments on the metabolic 
activation of DMN to an alkylating metabolite(s) (as detected by 
TA100) are shown in Table 6.4 and Figures 6.10 and 6.11 . 
DMN, like BP and AFB 1, was not detected as mutagenic with uninduced 
59 (in either control groups) (tests 17 and 19). 
59 from E2-pretreated rats, at either dose, did not cause any 
induction of the enzyme(s) responsible for the activation of DMN to 
metabolites mutagenic to TA100 (tests 21 and 23). 
Table 6.4 Res ults of TA100 I DMN Mutagenicity Assays 
Tester St ra in: TA 100 Mu t agen: OMN Mutagen Dose 1,48 mg 59 Concentration 100 J.l l 
Spontaneous Reversion Limits: 100 - 200 
Data represent 3 plate counts (visibl e revertant co lonies I plate), listed from sma ll est to largest count; 
count means, standa rd errors (5.E . ) . and 95% confidence intervals (C .I. ) of means, the latter calcu lated from 
antilogs of transformed data. Also shown are the logari thm ic transformations (base 10) of the original data. 
Plate 95% C.I .of Means Log
,O Transformations Test Means S.E. 
A B C l ower Upper Means 5.E. 
Revertant Colon ies/Plate ~ ~ 
01 124 129 135 129,33 3,18 11 6,31 143,65 2, 111 0,0 11 
02 124 130 132 128,67 2,40 11 8,60 139,48 2.,109 0,008 
03 120 130 139 129,67 5,49 107,82 155,38 2,112 0,0 19 
04 119 127 130 125,33 3,28 11 1,76 140,35 2,098 0,012 
05 124 129 137 130,00 3,79 114,66 147,13 2,114 0,013 
06 119 128 139 128,67 5,78 105,85 155,74 2,109 0 ,020 
07 122 128 132 127,33 2,91 115,32 140,44 2,105 0,010 
08 120 127 129 125,33 2,73 11 3,97 137 ,69 2 ,098 0,010 
09 119 128 130 125,67 3,38 111,69 141,19 2 ,099 0,012 
10 11 9 128 136 127,67 4,91 107,97 150,52 2,105 0,017 
11 11 9 130 136 128,33 4,98 108,24 151,71 2,108 0,01 7 
12 126 128 134 129 ,33 2,40 119,43 139,99 2,112 0,008 
13 11 6 125 132 124,33 4,63 105,68 145 ,88 2 ,094 0,016 
14 134 135 135 134,67 0,33 133 , 23 136,11 2,129 0,00 1 
15 129 134 139 134,00 2,89 122,07 146,96 2, 127 0,009 
16 11 6 128 137 127,00 6,08 102 ,92 155 ,99 2,103 0 ,021 
17 11 9 138 139 132,00 6,51 105,90 163,72 2 , 120 0 ,022 
18 283 310 339 310,67 16,17 247,57 387,70 2,491 0,023 
19 117 129 140 128,67 6,64 102,66 160 ,40 2,1 08 0,023 
20 297 343 352 330,67 17,03 262,66 414 ,00 2,518 0,023 
21 118 138 143 133,00 7,64 102 ,83 170 ,88 2,122 0,026 
22 274 312 331 305, 67 16,76 239 ,66 387 ,44 2,484 0,024 
23 11 2 126 133 123,67 6,17 99,15 153,43 2,091 0,022 
24 291 307 312 303,33 6,33 276 ,95 331,97 2,482 0,009 
25 237 253 264 251 ,33 7,84 219,38 287 ,41 2,400 0,014 
26 271 298 324 297,67 15,30 237,79 370,68 2,473 0,022 
27 281 295 306 294,00 7,23 264,24 326,74 2,468 0,011 
28 337 379 380 365,33 14,17 307,61 432,51 2,562 0,017 
C> 
!)ignif i cance of f in One-way Analysis at 'Variance ..... 
L0910 Oata : F-Prob = 0,0000 
P Values tor 2 Data Homoscedasticitl Tests 
1. Cochran's lest (Max.varianceis um of variances) 
Raw Data P = 0,286 (approx.) 
Lag lo Data P = 1,000 (approx.) 
2. 6art iett-Box Test (Max.va ri anceiM i n.va ri ar,ce) 
Raw Data P = 0,022 
L09lO Data P = 0,868 
See also Figure 6.10 and 6.11 
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Figure 6.10 Results of TA100/DMN Mutagenicity Assays 
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Figure 6.11 Effect of the 59-pretreatments on the Activation 
of DMN to mutagenic metabolites with TA100 
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The administration of PRG at 1 mg/kg (test 25; 59:E) caused a two-
fold increase in reversion rate over controls. 
An even greater increase occurred when PRG was administered at 
20 mg/kg (test 27; 59:F). In fact, the increase in reversion rate 
at the higher PRG level was not statistica lly dissimilar to the 
increase caused by the induction of 59 by PB. 
As with the other mutagens tested, the induction of 59 with PB 
increased considerably the number of his+ revertants/plate produced 
by DMN, and no other statistically significant differences were 
observed among the PB-induced groups (tests 18, 20, 22, 24, 26 and 
2B) . 
Two forms of DMN demethylase, controlled independently by the 
enzyme inducers 3MC and PB, are thought to exist (see Section 2.2). 
Induction of the rat microsomal MFO system by either PB or 3MC has 
been reported to cause a two-fold increase in the activation of DMN 
to mutagenic metabolites (38,71,195). In fact, an increase of this 
magnitude was observed in this study, with 59 induced by PB using 
the tester strain TA100, whi ch detects base-pair substitution and/ 
or frameshift mutagens . 
In a very similar pattern to that observed with AFB1 activation, 
pretreatment with PRG produced a dose-dependent induction of DMN 
activation, with the magnitude of induction at the higher dose 
being of the same order as that achieved by induction by PB. 
6.2.3.4 Mitomycin C 
The results of the mutageni city assays using MMC and TA102 are 
shown in Table 6.5 and Figures 6.12 and 6.13. 
The inclusion of untreated 59 caused no change in the reversion 
rates observed when MMC was tested without 59 (test 18, 20, 22, 24, 
26 and 28). 
Table 6.5 Results of TAI02 ( MMC Mutagenicity Assays 
Tester Straln : TA 102 Mutagen : MMC Muta2en Dose 0.25 .9 S9 Concentration 20 .t 
Spontaneous Reverslon limits: 240 - 360 
Data represent 3 plate counts (visible revertant colonies / plate), listed from sma llest to largest cQunt; 
count means, standard errors (S.E.), and 95% confidence intervals (c.r.) of means, the latter ca l cu lated from 
antilogs of transformed data. Also shown are the logarithmic transformation s (base 10) of the original data. 
Plate 95i C.I.of Means Lag l0 Transformations Test Means S.E. 
A 8 C Lower Upper Means S. E. 
Revertant Colonies/Plate !: !: 
01 175 203 250 209.33 21.88 132,7 1 323.22 2.316 0.045 
02 182 192 227 200.33 13.64 149,76 265.58 2.300 0.029 
03 171 183 197 183.67 7.5 1 153,78 218.63 2.263 0.018 
04 179 231 239 216.33 18.81 144.94 317.76 2.332 0.040 
05 173 184 235 197.33 19.10 130.77 292.48 2.291 0.041 
06 211 216 273 233.33 19.89 162.67 330.14 2.365 0.036 
07 171 213 248 210.67 22.26 130.92 331.28 2.3 19 0.047 ~i2nificance of F in One-way Anallsis of Variance 
08 177 233 245 218 .33 20.95 139.96 333.89 2.335 0,044 
09 166 179 218 187.67 15.62 131.43 264.42 2.27 1 0.035 L0910 Oata : F-Prob 0 0.0000 
10 194 257 266 239 .00 22 .65 153.96 363.92 2.374 0.043 
II 174 182 252 202.67 24.77 120.95 330.14 2.301 0 .051 
12 184 189 205 192.67 6.33 167,34 221.36 2.284 0 .014 P Va lues for 2 Data Homoscedasttcitl Tests 
13 168 179 202 183.00 10 .02 144.61 230.25 2.261 0 .024 
14 182 191 260 211 ,00 24.64 128.80 336·.90 2.319 0.049 1. Cochran's Test (Max. variance/sum at" variances) 
15 167 180 223 190.00 16.92 129,87 273 .72 2.275 0.038 
16 408 478 507 464.33 29.38 349,78 611.22 2.665 0.028 Raw Data P 0 0.036 (approx.) 
17 334 387 463 394.67 37 .44 260.56 587.22 2.592 0.041 
18 1060 1130 1300 1163.33 71.26 894.33 1502. 10 3.064 0.026 L0910 Oata P 0 1.000 (approx.) 
19 581 590 674 615.00 29.61 500.96 751 .62 2.788 0 .021 
20 981 982 1020 994.33 12 .84 940.81 1050.51 2.998 0.006 2. Bartlett-Box lest (Max.variance/M in . variance) 
21 464 467 583 504.67 39.18 363 .33 692.95 2.701 0.033 
22 990 1130 1200 1106.67 61,73 863.97 1408.64 3.043 0.025 Raw Data P 0 0 .049 
23 377 395 459 41 0.33 24,88 316.66 527.84 2.612 0.026 
24 1050 1250 1350 1216 .67 88.19 878.82 1666.10 3.083 0.032 L0910 Data P 0 0.964 
25 382 420 437 413 .00 16.26 347.30 489.55 2.615 0.017 
26 913 960 1010 961.00 28.01 847.03 1088.43 2.982 0.013 
27 460 512 540 504.00 23.44 410,S:! 616.03 2,702 0,021 
28 990 1020 1250 1086.67 82.12 788.50 1481.15 3.034 0.032 See also Figure 6.12 and 6.13 
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Figure 6.12 Results of TA102/MMC Mutagenicity Assays 
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Significantly more his+ revertants/plate were scored on plates 
which incorporated S9 from vehicle-injected rats (test 19; 
S9:B)than with untreated S9 (test 17; S9:A). This result is unusual 
when compared both with the results of similar tests with other 
strains and with the other steroid-pretreated groups with the same 
strain. 
The administration of either dose of E2 to rats caused no signifi-
cant increase in reversion rates over the untreated S9 control 
groups (tests 21 and 23). 
Although PRG administration at 20 mg/kg (test 27; S9:F) caused 
increased reversion over controls, this increase was not signifi-
cant. Therefore, unlike the findings with the other three tester 
strains, neither dose of PRG (see also test 25) caused an increase 
in mutagenic activation. 
Very high numbers of revertants/plate were observed when S9 induced 
with PB was incubated with MMC. As with the other mutagen/strain 
combinations, no significant differences were observed among the 
PB-induced groups (test 18, 20, 22, 24, 26 and 28). 
The metabol ism of MMC to mutagenically active species, described in 
Section 2.5, is essentially different to that of the other test 
mutagens. 
Alkylating species are produced by NADPH-dependent enzymatic reduc-
tion of MMC, and DNA cleavage can result from the formation of free 
radicals, in cyclic redox processes (147,192). Although MMC was 
recommended as a positive control for TA102 in the 1983 'methods' 
paper of Maron and Ames (202), correspondence received since that 
publication has advised that MMC no longer be so utilized as it 
causes extragenic suppressor mutations (7,201). These mutat ions 
result in slow-growing pin-point colonies associated with both 
scoring difficulties and wide 
the bacteria to the mutagen 
variations in the exposure time of 
(7,201). Danthron, an anthracene 
quinone, is now recommended as a positive control requiring S9 
activation (7,201). 
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It may be then that the somewhat unusual results observed with MMC 
and TA102 are related to the use of both difficult substrate and 
strain. 
Even so, a similar result to those observed with the other tester 
strain/mutagen combinations was observed on induction by PB. Thus 
it would appear that an enzyme inducible by PB plays an important 
role in MMC activation. Although the inclusion of a microsomal S9 
fraction was found to increase the mutagenic response several-fold, 
no details of the inducibility of the enzymes involved in MMC 
activation have been reported. The observed increase in the metabo-
lic activation of MMC, by microsomes induced by PB, to mutagenic 
metabolites in this study cannot therefore be corroborated by the 
literature. 
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CHAPTER 7 CONCLUSIONS 
Species- and sex-related differences in the metabolism of 
promutagens may be related to heterogeneity of the structural or 
regulatory genes associated with the synthesis of metabolic 
enzymes. Alternatively, they may result from the influence of 
secondary factors, such as environmental or hormonal parameters, on 
the activity of these enzymes. 
Because several of the natural and synthetic female sex-steroids 
(including components of the oral contraceptive formulations) have 
been implicated in the carcinogenic process, the elucidation of 
hormonal control of mutagen metabolism is considered to be of some 
importance. 
This study has confirmed, in SaLmoneLLa, the reported nonmutagen-
icity of the steroids, but on the other hand it has also indicated 
that the steroids may influence the metabolism of mutagens. These 
findings support the hypothesis that the sex-steroids may act as 
'promoters', rather than 'initiators' of tumours. 
Specifically, the results of this study suggest that supraphysiol-
ogical doses of PRG may cause a definite dose-related inductive 
effect on the activation of mutagens. With DMN , the degree of 
induction produced by PRG was as high as that produced by the 
classical inducer, PB. 
Pretreatment with high levels of E2 only induced the activation of 
one of the four test mutagens, AFB1 (and this only at the higher 
dose), and, therefore, it appears that pretreatment with E2 has 
little or no inductive effect on the metabolism of the other test 
mutagens. 
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The present results are in agreement with those of Bakshi et al. 
(31), who showed that pretreatment of mice with sex-steroids 
enhanced the in vitro mutagenic activation of DMN and 2-acetyl-
aminofluorene in the Ames test. Both PRG and E2, when administered 
at similar levels to those of this investigation, have also been 
reported to induce the activities of several of the mono-oxygenases 
of drug metabolism and to enhance the hepatic levels of cyt P-450 
(Chapter 4). 
A bacterial mutagenicity assay, coupled to a microsomal metabolic 
activation system, was used to monitor the formation of active 
metabolites. The rate of mutagenic activation, as measured by the 
reversion to prototrophy of histidine auxotrophes of Salmonella, 
was assumed to reflect the metabolic capacity of the liver in the 
intact animal. 
The Ames test, employed in this manner, does not constitute a 
specific assay for any of the enzymes involved in mutagen activa-
tion. The hepatic microsomal fraction used in the assay contains 
the complex array of enzymes involved in both the activation and 
detoxification of mutagens, including the cyt(s) P-450-dependent 
mono-oxygenases, EH, and the conjugating enzymes of detoxification 
(267,281). Therefore, the assay measures the overall result, under 
the different conditions of each test, of the set of complex reac-
tions involved in the activation and detoxification of each mutagen 
(13,267,281). 
For the purposes of this investigation, this situation may repre-
sent a more faithful reproduction of the in vivo situation than 
would assays for specific enzymes, although these have great value 
in the characterization of the activities of the enzymes of mutagen 
metabolism (281). 
It does follow however that the Salmonella/microsome test does not 
differentiate between the discrete cytochrome(s) species and will 
detect the induction of mono-oxygenases which are dependent on 
either cytochromes P-450 or cytochromes P-448. 
11 8 
The fact that the induction of the microsomal enzymes with PB was 
found to enhance the activation of all four test mutagens indicates 
that cytochrome P-450-dependent mono-oxygenases are important to 
the metabolism of each of the mutagens. In addition, no additive 
effects on the induction of mutagen metabolism were observed when 
steroid-pretreated rats were also induced by PB. These observations 
may indicate that the steroids induce the same cyt P-450-dependent 
isozymes which are inducible by PB. 
Similar findings were noted by other investigators (135,231), who 
have reported that combined treatment with PB and the sex-steroids 
enhance the levels of both cyt P-450 and CcR in the liver of the 
rat to levels similar to those observed after pretreatment with PB 
alone. 
Finally, in any appraisal of an ~n vitro investigation, such as the 
one described here, a number of factors must be considered : 
First and foremost is the relevance of an in vitro assay which 
utilizes an homogenate of rat liver as an approximation of the in 
vivo metabolism of the intact organism (Section 1.5.3). 
Also of considerable importance is the extent of the correlation 
between in vitro mutagenicity and the in vivo risk of carcinogeni-
city (Section 1.5.3). In particular, there have been reports that, 
while enzyme induction has enhanced the in vitro activation of 
mutagens, it has provided protection, in vivo, from the carcino-
genic effects of these same compounds (Section 2.2). 
Although this investigation confirms the reported inductive effects 
of high doses of steroids, the levels of administration were 
greater than those physiologically experienced by either the rat, 
or the human. This having been stated, it is possible that supra-
phYSiological doses administered over a short period of time may 
effect similar changes qualitatively, if not quantitatively, as 
does protracted treatment with lower doses. 
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Although high doses of the female sex-steroids appear to have a 
specific regulatory action on the metabolism of mutagens, hasty 
conclusions should therefore not be drawn concerning any physiolo-
gical regulation of carcinogenic risk by the endogenous steroids in 
animals exposed to environmental mutagens. 
Further studies, into the effects of both physiological and supra-
physiological level s of the sex-steroids, perhaps using the intact 
animal, may provide valuab le clues to further the eluc idation of 
hormonal regulation of mutagen metabolism. 
All reagents used were of analytical grade wherever possible, ana 
all water was double-disti lied. Where steri iization was by 
autociaving, 20 min at 121°e and 15 psi was employed. Bottle-tops 
were loosened prior to autociaving, and retightened on cooling. All 
media and solutions were stored in amber glass bottles at 4°e 
unless otherwise stated. All media plates were prepared one week 
before required (and stored at 4°C ), during which time microbial 
contamination could manifest itself, and any spoiled plates be 
discarded. Fonmulae used in the mutagenicity assays were largely 
those of the revised 'methods' paper of Maron and Ames (202). 
A. Rat Pretreatment and 59 Preparation 
A. t Stero id Pretreatment 
£2 or PRG 
ethyl oleate 
Per 20 ml 
1 mg/kg 
(0,4 mg/m1) 
8mg 
to 20 ml 
20 mg/kg 
(8,0 mg/m1J 
160 mg 
20 m1 
Both steroids were dissolved in ethy l oleate, in the concentrations 
indicated, and distributed into 20 ml amber injection vials, then 
sealed with multidose closures, and sterilized by maintaining at 
lS00e for one hour (206). Control ethyl oleate injections were 
similarly prepared and sterilized. 
B. Genotype Confi rmations 
B.I Crystal Violet Sensitivity (liscs 
Small discs were punched from filter paper and autoclaved. These 
discs were Impregnated with a sterile O,I~ (1 mg/ml) crystal violet 
so lution. 
Appendix 1 Formu I ae 
8.2 Nutrient Agar Plates 
Oxoid nutrient broth no. 2 
Difca-Bacto agar 
di sti lIed water 
Per litre 
25 g 
15 g 
to 1000 m1 
All the ingredients were dissolved in the water in a 21 flask, 
which was then autoclaved. When the agar was cooler, petri-plates 
were poured. 
B.3 0.1 M Histidine Solution 
L-histidine (mol.mass = 209,6) 
di st i lied water 
Per 10 ml 
209,6 mg 
to 10,0 mt 
So lution was prepared and sterilized by autoclaving. 
B.4 0,5 mM Biotin Solution 
D-biotin (mol.mass 244,3) 
disti lIed water to 
Per Ii tre 
122,15mg 
1000 m1 
Solution was prepared and sterilized by autoclaving. 
C. Mutagenicity Assays 
C.1 Nutrient Broth 
Oxoid nutrient broth no. 2 
disti lIed water 
Per litre 
25 g 
to 1000 m1 
Solution was prepared and sterilized by autoclaving. 
N 
o 
C.2 Soft Agar 
Difco-Bacto agar 
sodium chloride (Nael) 
disti lIed water 
Per litre 
6 9 
5 9 
to 1000 m1 
Ingredients were dissolved. and 100 ml aiiquots were transferred to 
250 ml screw-cap bottles, and then autoclaved. 
C.3 Vogel-Bonner Medium E {50 xl 
magnesium sulphate (MgS04 ,7H20) 
CitrIC acid monchydrate (C6Ha07·H20) 
Per litre 
dipotassium hydrogen phosphate (anhyd.) (K ZHP04) 
sodium ammonium phosphate (NaHNH4(P04 .4H20)) 
10 9 
100 9 
500 9 
175 9 
1000 m1 distilled water to 
The salts were added, in the order indicated, to some warm water in 
a 2 1. flask on a magnetic stirring hot plate, Each salt was allowed 
to dissolve completely before adding the next. After adjusting to 
volume, the solution was sterilized by autoclaving (292). 
C.4 0,5 mM Histidine / Biotin Solution 
D-biotin (mol.mass = 244,3) 
L-histidine.HCI (mol.mass = 209.6) 
disti lled water 
Per 250 m1 
30,54 mg 
26,20 mg 
to 250,0 m1. 
Solution was prepared and sterilized by autociaving. 
C.5 1,65 M Potassium Chloride/O,4 M Magnesium Chloride Solution 
Per 100 m1 
potassium chloride (KC!) 
magnesium chloride (MgCI
z
.6H2D) 
disti lled water 
12,30 9 
a ,14 9 
to 100,0 ml. 
Solution was prepared and sterilized by dutoclaving. 
C.6 0,2 M Sodium Phosphate Buffer (pH 7,4) 
Per 100 m1. 
0,2 M sodium dihydrogen phosphate (NaH2P04 .H20) (2,76 g/100 m1) 
0,2 M disodium hydrogen phosphate (Na2HP04) 
(2,84 g/100 m1) 
12 m1. * 
88 m1. * 
* These are approximate values. The pH was adjusted-to pH 7,4. 
The solution was sterilized by autoclaving. 
C.7 0,1 M Nicotinamide Adenine Dinucleotide Phosphate Solution 
NAOP (mol.mass = 853,5) 
sterile distilled water to 
Per 5 ml 
426,75 mg 
5,00 m1 
The solution was prepared and stored at -20°C. 
C.8 1 M Glucose-6-Phosphate Solution 
D-glucose-6-phosphate (mol.mass = 282,1) 
sterile distilled water to 
Solution was prepared and stored at -20°C. 
Per 5 ml. 
1,41 9 
5,00 m1 
N 
C.g Minimal Glucose Agar Plates 
Difco-Bacto agar 
* sterile 50 x Vogel-Bonner E salts 
* ster ile 40% glucose so luti on 
disti lied water 
* These were autoclaved separately. 
Per litre 
15 9 
20 ml 
50 ml 
930 ml 
Agar was added to 930 ml distilled water in a 2 1 flask containing a 
magnetic stirring bar. The flask was autoclaved, and when the 
solution had cooled s lightly, the 50 x V-B salts and then the 40% 
glucose solution were added. The solution was stirred thoroughly, and 
then 25 ml aliquots were poured into sterile petri-plates. 
C.l0 59 Mix (Rat liver microsomal fraction and cofactors) 
Per 50 mi 
Buffer only Standard $9 Mi x Hi gh 59 Mi x 
(no 59) (20 .1 59/plate) ( 100 .1 59/p late) 
(4~) ( 10~) 
m1 m1 ml 
rat liver 59 N/A 2,00 10,00 
MgCI 2-KCl salts 1,00 1,00 1,00 
I M glucose-6-phosphate 0,25 0,25 0,25 
O,IMNADP 2,00 2,00 2,00 
0,2 M buffer pH 7 ,4 25,00 25,00 25,00 
sterile disti lled water 21,75 19,75 11,75 
Ingredients were added in the reverse order indicated above, so that 
the liver wa s added to a buffered solution. Since thawed 59 
preparations should not be refrozen (202), any remaining 59 or 59 mix 
was discarded. 
C.II The Mutagen Solutions 
All mutagen solutions were prepared with the requi red amount of 
mutagen in 0, I ml. solution (40). All were prepared freshly and stored 
at 4°C in amber bottles. 
a) AFBI - I .9/ml 
I) Di lution I - 100 .9/mf 
AFBI (moLmass" 312,28) 1,00 mg 
steri Ie DM50 to 10,00 m1 
ii) Dilution II - 1 ~g/ml 
dilution 
sterl Ie OMSO to 
Contained 0,1 ~g/O, 1 mI. 
b) DMN - 14,81 mg/m1 
0,50 ml (equivalent to 50 .9) 
50,0 m1 
Reagent soluti on contai ned 1,01 g/m!. 
OMN reagent 0,50 mt 
steri Ie di stt lIed water to 34,10 mt 
Contained 1,4BI mg/O,1 m1. 
N 
N 
c) BP - 5 ~g/mt 
i) Dilution I - 2,5 mg/mf 
BP (mol,mass" 252,3) 
steri Ie DMSO 
ii) Dilution II - 5 )lg/mt 
to 
25,0 mg 
10,0 mf 
dilution I 0.10 mi (equivalent to 0,25 mg) 
sterile OMSO to 50,00 mf 
ContaIned 0,5 ,g/O,1 mf, 
d) MMC - 2,5 ,g/mf 
reagent vial was equivalent to 2 mg MMC (Mol.mass 334,3) 
MMC (1 vial) 2,00 mg 
sterile distilled water to 800,00 mt 
Conta~ned 0,25 )lg/O,l mI. 
e) ~. or PRG - 5 mg/mf 
E.2 or PRG 5,00 mg 
steri Ie OMSO to 1,00 ml 
Contained 500 )lg/O,l mI. 
f) Sodium Phenobarbital - 50 mg/mt 
sodium phenobarbital 500,00 mg 
sterile distilled water to 10,00 mt 
Contained 5 mg/O,1 mi. 
N 
W 
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Appendix 2 Statistics Programmes 
1. Programme used to Generate Statistical Analysis, by SPSS, of 
the Rat Pretreatment Data. 
FILE NAME NORflRAT 
COMMENT EFFECTS OF STEROIO PRETREATMENT ANO IN~UCTION ON RATS 
~UNCAN MULTIPLE RANGE TEST AT p"O,Os 
SNK MULTIPLE RANGE TEST AT P"O,OS 
RATGP REPRESENTS THE DIFFERENT RAT PRETREATMENT GROUPS 
Y " PERCENTAGE OF ORIGINAL MASS OR LIVER/SOMATIC INDEX 
NAME OF DATA FILE : 
VARIABLE LIST RATGP Y -----
INPUT FORMAT FIXED (F2.0,IX,F6.2) 
READ INPUT DATA 
ONEWAY Y BY RATGP (1,12)/ 
RANGES"OUNCAN (.05)/ 
RANGES"SNK/ 
STATISTICS ALL 
FINISH 
2. Programme used to Generate Statistical Analysis, by SPSS, of 
the Mutagenicity Assay Data. 
FILE NAME LPLATES 
COMMENT AMES TEST DATA ANALYSIS 
LOG (BASE 10) DATA TRANSFORMATIONS USED 
~UNCAN MULTIPLE RANGE TEST AT P"O,OS 
SNK MU LTIPLE RANGE TEST AT P"O,OS 
TESTGP IS THE EXPERIMENT NUMBER 
Y IS NO. OF REVERTANT S.TYPHIMURIUM COLONIES PER PLATE 
Z IS THE LOG (BASE 10) OF Y 
NAME OF DATA FILE : 
VARIABLE LIST TESTGP Y -----
INPUT FORMAT FIXED (F2.0,IX,F4.0) 
READ INPUT DATA 
·COMPUTE Z"LGIO(Y) 
ONEWAY Y BY TESTGP (I ,2B)I 
RANGES"OUNCAN (.05)/ 
RANGES"SNK/ 
STATISTICS ALL 
FINISH 
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Appendix 3 Sources 
A. Reagents 
Merck (Darmstadt) 
I. Calcium chloride. dihydrate (Z38Z) (CaCIZ.ZHZO) 
Z. Citric acid. monohydrate (Z4Z) (C6H807.HZO) 
3. Dimethyl sulphoxide, spectrophotometric grade (Z95D) (CZH60S) 
4. Dipotassium hydrogen phosphate, anhydrous (5101) (KZHP04) 
5. Oisodium hydrogen phosphate, anhydrous (6586) (NaZHP04) 
6. Magnesium chloride ( 5833) (MgCI Z·6HZO) 
7. Magnesium sulphate (588Z) (MgS04.7HZD) 
8. Potassium chloride (4936) (KC I) 
9. PotassiUm dihydrogen phosphate (4873) (KHZP04) 
10. Sodium ammonium phosphate (668Z) (NaNH4HP04. 4HZO) 
II. SOdium dihydrogen phosphate, dihydrate (6343) (NaHZP04.ZHZO) 
Sigma (St.Louis, Mo.) : 
1. Aflatoxin BI (A-6636) (CI7HIZ06) 
Z. D-Biotin (B-4501) (CIOHI6NZ03S) 
3. 0-Glucose-6-phosphate, monOSOdium salt (G-7879) (C6HI309P) 
4. Dimethylnitrosamine (N-7756) (CZH6NZO) 
5. Nicotinamide adenine dinucleotide phosphate (NAOP) 
(N-0505) (CZIHZ7N7017P3Na) 
6. 17e-Oestradiol (E-8875) (CI8HZ40Z) 
7. Progesterone (P-0130) (CZIH300Z) 
Other : 
I. Ampicillin and Tetracycline sensitivity discs - BBL, Maryland. 
Z. Benzo(a)pyrene (CZoH IZ ) - Nutritional Biochemical Corp., Cleveland, Ohio. 
3. Crystal Violet - BDH reagents, Poole. 
4. Difco-Bacto agar - Difce, Detroit, Michigan . 
5. Ethyl oleate (CZOH380Z) - Hopkins & Wilkins, London. 
6. D-Glucose, anhydrous (C6HIZ06) - BDH reagents, Poole. 
7. L-Histidine.HCI, monohydrate (C6H9N30Z.HCI.HZO) 
Calbiochem, San Diego, California. 
B. Mitomycin C (CI5HI8N405) - Kyowa Hakko Kogya Co., Tokyo. 
9. Oxoid Nutrient Broth no.Z - Oxoid, London. 
10. Sodium phenobarbital (ClzHIINZNa03) - SA Druggists, Jhb .• SA. 
B, Equipment 
I. FORMA ScientifiC Incubator Model 30Z8 - Forma Scientific, Ohio. 
Z. BRAUNSONIC 1510 Ultrasonicator, B. Braun, Melsu ngen . 
3. MSE 18 Centrifuge, MSE, London . 
4. UNICAM SP600 Seri es Z Spectrophotometer, Unicam, Cambridge, UK. 
126 
LITERATURE CITED 
1. Abul-Hajj, Y.J. (1978) Steroids 31(6), 841-847. 
2. Aeschbaucher, H.U., Friederich, U. & Seiler, J.P. (1983) Teratogen-
esis Carcinog.Mutagen. 3(2), 195-203. 
3. Agnese, G., Risso, D. & De Flora, S. (1984) Mutat.Res. 130(1), 27-44. 
4. AI-Turk, W.A., Stohs, S.J. & Roche, E.B. (1980) Drug Metab.Dispos. 
8, 143-146. 
5. AI-Turk, W.A., Stohs, S.J. & Roche, LB. (1980) Horm.Metab.Res. 
12(8), 404-409. 
6. Alvares, A.P., Bickers, D.R. & Kappas, A. (1973) ?roc.Nat_Acad.Sci. 
USA 70(5), 1321-1325. 
7. Ames, B.N., personal communication. 
8. Ames, B.N. (1972) in Mutagenic Effects of Environmental Contaminants, 
eds. Sutton, H.E. & Harris, M.I. (Academic Press, N.Y.), pp57-66. 
9. Ames, B.N. (1976) Science 191, 241-245. 
10. Ames, B.N. (1977) Fed. ?roc. 36(5), 1630. 
11. Ames, B.N. (1979) Science 204, 587-593. 
12. Ames, B.N. (1982) in Mutagens in our Environment, eds. Sorsa, M. & 
Vainio, H. (A.R.Liss, N.Y.), pp3-19. 
13. Ames, B.N., Durston, W.E., Yamasaki, E. & Lee, F.D. (1973) ?roc. 
Nat.Acad.Sci.USA 70(8), 2281-2285. 
14. Ames, B.N., Gurney, E.G., Miller, J.A. & Bartsch, H. (1972) ?roc . 
Nat.Acad.Sci.USA 69(11), 3128-3132. 
15. Ames, B.N. & Haroun, L. (1979) Mutat.Res. 62, 393-395. 
16. Ames, B.N. & Haroun, L. (1980) in Microsomes, Drug oxidations and 
Chemical Carcinogenesis, eds. Coon, M.J., Conney, A.H., Estabrook, 
R.W., Gelboin, H.V., Gillette, J.R. & O'Brien, P.J., (Academic Press, 
N.Y.), Vol.2, ppl025-1040. 
17 . Ames, B.N. & Hooper, K. (1978) Nature 274(5666), 19-20. 
18. Ames, B.N., Lee, F.D. & Durston, W.E. (1973) ?roc.Nat.Acad.Sci.uSA 
70(3), 782-786. 
19. Ames, B.N. & McCann, J. (1981) Cancer Res. 41, 4192-4196. 
20. Ames, B.N., McCann, J. & Yamasaki,E. (1975) Mutat.Res. 31(6), 347-
364. 
127 
21. Ames, B.N., Sims, P. & Grover, P.L. (1972) Science 176(4030), 47-49. 
22 . Ames, B.N. & Yanofsky, C. (1971) in Chemical Mutagens - Principles 
and Methods for Their Detection, ed. Hollaender, A. (Plenum Press, 
N.Y.), Vo!.l, pp267-282. 
23. Anderson, D., Green, M.H.L., Mattern, I.E. & Godley, M.J. (1984) 
Mutat.Res. 130, 1-10. 
24. Anderson, K.E., Freddara, U. & Kappas, A. (1982) Arch . Biochem. 
Biophys. 217, 597-608. 
25. Anderson, K.E., Kappas, A., Canney, A.H., Bradlow, H.L. & Fishman, 
J. (1984) J.Clin.EndocrinoLMetab. 59(1), 103-107. 
26. Arcos, J.C., Davies, O.L., Brown, Ch.E.L. & Argus, M.F. (1977) z. 
Krebsforsch. 89, 181-199. 
27. Ashby, J. & Styles, J.A. (1978) Nature 271,452-455. 
28 . Ashby, J. & Styles, J.A. (1978) Nature 274, 20-22. 
29. Ashwood-Smith, M.J. (1980) Mutat.Res. 69, 199-200. 
30. Aufrere, M.B. & Benson, H. (1976) J.Pharm.Sci. 65, 783-800. 
31. Bakshi, K., Brusick, D., Bullock, L. & Bardin, C. (1977) in Origins 
of Human Cancer, eds. Hiatt, H.H., Watson, J.D., & Winsten, J.A. 
(Cold Spring Harbor Laboratory , Cold Spring Harbor, N.Y.), Bk.B, 
pp683-695. 
32. Ball, P., Gelbke, H.P. & Knuppen, R. (1975) J.Clin.Endocr.Metab. 40, 
406-408. 
33. Barber, E.D., Donish, W.H. & Mueller, K.R. (1983) Mutat.Res. 113(2), 
89-101. 
34. Baron, J.A. (1984) Am.J.Epidemiol. 119(1),9-22. 
35. Bartsch, H. (1983) Ann.N.Y.Acad.Sci. 407, 351-361. 
36. Bartsch, H., Camus, A. & Malaveille, C. (1976) Mutat.Res. 37, 149-
162. 
37. Bartsch, H., Kuroki, T., Roberfroid, M. & Malaveille, C. (1982) in 
Chemical Mutagens - Principles and Methods for Their Detection, eds. 
De Serres, F.J. & Hollaender, A. (Plenum, N.Y.), Vol.7, pp95-161. 
38. Bartsch, H., Malaveille, C. & Montesano, R. (1975) Cancer Res. 35, 
644-651. 
39. Bartsch, H., Malaveille, C. & Montesano, R. (1976) in Screening 
Tests in Chemical Carcinogenesis, eds. Montesano, R., Bartsch, H., 
Tomatis, L. & Davis, W. (IARC publ ication no. 12, Lyons), pp467-491. 
128 
40. Belser , W.L., Shaffer, S.D., Bliss, R.D., Hynds, P.M., Yamamoto, L., 
Pitts, J.N. & Winer, J.A. (1981) Environ.Mutagen. 3, 123-139. 
41. Bernstein, L., Kaldor, J., McCann, J. & Pike, M.C. (1982) Mutat.Res. 
97, 267-281. 
42. Bigger, C.A.H., Tomaszewski, J.E., Dipple, A. & Lake, R.S. (1980) 
Science 209, 503-505. 
43. Blackham, A. & Spencer, P.S.J. (1969) Br.J.PharmacoL 37, 129-139. 
44. Bolt, H.M. (1979) Clin.Pharmacol.Ther. 4, 155-181. 
45. Booth, J. & Gillette, J.R. (1962) J.Pharmacol.Exp.Ther. 137, 374-379. 
46. Booth, J., Keysell, G.R. & Sims, P. (1974) Biochem.PharmacoL 23, 
735-744. 
47. Bos, R.P., Neis, J.M., van Gemert, P.J. & Henderson, P.T. (1983) 
Mutat.Res. 124(2), 103-112. 
48. Bowman, W.C. & Rand, M.J. (1980) Textbook of Pharmacology, 2nd Edit ., 
(Blackwell Scientific Publications, London), pp39.68-39.69. 
49. Breuer, H. (1972) in Methods in Steroid Toxicology, eds. Plotz, E.J . 
& Haller, J. (Geron X, Los Altos, California), ppl00-116. 
50. Bridges, B.A. (1976) Nature 261,195-200. 
51. Briggs, N.H. & Brotherton, J. (1970) Steroid Biochemistry and Pharma-
cology (Academic Press, London), pp52-138. 
52. Brock, W.J. & Vore, M. (1982) Drug Metab.Dispos. 10(4), 336-343. 
53. Brooks, S.C. (1976) in Steroid Hormone Action and Cancer, eds. Menon, 
K.M.J. & Reel, J.R. (Plenum Press, N.Y.), pp36-49. 
54. Brusick, D.J. (1978) Pharm.Technol. 2, 37-40, 65. 
55. Brusick, D.J. (1983) Ann.N.Y.Acad.Sci. 406, 68-73. 
56. Brusick, D.J. (1983) Ann.N.Y.Acad.Sci. 407, 164-176. 
57 . Bulger, W.H. & Kupfer, D. (1983) Biochem.Pharmacol. 32(6), 1005-1010. 
58. Burke, M.D ., Vadi, H., Jernstrbm, B. & Orrenius, S. (1977) J.BioL 
Chem. 252(18), 6424-6431. 
59. Capdevila, J . & Orrenius, S. (1980) FEBS letters 119(1), 33-37. 
60. Carlson, S.E., Mitchell, A.D., Carter, M.L. & Goldfarb, S. (1980) 
Biochim.Biophys.Acta 633(2), 154-161. 
61. Carter, D.E., Goldman, J.M., Bressler, R., Huxtable, R.J., Christian, 
C.D. & Heine, M.W. (1974) Clin.Pharmacol.Ther. 15(1), 22-31. 
62. Cheli, C., De Francesco, D., Petrullo, L.A., McCoy, E. & Rosenkranz, 
H.S. (1980) Mutat.Res. 74, 145-150. 
63. Colby, H.D. (1980) Adv.Sex Horm.Res. 4, 27-71. 
129 
64. Commoner, B., Vithayathil, A.J. & Henry, J.l. (1974) Nature 249, 
850-852. 
65. 
66. 
Commoner, B., Vithayathil, A.J., Henry, J.l., Gold, J.C. & 
M.J. (1976) U.s. EnvironmentaL Prote~tion Agen~y Report 
(1-76-022), (E.P.A.publication, Springfield, Va.). 
Conney, A.H. (1967) Pharma~oLRev. 19(3), 317-366. 
Reding, 
EPA-600 
67. Conney, A.H. (1971) in FundamentaLs of Drug MetaboLism and Drug Dis-
tribution eds. La Du, B.N., Mandel, H.G. & Way, E.L. (Williams & 
Wilkins, Baltimore), pp253-278. 
68. Conney, A.H., Levin, W., Jacobson, M. & Kuntzman, R. (1973) CUn. 
Pharma~oLTher. 14(4), 727-741. 
69. Crawford, J.S. & Rudofsky, S. (1966) Brit.J.Anaesth. 38, 446-454. 
70. Crooke, S. T. (1979) in Mitomy~in C - CUI'rent Status and New DeveLop-
ments eds. Carter, S.K., Crooke, S.T. & Alder, N.A. (Academic Press, 
N.Y.), ppl-4. 
71. Czygan, H.G., Greim, H., Garro, A.J., Hutterer, F. , Schaffner, F. 
Popper, H., Rosentha I, D. & Cooper, D. Y . (1973) Cancer Res. 33, 
2983-2986. 
72. Davis, M., Simmons, C.J., Dordoni, B., Maxwell, J.D. & Williams, R. 
(1973) J . Obstet.Gynaec.Brit.CmwLth. 80(8), 690-694. 
73. Dean, M.E. & Stock, B.H. (1975) Drug Metab.Dispos. 3(5), 325--331. 
74. De Flora, S., Zanacchi, P., Camoirano, A., Bennicelfi, C. & Badolati, 
G.S. (1984) Mutat.Res. 133,161-198. 
75. De Serres, F.J . (1972) in Mutagenic Effects of EnvironmentaL Contam-
inants eds. Sutton, H.E. & Harris, M.l. (Academic Press, N.Y.), 
pp41-55. 
76. De Serres, F.J. & Shelby, M.D. (1979)Science 203,563-565. 
77. De Serres, F.J. & Shelby, M.D. (1979)Environ.Mutagen. 1,87-92. 
78. De Serres, F.J. & Shelby, M.D. (1979)Mutat.Res. 64, 159-165. 
79. Deveret, R. (1979) s~i.Am. 241(2),40-49. 
80. Drake, J. W. ( 1970) The MoLe~uLar Basis of Mutation (Ho lden Day, 
San Francisco), pp82-185. 
81. Drake, J.W. & 8altz, R.H. (1976) Ann.Rev.Biochem. 45, 11-38. 
82. Duffel, M.W., Graham, J.M. & Ziegler, D.M. (1981)MoLPharma~oL 19, 
134-139. 
83. Dunkel, V.C. (1979) J.Assoc.Off·AnaLChem. 62,874-882. 
84. Durston, W.E. & Ames, B.N. (1974) Proc.Nat.A~ad.S~i.uSA 71(3), 
737-741. 
130 
85. Einarsson, K., Ericsson, J.L., Gustafsson, J-A., Sjovall, J. & Zietz, 
E. (1974) Biochim.Biophys.Acta 369, 278-288. 
86. Estabrook, R.W, Martinez-Zadillo, G., Young, S., Peterson, J.A. & 
McCarthy, J. (1975) J.Steroid Biochem. 6, 419-425. 
87. Feuer, G. & Kardish, R. (1975) Int.J.CLin.PharmacoL.Biopharm. 11(4), 
366-374. 
88. Feuer, G., Kardish, R. & Farkas, R. (1977) Biochem.PharmacoL. 26 , 
1495-1499. 
89. Feuer, G. & Liscio, A. (1969) Nature 223, 68-70. 
90. Feuer, G., Sosa-Lucero, J.C. & De La Iglesia, F.A. (1977) ToxicoLogy 
7, 107-114. 
91. Fishman, J., Hellman, L., Zumoff, B. & Gallagher, T.F. (1965) J.cZin. 
Endocr.Metab. 25, 365-368. 
92. Forlin, L. & Hansson, T. (1982) J.EndocrinoL 95(2) , 245-252 . 
93. Fouts, J.R. & Rogers, L.A . (1965) J. PharmacoL EXp. Ther. 147, 
112-117. 
94. Franklin , T.J. & Snow, G.A. (1981) Biochemistry of AntimicrobiaL 
Action (Chapman & Hall, London) , 95-98. 
95. Freese, E. (1971) in ChemicaL Mutagens - ' PrincipLes and Methods for 
Their Detection, ed. Hollaender , A. (Plenum Press, N.Y.), Vol.l, 
ppl-56. 
96. Freudenthal, R.I. & Amerson, E. (1974) Biochem.PharmacoL. 23, 2651-
2656. 
97. Friederich, U. & Wurgler, F.E. (1983) Teratogenesis Carcinog.Mutagen. 
3(2), 177-182. 
98. Gallagher, T.F.{Jr.), Mueller, M.N. & Kappas, A. (1966) Medicine 45, 
471-479. 
99. Garner, R.C. (1979) Proc.R.Soc.Fond.(BioL.J 205(1158), 121-134. 
100. Garner, R.C., Miller, E.C. & Miller, J.A. (1972) Cancer Res. 32, 
2058-2066. 
101. Gielen, J.E., Van Cantfort, J. & Kremers, P. (1976) Arch.ToxicoL 
36{3-4), 255-266. 
102. Gillette, J.R. (1963) Prog.Drug Res. 6, 11-73. 
103. Gillette, J.R. (1979) Ann.N.Y.Acad.Sci. 179, 43-66. 
104. Gletten, E., Weekes, U. & 8rusick, D. (1975) Mutat.Res. 28, 113-122. 
105. Goggelmann, W., Grafe, A., Vollmar, J., Baumeister, M., Kramer, P.J. 
& Poole, B.L. (1983) Teratogenesis Carcinog.Mutagen. 3(2), 205-213. 
131 
106. Goodman, L.S. & Gillman, A. (eds.) (1975) The Pharmacological Basis 
of Therapeutics, 5th edit. (Macmillan,N.Y.), ppI423-1450. 
107. Gower, D.B. (1974) J.Steroid Biochem. 5, 501-523. 
108. Gower, D. B. (1979) Steroid Hormones, (C room He 1m, London), pp 1-40. 
109. Gram, T.E. & Gillette, J.R. (1969) in MetaboLic Effects of GonadaL 
Hormones and Contraceptive Steroids, eds. Salhanick, H.A., Kipnis, 
D.M. & Van de Wiele, R.L. (Plenum Press, N.Y.), pp86-94. 
110. Gram, T.E., Guarino, A.M., Schroeder, D.H., Davis, D.C., Reagan, R.L. 
& Gillette, J . R. (1970) J.PharmacoL.Exp.Ther. 175(1), 12-20. 
111. Green, M.H.L. (1981) in Progress in Mutation Research, ed. Kappas, A. 
(Elsevier/North-Holland, Amsterdam), Vol.2, ppI59-165. 
112. Greim, H.A. (1981) in Concepts in Drug MetaboLism: Part B, eds. 
Jenner, P. & Testa, B. (Marcel Dekker, N.Y.), pp219-263. 
113. Grover, P.L. (ed.) (1979) ChemicaL Carcinogens and DNA (CRC Press, 
Florida), Vols. 1 & 2. 
114. Guengerich, F.P. (1979) CLin.pharmaco2.Ther. 6, 99-121. 
115. Guenthner, T., Jernstrom, B. & Orrenius, S. (1979)Biochem.Biophys . 
Res.Commun. 91 (3), 842-848. 
116. Guenthner, T., Jernstrom, B. & Orrenius, S. (1980) Carcinogenesis I, 
407-418. 
117 . Guenthner, T. & Mannering, G. (1977) Biochem.PharmacoL. 26,567-575. 
118. Guenthner, T. & Mannering, G. (1977) Biochem.PharmacoL. 26, 577-584. 
119. Guenthner, T. & Oesch, F. (1983) in Drug MetaboLism and Distribution, 
ed. LambIe, J.W. (Elsevier Biomedical Press, Amsterdam), pp30-35. 
120. Gumbmann, M. & Williams, S. (1970) Biochem.PharmacoL. 19, 2861-2866. 
121. Gustafsson, J-A., Carlstedt-Duke, J., Mode, A. & Rafter, J. (eds.) 
(1980) Biochemistry, Biophysics and Regulation Of Cytochrome P-450 
(Elsevier/North-Holland Biomedical Press, Amsterdam), pp405-441. 
122. Gustafsson, J-A. & Skett, P. (1979) Acta BioL.Med.Ger. 38(2-3), 
307-320. 
123. Gustafsson, J-A. & Stenberg, A. (1974) EndocrinoLogy 95(3), 891-896. 
124. Hamrick, M.E., Zampaglione, N.G., Stripp, B. & Gillette, J.R. (1973) 
Biochem.PharmacoL. 22, 293-310. 
125. Haroun, L. & Ames, B.N. (1981) in Short Term Tests for ChemicaL Car-
cinogens, eds. Stich, H.F. & San, R.H.C. (Springer-Verlag,Berlin) , 
ppl08-119. 
132 
126. Heath, E.C. & Dingell, J.V. (1974) Drug Metab.Dispos. 2(6), 556-565. 
127 . Heddle, J.A. & Bruce, W.R . (1977) in Origins of Human Cancer, eds. 
Hiatt, H.H., Watson, J.D. & Winsten, J.A . (Cold Spring Harbor Labor-
atory, Cold Spring Harbor, N.Y.), Bk.C, pp1549-1557. 
128. Herbold, B.A. (1982) Mutat.Res. 97, 191-192. 
129. Herbold, B.A., Arni, P., Driesel, A., Engelhardt, G., Jager, J., 
Joosten, H.F., King, M.T., Klemp, H., Lang, R., Miltenburger, H.G., 
de Raat, W.K., Trager, H., Waalkens-Berendsen, D.H., Wallat, S. & 
Willems, M. (1983) Teratogenesis Carcinog.Mutagen. 3(2), 187-193. 
130. Herbold, B. & Buselmaier, W. (1976) Mutat.Res. 40, 73-84. 
131. Hesse, S., Jernstrom, B., Martinez, M., Guenthner, T. & Orrenius, S. 
(1980) Biochem.Biophys.Res.Commun. 94(2), 612-617. 
132. Holder, G., Yagi, H., Dansette, P., Jerina, D.M., Levin, W., Lu, 
A.Y.H. & Canney, A.H. (1974) Proc.Nat.Acad.Sci.USA 71(11),4356-4360. 
133. Hollstein, M., McCann, J., Angelosanto, F.A. & Nichols, W.W. (1979) 
Mutat.Res. 65, 133-226. 
134. Horn, L., Kaldor, J. & McCann, J. (1983) Mutat.Res. 109(2), 131-141-
135. Ho Yuen, E. (1977) Secondary Effects of Oral Contraceptives (M.Sc. 
thesis, School of Pharmaceutical Sciences, Rhodes University). 
136. Hsieh, D.P.H., Wong, J.J., Wong, Z.A., Michas, C. & Ruebner, B.H. 
(1977) in Origins of Human Cancer, eds. Hiatt, H.H., Watson, J.D. & 
Winsten, J.A. (Cold Spring Harbor Laboratory, Cold Spring Harbor, 
N.Y.), Bk.B, pp697-707. 
137. Huberman, E., Sachs, L., Yang, S.K. & Gelboin, H.V. (1976) Proc.Nat. 
Acad.Sci.USA 73(2), 607-611. 
13B. lARC Monograph on the Evaluation of Carcinogenic Risk of Chemicals 
to Humans (1973) (IARC, Lyons) VoL3, 91-131-
139. lARC Monograph on the Evaluation of Carcinogenic Risk of Chemicals 
to Humans (1974) (IARC, Lyons) VoL6, 19-51,99-115, 135-145. 
140. lARC Monograph on the Evaluation of Carcinogenic Risk of Chemicals 
to Humans (1976) (jARC, Lyons) VaLlO, 51-71, 171-179. 
141. lARC Monograph on the Evaluation of Carcinogenic Risk of Chemicals 
to Humans (1978) (jARC, Lyons) VoL17, 125-135. 
142. lARC Monograph on the Evaluation of Carcinogenic Risk of Chemicals 
to Humans (1979) (rARC, Lyons) Vol.21, 83-134, 279-326, 491-515. 
143. lARC Monograph on the Evaluation of Carcinogenic Risk of Chemicals 
to Humans (1980) (rARC, Lyons), Supplement No.2. 
133 
144. Ingelman-Sunberg, M. (1983) in Drug Metabolism and Distribution, ed. 
Lambie, J.W. (Elsevier Biomedical Press, Amsterdam), pp22-29. 
145. Ingerowski, G.H., Scheutwinkel-Reich, M. & Stan, H-J (1981) Mutat. 
Res. 91, 93-98. 
146. Isono, K. & Yourno, J. (1974) Proc.Nat.Acad.Sci.USA 71(5), 1612-1617. 
147. Iyer, V.N. & Szybalski, W. (1964) Science 145,55-58. 
148. Jacob, F. & Monod, J. (1961) J.MoLec.BioZ. 3,318-356. 
149. Jerina, D.M. & Daly, J.W. (1974) Science 185(4151), 573-582. 
150. Jernstrom, B., Guenthner, T., Hesse, S. & Orrenius, S. (1980) in 
Carcinogenesis: FundamentaL Mechanisms and EnvironmentaL Effects, 
eds. Pullman, B., Ts '0, P.O.P. & Gelboin, H. (D.Reidel, Dordrecht), 
pp157-165. 
151. Jernstr~m, B., Orrenius, S., Undeman, D., Grashund, A. & Ehrenberg, 
A. (1978) Cancer Res. 38, 2600-2607. 
152. Jori, A., Bianchetti, A. & Prestini, P.E. (1969) Eur.J.PharmacoL. 
7, 196-200. 
153. Jori, A., Guiso, G. & Ravazzani, C. (1976) J.Pharm.PharmacoL 28, 
714-716. 
154. Juchau, M.R. & Fouts, J.R. (1966) Biochem.PharmacoL 15, 891-898. 
155. Juchau, M.R., Namkung, M.J. & Chao, S.T. (1982) Drug Metab.Dispos. 
10(3), 220-224. 
156. Kado, N.Y. (1983) Mutat.Res. 121(1), 25-32. 
157. Kahl, R. (1983) in Drug MetaboLism and Distribution, ed. Lambie, J.W. 
(Elsevier Biomedical Press, Amsterdam), pp70-75. 
158. Kamataki, T., Ando, M., Yamazoe, Y., Ishii, K. & Kato, R. (1979) 
Biochem.PharmacoL. 29, 1015-1022. 
159. Kapitulnik, J., Levin, W., Yagi, H., Jerina, D.M. & Conney, A.H. 
(1976) Cancer Res. 36, 3625-3628. 
160. Kappas, A., Anderson, K.E., Conney, A.H., Pantuck, E.J., Fishman, J. 
& Bradlow, H.L. (1983) Proc.Nat.Acad.Sci.uSA 80(12), 7646-7649. 
161. Kastenbaum, M.A. & Bowman, K.O. (1970) Mutat.Res. 9, 527-549. 
162. Kato, R. (1974) Drug Metab.Rev. 3(1), 1-32. 
163. Kato, R., Chiesara, E. & Fromtino, G. (1962) Biochem.PharmacoL. 11, 
221-224. 
164. Kato, R. & Onoda, K. (1970) Biochem.PharmacoL. 19(5), 1649-1660. 
165. Kawajiri, K., Yonekawa, H., Gotoh, D., Watanabe, J., Igarashi, S. & 
Tagashira, Y. (1983) Cancer Res. 43, 819-823. 
134 
166. Kier. L.D .• Yamasaki. E. & Ames. B.N. (1974) Proc.Nat.Acad.Sci.USA 
71(10). 4159-4163. 
167. King. H .. Thompson, M. & Brookes, P. (1976) Int.J.Cancer 18,339-344. 
168. Kirk, R.E. (1968) ExperimentaL Design: Procedures for the Behaviour-
aL Sciences (Brookes/Cole, Belmont, California). 
169 . Krahn, D.F. & Heidelburger. C. (1977) Mutat.Res. 46, 27-44. 
170. Kramer, R.E., Greiner, J.W., Rumbaugh, R.C., Sweeney, T.D. & Colby, 
H.D. (1979) J.PharmacoL.Exp.Ther. 208, 19-23. 
171. La Du, B.N., Mandel, H.G. & Way, E.L. (eds.) (1971) FundamentaLs of 
Drug MetaboLism and Drug Disposition (Williams & Wilkins, Baltimore). 
172. Lake, B. G. & Gango II i, S.D. (1981) in concepts in Drug Metabo Hsm , 
eds. Jenner, P. & Testa, B. (Marcel Dekker, N.Y.), Part B, pp167-218. 
173. Lake. l.M. & Gerschenson, L.E. (1983) Cancer Lett. 19(2), 173-179. 
174. Lang, R. & Redmann, U. (1979) Mutat.Res. 67, 361-365. 
175. Lawley, P.O. (1979) Nature 282, 134-135. 
176. Lax, E.R., Baumann, P. & Schriefers, H. (1983) Exp.CLin.Endocrinol. 
82(2), 145-152. 
177. Lax, E.R., Ghraf, R. & Schriefers, H. (1978) Acta EndocrinoL. 89(2), 
352-358. 
178. Lax, E.R., Kreuzfelder, E. & Schriefers, H. (1979) Hoppe-Seylers Z. 
PhysioZ.Chem. 360, 1807-1812. 
179. Lax, E.R., Kreuzfelder, E. & Schriefers, H. (1980) Steroids 36(5), 
521-529. 
180. Lax , E.R., Rumstadt, F., Plasczyk, H., Peetz, A. & Schriefers, H. 
(1983) Endocrinology 113(3), 1043-1055. 
181. Lee, S. & Chen, C. (1971) Steroids 18(5), 565-575. 
182. Leg ator, M.S. (1972) in Mutagenic Effects of Envi ronmental Contamin-
ants, eds. Sutton, H.E. & Harris, M.I. (Academic Press, N.Y.), 67-79. 
183. Lemon, H.M. (1977) Cancer 40, 1825-1832. 
184 . Levin, D.E., Hollstein, M., Christman, M.L & Ames, B.N. (1984) Meth-
ods EnaymoZ. 105, 249-254. 
185. Levin, D.E., Hollstein, M., Christman, M.F., Schwiers, E.A. & Ames, 
B.N . (1982) Proc.Nat.Acad.Sci.uSA 79(12), 7445-7449, including two 
addenda on storage conditions. 
186 . Levin, D.E., Yamasaki, E. & Ames, B.N. (1982) Mutat.Res. 94 , 315-330. 
187. Levin, W., Welch , R.M. & Conney, A.H. (1968) EndocrinoZ. 83, 149-156. 
188. Levin, W., Wood, A.W., Yagi, H., Dansette, P., Jerina, D.M. & Conney, 
A.H. (1976) Proc.Nat.Acad.Sci.USA 73(1), 243-247. 
135 
189. Li, S.A., Lam, L.K.T. & Li, J .J. (1983) Biochem.pharmacoL 32(19), 
2847-2850. 
190 . Lijinsky, W., Loa, J. & Ross, A.E. (1968) Nature 218, 1174-1175. 
191. Lipsett, M.B. (1971) Ann.N.Y.Acad.Sci. 179, 442-449. 
192. Lawn, J. (1979) in Mitomycin C - Current Status and New DeveLopments 
eds. Carter, S.K., Crooke, S.T. & Alder, N.A. (Academic Press, N.Y.), 
pp5-26. 
193. Lawn, J.W. (1982) Acc.Chem.Res. 15, 381-387. 
194. Lu, A.Y., Somogyi, A., West, S., Kuntzman, R. & Conney, A.H. (1972) 
Arch.Biochem.Biophys. 152, 457-462. 
195. Magee, P.N. (1974) Essays Biochem. 10, 105-136. 
196. Malaveille, C., Planche, G. & Bartsch, H. (1977) Chem. -BioL.Interact. 
17, 129-136. 
197. MaIling, H.V. (1971) Mutat.Res. 13,425-429. 
198. MaIling, H.V. (1974) Mutat.Res. 26,465-472. 
199. Margolin, B.H., Kaplan, N. & Zeiger, E. (1981) Proc.Nat.Acad.Sci.USA 
78(6), 3779-3783. 
200. Margolin, B.H., Risko, K.J., Shelby, M.D. & Zeiger, E. (1984)Mutat. 
Res. 130(1), 11-25. 
201. Maron, D.M., personal communication. 
202. Maron, D.M. & Ames, B.N. (1983) Mutat.Res. 113(3-4), 173-215. 
203. Maron, D.M., Katzenellenbogen, J. & Ames, B.N. (1981) Mutat.Res. 88, 
343-350. 
204. Marr, W., White, J.O., Elder, M.G. & Lim, L. (1980) Biochem.J. 190, 
17-23. 
205. Marshall, W.J. & McLean, A.E.M (1969) Biochem.PharmacoL 18, 153-157. 
206. MartindaLe: The Extra Pharmacopoeia (1977), 27th edition (The Pharm-
aceutical Press, London), pp1415-1424. 
207. Matsushima, T., Sugimura, T., Nagao, M., Yahagi, T., Shirai, A. & 
Sawamura, M. (1980) in Short-Term Test Systems for Detecting Carcin-
ogens, eds. Norpoth, K.H. & Garner, R.C. (Springer-Verlag, Berlin), 
pp273-285. 
208. Maugh II, T.H. (1978) Science 201, 1200-1205 . 
209. Mayne, R., Forsyth, I.A. & Barry, J.M. (1968) J .EndocrinoL. 41, 
247-251. 
210. Mazel, P. in FundamentaLs Of Drug MetaboLism and Drug Distribution 
136 
eds. La Du, B.N., Mandel, H.G. & Way, E.L. (Williams & Wilkins, Bal-
timore), pp546-582. 
211. McCann, J. (1976) Chemtech.US 6, 682-687. 
212. McCann, J. (1983) HospitaL Practice Sept, 73-85. 
213. McCann, J. & Ames, B.N. (1976) Proc.Nat.Acad.Sci.USA 73(3), 950-954. 
214. McCann, J. & Ames, B.N. (1977) in Origins of Human Cancer, eds. 
Hiatt, H.H., Watson , J.D. & Winsten, J.A. (Cold Spring Harbor Labor-
atory, Cold Spring Harbor, N.Y.), Bk.C, ppI431-1450. 
215. McCann, E., Choi, E., Yamasaki, E. & Ames, B.N. (1975) Proc.Nat.Acad. 
Sci.USA 72(12), 5135-5139. 
216. McCann, J., Spingarn, N.E., Kobori, J. & Ames, B.N. (1975) Proc.Nat. 
Acad.Sci.USA 72(3), 979-983. 
217. McLean, A.E.M. & Marshall, A. (1971) Br.J.Exp.PathoL. 52,322-329. 
218. McCulloch, B., personal communication. 
219. Meselson, M. & Russell, K. (1977) in Origins of Human Cancer, eds. 
Hiatt, H.H., Watson, J.D. & Winsten, J.A. (Cold Spring Harbor Labor-
atory, Cold Spring Harbor, N.Y.), Bk.C, ppI473-1482. 
220. Miller, E.C. & Miller, J.A. (1966) PharmacoZ.Rev. 18, 805-838. 
221. Miller, E.C. & Miller, J.A. (1971) in ChemicaL Mutagens - PrincipLes 
and Methods for Their Detection, ed. Hollaender, ·A. ( Plenum Press, 
N.Y.), Vo!.l, pp 83-119. 
222. Miller, J.A. (1970) Cancer Res. 30, 559-576. 
223. Miller, J.A. & Miller, E.C. (1977) in Origins of Human Cancer, eds. 
Hiatt, H.H., Watson, J.D. & Winsten, J.A. (Cold Spring Harbor Labor-
atory, Cold Spring Harbor, N.Y.), Bk.B, pp605-627. 
224. Mitchell, I de G. (1978) Mutat.Res. 54, 1-16. 
225. Moore, D. & Felton, J.S. (1983) Mutat.Res. 119,95-102. 
226. Neale, M.G. & Parke, D.V. (1973) Biochem.PharmacoL. 22, 1451-1461. 
227. Nebert, D.W., Bausserman, L.L. & Bates, R. (1970) Int.J.Cancer 6, 
470-480. 
228. O'Malley, B.W. & Means, A.R. (1974) Science 183, 610-620. 
229. O'Malley, B.W. & Schrader, T.W . (1976) sci.Am. 234(2), 32-43. 
230. O'Malley, K., Stevenson, I. & Crooks, J. (1972)CLin.PharmacoL.Ther. 
13, 552-557. 
231. Orrenius,S., Das, M. & Gnosspelius, Y. (1969) in Microsomes and 
Drug Oxidations, eds. Gillette, J.R., Conney, A.H., Cosmides, G.J., 
Estabrook, R.W., Fouts, J.R. & Mannering, G.J. (Academic Press,N.Y.), 
pp251-277 . 
137 
232 . Paine, A.J. (1981) Essays Biochem. 17, 85-126. 
233. Pasleau, F., Kremers, P. & Gielen, J.E. (1981) Chem.-Bi02.Interact. 
34(3), 279-286. 
234. Pence, D.H . & Schnell, R.C. (1979) Pharmac020gy 18(1), 52-56. 
235. Peraino, C., Fry, P.J.M. & Staffeldt, E. (1971) Cancer Res. 31, 
1506-1512. 
236. Peto, R. (1977) in Origins of Human Cancer, eds. Hiatt, H.H., Watson, 
J.D. & Winsten, J.A. (Cold Spring Harbor Laboratory, Cold Spring 
Harbor, N.Y.), Bk.C, ppI403-1428. 
237. Prival, M.J. (1983) Ann.N.Y.Acad.Sci. 406, 154-163. 
238. Prival, M.J., King, V.D. & Sheldon, A.T. (1979) Environ.Mutagen. 1, 
95- 104. 
239. Purchase, I.F .H. (1982) Mutat.Res. 99 , 53-71. 
240. Purchase, I.F.H., Longstaff, E., Ashby, J., Styles, J.A., Anderson, 
D., Lefevre, P.A. & Westwood, F.R. (1976) Nature 264, 624-627. 
241. Purchase, I.F.H., Longstaff, E., Ashby, J., Styles, J.A., Anderson, 
D., Lefevre, P.A. & Westwood, F.R. (1978) Br.J.Cancer 37, 873-959. 
242. Quinn, G.P, Axelrod, J. & Brodie, B.B. (1958) Biochem.Pharmacol. 1, 
152-159 . 
243. Ramel, C. (1983) Environ. Health Per.,pect. 47, 153-159 . 
244. Rao, G.S., Haueter, G., Rao, M.L. & Breuer, H. (1977) Biochem.J. 
162(3), 545-556. 
245. Rasmussen, R.E. & Wang, I.Y. (1974) Cancer Res. 34, 2290-2295. 
246. Reich, S.D. (1979) in Mitomycin C - Current status and New Develop-
ments, eds. Carter, S.K., Crooke, S.T. & Alder, N.A. (Academic Press, 
N.Y.), pp243-250. 
247. Remers, W.A. (1979) in Mitomycin C - Current Status and New Develop-
ments, eds. Carter, S.K., Crooke, S.T. & Alder, N.A. (Academic Press, 
N. Y . ), pp27 -32. 
248. Remmer, H. (1969) J.Mond.Pharm. 3(12), 169-185. 
249. Rinkus, S.J. & Legator, M.S. (1979) Cancer Res. 39, 3289-3318. 
250. Rinkus, S.J. & Legator, M.S. (1981) Cancer Res. 41, 4196-4203. 
251. Rubin, H. (1976) science 191, 241. 
252. Rumbaugh, R.C. & Colby, H.D. (1980) Endocrinology 107(3), 719-724 . 
253. Rumke, C.L. & Noordhoek, J. (1969) Eur.J.Pharmacol. 6, 163-168. 
254. Russell, J.F.(Jr.) & Krahn, D. F. (1981) Environ.Mutagen. 3,352. 
138 
255. Sachan, 0.5. (1976) J .Nutr. 106, 1569-1576. 
256. Sailer, D. (1978) Fortschr.Med. 96(9), 446-449. 
257. Salmeen, 1. & Durisin, A.M. (1981) Mutat.Res. 85,109-118. 
258. Schenkman, J.B. & Gibson, G.G. (1983) in Drug Metabolism and Dist-
ribution, ed. LambIe, J.W. (Elsevier Biomedical Press, Amsterdam), 
pp7-11. 
259. Scheutwinkel-Reich, M., Ingerowski, G.H. & Stan, H.-J. (1981) Mutat. 
Res. 85, 265-266. 
260. Seiler, J.P. (1983) Teratogenesis Carcinog.Mutagen. 3(2), 183-185. 
261. Seiler, J.P. (1983) Teratogenesis Carcinog.Mutagen. 3(2),215-217. 
262. Selkirk,J.K. (1977) Nature 270, 604-607. 
263. Shelby, M.D. & Purchase, 1.F.H. (1981) in Evaluation of Short-Term 
Tests for Carcinogens, eds. De Serres, F.J. & Ashby, J. (Elsevier 
(North-Holland, Amsterdam), Vol.l, pp16-20. 
264. Sims, P. & Grover, P.L. (1974) Adv.Cancer Res. 20, 165-274. 
265. Slater, E.E., Anderson, M.D. & Rosenkranz, H.S. (1971) Cancer Res. 
31, 970-973. 
266. Snee, R.D. & Irr, J.D. (1984) Mutat.Res . 128, 115-125. 
267. S6derkvist, P., Busk, L., Toftgard, R. & Gustafsson, J-A. (1983) 
Chem.-Biol.Interact. 46, 151-163. 
268. Solymoss, B., Varga, S. & Classen, H.G. (1970) Eur.J.Pharmacol. 10, 
127-130. 
269. Solymoss, B., Werringloer, J. & Toth, S. (1971) Steroids 17, 427-433. 
270. Soyka, L.F. & Deckert, F.W. (1974) Biochem.Pharmaool. 23, 1629-1639. 
271. Soyka, L.F. & Long, R. (1972) J.Pharmaool.Exp.Ther. 182(2), 320-327. 
272. Stanton, C.A., Riley, S. & Garner, R.C. (1984) Mutat.Res. 141, 7-9. 
273. Stark, A.A., Essigmann, J.M., Demain, A.L., Skopek, T.R. & Wogan, 
G.N. (1979) Proo.Nat.Aoad.soi.USA 76(3), 1343-1347. 
274. Stead, A.G., Hasselblad, V., Creason, J.P. & Claxton, L. (1981) 
Mutat.Res.85, 13-27. 
275. Stegeman, J.J., Pajor, A.M. & Thomas, P. (1982) Bioohem.Pharmaool. 
31(24), 3979-3989. 
276. Stohs, S.J., AI-Turk, W.A. & Roche, E.B. (1980) in Miorosomes, Drug 
Oxidations and Chemioal Caroinogenesis, eds. Coon, M.J., Conney, 
A.H., Estabrook, R.W., Gelboin, H.V., Gillette, J.R. & O'Brien, P.J. 
(Academic Press, N.Y.), Vol.2, pp1239-1242. 
277. Sugimura, T., Kawachi, T., Matsushima, T., Nagao, M., Sato, S. & 
139 
Yahagi. T. (1977) in Progress in Genetic ToxicoLogy. eds. Scott. D .• 
Bridges. B.A. & Sobels. F.H. (Elsevier/North-Holland .• Amsterdam). 
ppI25-140. 
278. Sugimura. T.. Nagao. M .• Kawachi. T.. Honda. M .• Yahagi. T.. Seino. 
Y . . Sato. S .• Matsukura. N .• Matsushima. T .. Shirai. A .• Sawamura. M. 
& Matsumoto. H. (1977) in Origins of Human Cancer. eds. Hiatt. H.H .. 
Watson. J.D. & Winsten. J.A. ( Cold Spring Harbor Laboratory. Cold 
Spring Harbor. N.Y.). Bk.C. 1561-1577. 
279. Sugimura. T.. Yahagi. T.. Nagao. M .• Takeuchi. M .• Kawachi. T.. Hara. 
K .• Yamasaki, E.. Matsushima. T., Hashimoto, Y. & Okada, M. (1976) 
in Screening Tests in ChemicaL Carcinogenesis. eds. Montesano, R., 
Bartsch, H .. Tomatis, L. & Davis, W. ( IARC Scientific Publication 
no.12), pp81-101. 
280. Tan, L., Rao, A.J. & Yu, P. (1982) J.Steroid Biochem. 17(1),89-94. 
281. Tauc, M., Hermann, M., Dansette, P.M. & Vandersteele, J.P. (1984) 
Mutat.Res. 125(2), 123-133. 
282. Tephly, T.R. & Mannering, G.J. (1968) MoLPharmacoL 4, 10-14. 
283. Teschke, R. & Wiese, B. (1982) J.EndocrinoLInvest. 5(4). 243-250. 
284. Tomatis, L., Agthe, C., Bartsch, H., Huff , J .• Montesano, R., 
Saracci, R., Walker, E. & Wilborn, J. (1978) Cancer Res. 38,877-885. 
285. Trosko, J.E. & Chu. E.H.Y. (1975) Adv.Cancer Res. 21,391-392. 
286. Tuttenberg , K.H .. Huthwohl, B., Kahl, R. & Kahl, G.F. (1974) Biochem. 
Pharmacol. 23, 2037-2043. 
287. Vadi, H., Jernstrom. B. & Orrenius, S. (1976) in Polynuclear Aromatic 
Hydrocarbons : Chemistry, Metabolism, and Carcinogenesis, eds. 
Freudenthal, R.I . & Jones, P.W. (Raven Press, N.Y.), pp45-61. 
288. Van den Berg, A., Noordhoek, J., Savenije-Chapel, E.M. & Koopman-
Kool. E. (1978) Biochem.PharmacoZ. 27, 627-633. 
289. Vesell, E.S., Lang, C.M., White, W.J., Passananti, G.T. & Tripp, S.L. 
(1973) Science 179, 896-897. 
290. Vodicnik. M.J., Franklin. R.B., Elcombe, C.R. & Lech, J.J . (1981) 
Biochem. PharmacoZ . 30(10). 1091-1097. 
291. Vodicnik, M.J. & Lech, J. (1983) J.Steroid Biochem. 18(3), 323-328. 
292. Vogel. H.J. & Bonner, D.M. (1956) J.BioLchem. 218. 97-106. 
293. Vollmar, J. (1981) in Progress in Mutation Research, ed. Kappas, A. 
(Elsevier/North-Holland, Amsterdam), Vol.2. pp179-186. 
294. Vore, M. & Soliven, E. (1979) Drug Metab.Dispos. 7(5), 247-251. 
140 
295. Watanabe, M., Tamura, Y. & Abe, T. (1980) ToxicoL.&ett. 5(1), 55-60. 
296. Watanabe, K. & Yoshizawa, I. (1983)J.Pharmacobiodyn. 6(6), 438-440. 
297. Weinberger, M.J., Aten, R.F. & Eisenfeld, A.J. (1978) Biochem.Pharm-
acoL. 27, 2469-2474. 
298. Weinstein, D. & Lewinson, T.M. (1978) Hutat.Res. 51, 433-434. 
299. Weisburger, J.H. (1980) Ann.N.Y.Acad.sci. 349, 228-231. 
300. Welch, R.M., Levin, W. & Conney, A.H. (1968) J.PharmacoL.Exp.Ther. 
160, 171-178. 
301. Williams, K., Inmon, J . & Lewtas, J. (1983) Teratogenesis Carcinog. 
Mutagen. 3(4), 367-376. 
302. Williams, M.T. & Hendley, R. (1982) Biochem.Biophys.Res.Commun. 
104(4), 1349-1355. 
303. Wislocki, P.G., Wood, A.W., Chang, R.L., Levin, W., Vagi, H., Hernan-
dez, D., Dansette, P.M., Jerina, D.M. & Conney, A.H. (1976) Cancer 
Res. 36, 3350-3357. 
304. Wong, J.J. & Hsieh, D. (1976) Proc.Nat.Acad.Sci.USA 73(7), 2241-2244. 
305. Wood, A.W., Goode, R.L., Chang, R.L., Levin, W., Conney, A.H., Vagi, 
H., Dansette, P.M. & Jerina, D.M. (1975) Proc.Nat.Acad.Sci.USA 72(8), 
3176-3180. 
306. Wood, A.W., Wislocki, P.G., Chang, R.L . , Levin, W., Lu, A.Y.H., Vagi, 
H., Hernandez, 0., Jerina, D.M. & Canney, A.H. (1976) Cancer Res. 36, 
3358-3366. 
307. Yahagi, T., Nagao, M., Sein~, Y., Matsushima, T., Sugimura, T. & 
Okada, M. (1977) Mutat.Res.48, 121-130. 
308. Yamasaki, E. & Ames, B.N. (1977) Proc.Nat.Acad.Sci.uSA 74(8), 3555-
3559. 
309. Zeiger, E., Pagano, D.A. & Robertson, l.G.C. (1981) Environ.Mutagen. 
3, 205-209. 
310. Zeigler, D.M., Duffel, M.W. & Poulsen, L.L. (1979) ciba Found.Symp. 
72, 191-204. 
